key: cord-0039005-0gzaonz9
authors: nan
title: ECC -6 Abstracts
date: 2004-11-17
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2004.10.003
sha: d98f00b09ea913c492633de237549b521f90d12f
doc_id: 39005
cord_uid: 0gzaonz9

nan

Carret G a , Mihaila-Amrouche L b , Chirouze C b , J. Loubinoux b , A. Bouvet b . a Hospices Civils de Lyon, Faculté de Médecine, Lyon Sud, France, b Centre National de Référence des Streptocoques, Hôtel Dieu, Université Paris 5, France Clinical data on nosocomial infections due to Streptococcus pyogenes voluntarily reported from January 2003 to June 2004 to the French National Reference Center for Streptococci were analyzed, together with the microbiological traits of the strains. During this 18-month period the surveillance of invasive infections has been enhanced according to the Strep-EURO project and active surveillance has been exercized in the Rhône region of France from December 2003 to February 2004 by the National Health Services, i.e. Institut de Veille Sanitaire and Direction Départementale des Affaires Sanitaires et Sociales.

A total of 30 unrelated episodes of nosocomial infections involved 50 patients (1-6 patients per episode). The 32 invasive nosocomial infections accounted for 13% of the total of 249 invasive streptococcal infections reported during the same period. Predisposing factors were mostly surgical operation or child delivery. Post-surgical infections included: superficial and deep-tissue infections, such as soft-tissue necrosis, abcesses, or erysipelas; pneumonia, peritonitis, bacteremia, with or without toxic shock syndrom and death. Post-partum infections were suspected as nosocomial, although evidence of hospital acquisition were rarely obtained. Bacteremia, endometritis or peritonitis occured early after vaginal delivery or caesarian. They were less frequently associated with malignant outcome.

More than 10 different emm types were represented among the 50 S. pyogenes isolates. Three predominant emm types account for 66% of the virulent strains: emm1 (17%), emm4 (19%) and emm28 (30%). Strains of emm type 1, mostly associated with invasive infections, toxic shock, necrotizing fasciitis and death, were the sole responsible for five episodes; emm4 strains, mostly associated with post-surgical infections, were responsible for five episodes; and emm28, mostly associated with puerperal sepsis, were responsible for six episodes. In addition one cluster of six cases of puerperal sepsis involved these three different emm types simultaneously.

These results indicate the diversity of the streptococcal strains and the risk for nosocomial infections associated with post-partum or surgical wounds. Because of the burden and severity of invasive S. pyogenes diseases the national health authorities have mandated a workshop which is currently in the process of drafting recommendations. Guidelines include, inter alia, isolation of the patient and reinforcement of infection control practices in each case of post-partum or -surgical infection.

0924-8579/$ -see front matter doi:10.1016/j.ijantimicag.2004.10.003 A marked increase of soft tissue and other invasive infections caused by GAS was noted during the mid-1980s; this was also observed amongst children, where superficial GAS infections have always been prominent. Children can also serve as potential reservoirs for virulent GAS strains, which may in turn be transmitted, to 'high risk' adults and cause invasive disease. The profile of severe GAS infections amongst children (in particular, those in Greece) were analysed by identification of the organism source, the clinical predisposing factors, outcome according to treatment regimen, and microbiological characteristics.

A total of 51 invasive GAS isolates from 29 male and 22 female children hospitalised between January 2003 to June 2004, in the 'Aghia Sophia' and the 'P and A Kyriakou' Children's Hospitals in Athens were examined. The isolates were characterised by M/emm type, sensitivity to penicillin, erythromycin, clindamycin and tetracycline (using the Kirby-Bauer and E-test methods), and identification of the streptococcal exotoxins (spe) and antimicrobial resistance genes. The mean age of the patients was 4 years (age range 17 months to 14 years). A total of 20 patients presented with varicella infection and were admitted to hospital on the sixth day (mean average) after the eruption of the vesicles (overall admission range 1-17 days). From the available data on 26 children, the mean duration of hospitalisation was 12.4 days (range 1 h to 42 days); three of 51 children were admitted to the ICU, one presented with both varicella and meningitis and died within the first hour of admission. A total of 16/51 patients (31.4%) had bacteraemia (nine with varicella); 14 had cellulitis (eight with varicella). Other clinical manifestations included septic arthritis (6), osteomyelitis (3), pneumonia/empyema (3), STSS (2), necrotising fasciitis/myositis (2), meningitis (1), brain abscess (1) and upper respiratory abscess (1). The primary focus of infection was the upper respiratory tract in 18 of the 51 children (35.3%) followed by the skin (15.7%).

Resistance to penicillin was not found, however, MLS B resistance was found amongst six isolates (11.8%), four of which belonged to the M phenotype, the other two exhibited IR and CR MLS B resistance. The resistance gene profiles correlated with the antimicrobial resistance patterns. Six and four strains were resistant and intermediary resistant to tetracycline, respectively. Amongst the GAS strains serotyped (34/51), 13 belonged to M1 (38.2%) and all bar one possessed the spe A gene.

Acknowledgements to M Foustoukou and team from the 'P and A Kyriakou Hospital'.

The immunopathogenesis of invasive group A streptococcal (GAS) infections involves a complex interplay between bacterial virulence factors and host factors. Cytokines elicited by bacterial superantigens have been suggested to play a central role in severe systemic clinical manifestations of gram-positive sepsis. Analyses of in vivo and in vitro cytokine responses in patients with severe (streptococcal toxic shock syndrome and/or necrotizing fasciitis) or nonsevere (no toxic shock or deep-tissue involvement) invasive GAS infection revealed a direct correlation between cytokine responses and severity of invasive disease. Significantly elevated frequencies of pro-inflammatory cytokines were observed in acute phase peripheral blood mononuclear cells from severe cases as compared to non-severe cases. Analyses of tissue biopsies from patients with GAS tissue infections revealed a similar correlation between the magnitudes of pro-inflammatory cytokines, in particular Th1 cytokines, and severity of infection. This difference in in vivo cytokine responses during acute phase could be reproduced when paired age and sex-matched severe and non-severe cases infected with a clonal GAS strain were tested in vitro during their convalescent phase for immune response to culture supernatants from their infecting isolate. These findings indicated that the propensity to be either a high or a low responder to superantigens is a stable feature of the host, which may contribute to severity of disease. Further studies revealed that specific HLA class II haplotypes conferred protection from severe disease, whereas others increased the risk of severe disease. Functional analysis revealed that the risk HLA types promoted significantly higher cytokine responses against GAS superantigens than did the protective ones. Taken together the studies show that HLA class II molecules that influence the magnitude of immune responses to GAS superantigens play a pivotal role in determining the outcome of invasive GAS infection.

In vitro studies revealed synergy between colistin and rifadin on MDR A. baumannii (Giamarellos-Bourboulis et al. DMID 2001, 40: 117) . To test that hypothesis in an experimental model, 40 Wistar rats became neutropenic after i.p. injection of two doses of 150 mg/kg of cyclophosphamide. Sepsis was induced after i.m. injection in the right femor of 1 × 10 8 cfu of one isolate of A. baumannii resistant to rifadin, imipenem and ciprofloxacin and susceptible to colistin. Five hours after induction of sepsis animals were divided into four groups, as follows: (A) controls; (B) im administered once 3 mg/kg of colistin in the left femor; (C) i.v. administered once 5 mg/kg of rifadin by a catheter inserted in the right jugular vein; and (D) administered both agents. Four hours after treatment animals were sacrificed, blood was sampled after puncture of the inferior cava for culture and segments of liver, lung and spleen were cut for culture. Quantitative cultures were performed after homogenization of tissue and consecutive diluting. Mean log 10 of viable cell counts are given in the table:

Group Blood (cfu/ml) Liver (cfu/g) Lung (cfu/g) Spleen (cfu/g) It is concluded that rifadin intensifies the in vivo bactericidal effect of colistin. It seems that despite the indications of the antibiogram, colistin does not provide rapid bacterial eradication and its co-administration with rifadin is necessary for infections by MDR nosocomial isolates.

The clinical significance of MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is replacing its susceptible predecessor across the world. Whilst this can be perceived as an inevitable consequence of antimicrobial consumption, acquisition by the individual, and collectively for hospitals, has important implications regarding healthcare and societal costs for every country affected. The crux of the problem lies with the difficulties in managing colonised and infected patients, as well as the organism's propensity for survival and spread. Such difficulties have created opposing opinions on whether there is any point funding rigorous infection control activities, when many countries continue to witness a persistent increase.

Tempting though it is to abandon search and destroy policies for MRSA, there are convincing reasons why control should remain a priority. Managerial interests could be directed towards the financial consequences of MRSA since there is robust evidence demonstrating cost-benefits for hospitals from various control initiatives. We should also consider the cost to an individual patient as well as society itself. Some of these are non-calculable. Savings can be obtained from both general and specific control interventions-the former encompassing estimates such as reduction in hospital bed-days or overall costs of hospital-acquired infection; the latter alludes to hand-washing programmes, screening or antibiotic prescribing. Hospitals with rising numbers of MRSA patients experience an increasing financial burden, which influences both healthcare policies and overall societal costs. As with the indefinable impact upon human health and well-being, these will escalate without managerial and political commitment. Before the introduction of any clinical improvement programme, resources must first be released before implementation. From the evidence presented, it is clear that control efforts will not only pay for themselves, but would generate other direct and indirect benefits to individual patients and society as a whole.

Objective: Description of a monocentric series of 26 patients with chronic pulmonary necrotizing aspergillosis and testing of a recent radiological classification.

Methods: Retrospective analysis of medical records with special focus on evolution and radiological aspects.

Results: Six patients had a negative search for Aspergillus, all had a positive serology. Intratissulary rods were seen in only three of the 10 patients going through surgery. First line treatments consisted in itraconazole for 15 patients, amphotericin B for 10 and voriconazole for 5. Primary failure rate was 22%. During follow-up (47 months), 61% of the respondors relapsed. There was no relapse among the patients with a normalized serology at the end of the treatment. Only 15 patients were easily classified using Denning's recent sub-classification: nine chronic cavitary forms, two chronic fibrosing forms and four sub-acute invasive forms. Ambiguity between the "cavitaryänd the "fibrosingforms was frequent, the role of Aspergillus in generating fibrosis being uncertain. Simplifying Dennings' classification into sub-acute and chronic pulmonary aspergillosis, allowed an easy classification of 88% of our patients: in the sub-acute form, systemic immunodepression was usual, there was one or no excavation, no fibrosis, the search for Aspergillus was usually positive, tissular invasion was seen, locoregional extension was possible, relapses were unusual, surgery was an interesting radical treatment: in the chronic form, systemic immunodepression was rare, there were multiple excavations, pleural or pulmonary fibrosis was usual and sometimes extensive, search for Aspergilluswas often negative, tissular invasion was not easily seen, there was no locoregional extension, relapses were usual with frequent bilateralisation, surgery was often difficult and followed by frequent relapses.

Conclusion: Dennings' recent radiological classification allows a better understanding of this complex disease. We propose a simplified use of this classification, which should help physicians in managing these patients. These two forms of pulmonary aspergillosis should also be carefully separated in studies comparing treatment strategies. A sustained antifungal treatment might be interesting in patients with the chronic form.

False positive Aspergillus antigenemia related to semisynthetic penicillin therapy is more complex than expected: new facts and new hypothesis Bart-Delabesse E, Souville D, Danis M, Datry A. Laboratoire de Parasitologie-Mycologie,G.H. Pitié-Salpêtrière, Paris, France Purpose: Detection of the Aspergillus galactomannan in serum by the Platelia ® Aspergillus enzyme immunoassay (EIA) is a useful tool for the early diagnosis of invasive aspergillosis (IA). Recently, false-positive tests have been reported in patients at risk for IA as related to the use of piperacillin-tazobactam (PPR-TZB). Since we found that other hemisynthetic penicillins may cross-react with this EIA, we sought to study the kinetics of antigenemia in patients receiving these drugs and to understand how false EIA positivity may be circumvented.

Methods: We reviewed 65 patients for which at least one positive serum (cut-off at 0.8 ng/ml) was detected in absence of IA from June 2003 to july 2004. The antibiotic regimen was prospectively investigated, and drug batches tested with the Aspergillus EIA.

Results: Antibiotherapy including either amoxicillin (AMX), amoxicillin-clavulanic acid (AMX-CLV) or PPR-TZB was recorded among 62 patients. Follow-up of antigenemia in 26 patients revealed two types of kinetics, each observed with either drug, including per os AMX-CLV. In the first type, values above 3 ng/ml were obtained within the first 24 h and remained high whatever the time lapse between serum sampling and infusion period was (0.5-8 h). Upon the last dose, decline and negativity occurred at 24 and 72-96 h, respectively. In the second type, values were lower (1.0-2.6 ng/ml) with shorten delay to negativity. Whereas all drug batches tested positive, the deduced antigen concentrations at peak serum drug concentration were at least a tenfold lower than that obtained from patient sera.

Conclusion: AMX or AMX-CLA can generate false EIA positivity like PPR-TZB whatever the formulation is. While testing every batch is demanding and costly, it is the only indicator of a possible false EIA positivity since testing serum collected prior to the next antibiotic dose does not prevent from it. Our data suggest that EIA positivity presumably due to the fungal galactomannan present in certain batches of these hemisynthetic penicillins, is amplified by serum components which nature remains to be determined. Expertise of the biologist is important for clinicians to avoid misleading diagnosis of IA, useless antifungal therapy or antibiotic switching.

Brun S a , Dalle F d , Saulnier P c , Renier G b , Bonnin A d , Chabasse D a , Bouchara JP a . a Groupe d'Etudes des Interactions Hôte-parasite, France, b Respiratory-deficient mutants of Candida glabrata, which present a reduced susceptibility to azole antifungals, are easily induced in vitro by exposure to azole drugs or ethidium bromide and may be selected in vivo in patients undergoing fluconazole prophylaxis or therapy. The present study was therefore conducted in order to define the pathogenicity of these petite mutants. To do this, two wild-type isolates of C. glabrata were compared with their respective fluconazole or ethidium bromide-induced petite mutants, regarding the carbohydrate and protein composition of the cell wall, as well as their surface physical properties and expression of CgEPA1 gene encoding an adhesin, but also their adherence capabilities and their virulence in mice. Thus, flow cytometric analysis of cell wall carbohydrates using several fluorescent lectins showed an increased binding of mutant cells to concanavalin A compared with their parent isolates, suggesting a greater availability or an increased amount of glucose-mannose residues at the cell surface in petite mutants. Likewise, quantitative differences were shown by SDS-PAGE in the surface proteins of blastoconidia between parent and mutant isolates. Regarding the surface physical properties, no significant differences were seen in the electrophoretic mobility determined by microelectrophoresis, but two-phase partitioning using hexadecane as the organic phase revealed a lower hydrophobicity for all petite mutants compared with parent isolates. Moreover, mutant cells exhibited an important overexpression of the gene CgEPA1 as revealed by real-time reverse transcription-PCR compared with their parent isolates, but the adherence capacities to Caco-2 cells, a human enterocyte cell line, were not significantly different. Finally, as suggested by their slower growth, petite mutants were less virulent than parent isolates in an experimental model of systemic infection using immunocompetent mice. Together these results suggest that one can disregard C. glabrata petite mutants clinically. However, due to their markedly decreased virulence, these mutants may constitute valuable tools for the characterization of virulence factors of this yeast, and proteomic studies of the changes associated with petite mutations are now in progress.

Survey of azole-resistant candida species after implementation of pre-emptive antifungal strategy in a surgical intensive care unit Grenouillet F b , Boisson K a , Biot I b , Blasco G c , Millon L b , Balvay P c , Boillot A c , Piarroux R b . a Bactériologie, France, b Mycologie, France, c Soins intensifs en Chirurgie, France, Hôpital Universitaire, Besançon, France Background: Early targeted pre-emptive antifungal therapy in surgical critically ill patients led to significative decrease of occurrence of acquired severe candidiaisis (Piarroux et al., Crit Care Med 2004, in press ). However, its impact, in terms of selection of resistant Candida strains, especially C. glabrata (C.g) and C. krusei(C.k), should be checked.

Patients and methods: Mycological screening were performed on patients admitted in a surgical intensive care unit (SICU), at admittance then weekly until discharge, during a 24-month prospective survey. Patients with corrected colonization index ¡Ý 0.4 received pre-emptive therapy (fluconazole 400 mg/day for two weeks). Study focused on C.g and C.k epidemiology and origin of C.g/C.k colonization (imported versus SICU-acquired). Molecular typing of C.k isolates (microsatellite polymorphism and IGR-PCR) was undertaken to identify possible patient-to-patient C.k transmission.

Results: C.g and C.k represented respectively 13.2% and 4.4% of yeast isolates and colonized respectively, 12.4% and 6.0% of 745 SICU patients included for analysis. One hundred and twenty out of 133 C.g/C.k colonized patients presented imported colonization whereas the 13 remaining patients were not apparently colonized at admittance. However, only one out of these 13 patients previously received pre-emptive fluconazole therapy. Molecular typing showed that each patient had his own specific C.kstrain and noC.k cross-contamination could be demonstrated.

Discussion: Implementation of pre-emptive strategy in SICU did not open on acquisition of fluconazole resistant Candida species during SICU-stay of the patients. These reassuring data should be completed by a long-term epidemiological survey and molecular study on C.g transmission.

Posaconazole treatment in rhino-cerebro-ocular zygomycosis Bregenzer T b , Schöneborn P a , Podvinec M c . a Augenklinik, Switzerland, b Division of Infectious Diseases, Switzerland, c HNO-Klinik, Katonsspital Aarau, Aarau, Switzerland Posaconazole (POS) is an investigational triazole antifungal agent that has activity against Zygomycetes in vitro and has shown activity in animal models of zygomycosis. This case describes the successful treatment of a diabetic patient with zygomycosis who was intolerant of and had disease refractory to amphotericin B (AMB).

A 31-year-old man with congenital deafness and a 12 year history of type 1 diabetes mellitus complicated by diabetic retinopathy of the right eye was admitted to the hospital in August 2003 with suspected facial erysipelas and impaired vision in his left eye. On admission his temperature was 38.4 • C and his HbA1c was >10%. Empiric therapy with amoxicillin/clavulanic acid was started. One day later, his vision further deteriorated because of occlusion of central retinal veins and arteries. Staphylococcus aureus was isolated from nasal swabs, and sinusitis with orbital cellulitis was suspected; however, biopsies of orbital fat obtained during decompression surgery showed histological evidence of zygomycosis. Enucleation of the left eye was performed and AMB 1 mg/kg/day was started (baseline serum creatinine = 76 umol/L). Despite four surgical revisions and >5 weeks of AMB, there was no clinical improvement or eradication of the fungus. MRI showed infiltration of the sinuses. Development of AMB-related renal failure (serum creatinine = 231 umol/L) necessitated switching therapy to liposomal AMB 5 mg/kg/day; however, the zygomycosis continued to worsen. Because of the patient's severely impaired vision and deafness, communication with the patient became difficult.

The patient was enrolled in an open-label compassionate treatment use protocol in November 2003. POS 200 mg four times daily was started. During the first 3 weeks of therapy, involvement of the cavernous sinus and optic chiasma were noted. After 8 weeks of therapy, the zygomycosis became stable and there were no signs of progressive periorbital fungal infiltration. MRI showed no further progression of the disease. POS treatment was completed after 26 weeks. One year after the diagnosis, the patient has regained the ability to communicate and care for himself. The successful outcome observed in this patient indicates that POS may be an effective treatment for zygomycosis.

Talon D a , Wollner A b , Bonin S b , Bertrand X a . a Hygiène Hospitalière, CHU, France, b CLS Bellevaux, Besançon, France Whereas the infectious MRSA risk is considered as key quality indicator of the level of hand hygiene practices in healthcare settings, long-term-care facilities (LTCF) appeared very powerful in this field. Indeed, during a 3-year surveillance in facilities of Franche-Comté region, incidence of MRSA colonisations/infections was 0.09 and 0.9, respectively, in LTCF and acute care facilities. The objectives of this study were to establish the frequency of MRSA acquisition in a 250 beds-LTCF and to discuss the roles of screening for MRSA carriers, the type of isolation to be implemented and the efficiency of chemical decontamination. The combination of the prevalence of MRSA carriage and MRSA screening upon admission allowed us to evaluate the MRSA acquisition risk according to the characteristics of the patients and the inter-hospital transfers. The prevalence study showed that 15.2% of the patients were MRSA carriers. On the admission, 23.3% of the patients were positive with MRSA. Among MRSA-free patients on admission, without any transfer, 14% became positive for MRSA, all had lost their autonomy. Chemical decolonisation (nasal mupirocin + cutaneous chlorexidine) was efficient for 22 patients out of 25 (88%). In LTCF, the frequency of MRSA cross-transmission could not be evaluated on the basis of clinical samples. MRSA acquisition occurred exclusively among totally dependent patients. Thus, technical isolation rules should be respected when carrying out treatments, the efficacy of such isolation being unaffected by the mobility of patients and their "resocialisation". Chemical decolonisation was efficient and made it possible to reduce the number of days of technical isolation. Given the increase in morbidity associated with MRSA observed in numerous hospitals, the emergence of a community-based disease linked to these strains and the emergence of glycopeptide-resistant strains, the application of a voluntary strategy including screening, isolation and decolonization in R-CCF appears to be an urgent matter of priority.

Lucet JC, Armand-Lefevre L, Rioux C, Merabet W, Régnier B, Andremont A. Hôpital Bichat-Claude Bernard, Paris, France Background and objectives: Despite the increasing incidence of MRSA, little is known about MRSA acquisition outside of the intensive care units. A prospective observational study was designed to assess (i) the prevalence and factors associated with MRSA on admission to four high-risk acute care wards (acute geriatric, dermatology, diabetology, and septic surgical wards), and (ii) incidence and risk factors for MRSA acquisition.

Methods: During 5 months, a nasal swab was obtained at admission to, and discharge from these units, together with a skin swab of chronic skin break (CSB), if present. At admission, patients (Pts) with at least one risk factor for MRSA were screened: transfer from another health-care institution or receiving home care, history of hospitalization in the last 12 months (Hosp), prior MRSA carriage, poor chronic health status or CSB. After admission, parameters obtained were workload (as assessed with the SIIPS score) and duration of unit stay (DUS). Contact precautions were used for MRSA-positive Pts.

Results: Of the 1193 admitted Pts, 846 were included (first admission during the study, hospital stay >48 h, and admission to the study unit <3 days. after hospital admission). MRSA prevalence was 6.6% (56/846, 22/56 previously known as MRSA carriers). Without admission screening, 29/56 (52%) MRSA carriers would have been missed. Parameters associated with MRSA carriage at hospital admission in unknown MRSA carriers (n = 34) were: age >70 years (aOR, 2.84, P < 0.0001), home care (2.32, 0.04), Hosp (2.52, 0.02) and CSB (3.78, 0.008). A targeted screening strategy using these four risk factors required to screen 62% of admitted Pts, with a sensitivity of 97%. Of the 1193 admitted Pts, 711 were MRSA-negative at admission, and were screened at discharge, 22 (3.1%) acquired MRSA, 21/22 being identified through screening specimens only. Risk factors for MRSA acquisition were: CSB (3.59, 0.009), SIIPS at day 2 (1.45, 0.006) and DUS (population average, 10.5 days) (1.067, 0.001).

Conclusions: In these high-risk units, the incidence of MRSA acquisition was half of MRSA prevalence at admission. Identifying the MRSA reservoir at admission required to screen more than half of admitted Pts. MRSA spreading was by far more important than that identified with clinical samples only.

Epidemiology and antimicrobial resistance of pneumococci in Greece: a preliminary report of the Hellenic Study for the susceptibility of Purpose: To present preliminary data of an ongoing nation-wide surveillance study on the susceptibility of Streptococcus pneumoniae strains from nasopharyngeal colonization (NPC) or invasive pneumococcal disease.

Methods: Nasopharyngeal sampling from healthy children (2-6 years old) attending day-centers was performed from February to May 2004. Collection of clinical isolates started in January 2004 and will end in December 2004. Pneumococci were identified by use of optochin sensitivity, bile solubility and slide agglutination (Pneumolatex) assays. Susceptibility testing was performed for penicillin (PG), cefuroxime (CXM), ceftriaxone (CXT), erythromycin (ERY), tetracycline (TET), cotrimoxazole (COT), levofloxacin (LE) and moxifloxacin (MX) by E-test. NCCLS methodology and breakpoints for intermediate resistance (IR) and resistance (R) were used.

Results: A total of 886 NPC pneumococcal strains was isolated from 2927 children, yielding 30.26% mean pneumococcal carriage over the sampling period. Twenty-eight clinical strains were also collected until Only nine NPC PG resistant strains (out of the total 461 studied, i.e. 1.95%) had an MIC > 2 g/ml (range 2-4). No resistance to respiratory quinolones was observed. PG + EM R strains account for 11% of the total. Susceptibility patterns varied among different geographic departments. For clinical strains, rates were as follows: PG IR 14.3% and PG R 14.3%, XT R 3.6% and EM R 33.3%. No quinolone resistance was observed as well.

Conclusions: Data suggest an increasing trend in the resistance rates for both penicillin and erythromycin. Geographic variation of resistance may reflect climatologic conditions or antibiotic consumption behaviour, and warrants further investigation. Despite increasing trends in resistance, the very low number of strains beyond clinical resistance cut-offs (MIC for PG > 4 g/ml) render ␤-lactams still potent agents against pneumococcal disease.

Persistence of animal and human glycopeptide resistant enterococci on Norwegian poultry farms formerly exposed to avoparcin is associated with a widespread plasmid-mediated vanA-element Johnsen P b , Sørum M a , Sletvold H b , Rosvoll T b , Østerhus JI b , Kruse H a , Nielsen K b , Simonsen GS b , Sundsfjord A b . a Norwegian Zoonosis Center, National Veterinary institute, Oslo, Norway, b Microbiology and Virology, University of Tromsø, Tromsø, Norway

The evolutionary processes responsible for long-term persistence of glycopeptide resistant Enterococcus faecium (GREF) in non-selective environments were addressed by genetic analyses of animal and human E. faecium populations on two Norwegian poultry farms previously exposed to avoparcin. A total of 222 faecal GREF (N = 136) and glycopeptide susceptible (N = 86) E. faecium (GSEF) isolates were obtained from farmers and poultry on three separate occasions in 1998-1999. Pulsed-field gel electrophoresis (PFGE) and plasmid DNA analyses discerned 22 GREF and 32 GSEF PFGE types within shifting polyclonal animal and human E. faecium populations and transferable plasmid mediated vanA-resistance. Examples of dominant persistent GREF PFGE types supported the notion that environmentally well-adapted GREF-types may counteract the reversal of resistance. PFGE analyses, sequencing of thepurK housekeeping gene, and partial typing of the vanA-containing Tn1546 suggested a common animal and human reservoir of glycopeptide resistance. Inverse PCR amplification and sequence analyses targeting the right end of the Tn1546-plasmid junction fragment strongly indicated the presence of a common single Tn1546-plasmid mediated element in 20 of 22 GREF PFGE types. This observation was further strengthened by vanY-Z hybridization analyses of plasmid DNA as well as the finding of physical linkage between Tn1546 and a putative postsegregation killing system (PSK) in seven GREF PFGE types. In conclusion, our observations suggest that the molecular unit of persistence of glycopeptide resistance is a common mobile plasmid mediated vanA-containing element within a polyclonal GREF-population changing over time. In addition we propose that "plasmid addiction systems" may contribute to persistence of GREF in non-selective environments.

Segonds C c , Clavel-Batut P c , Eydieux-Laporte K c , Le Thomas-Bories I c , Bingen E a , Mariani P a , Brahimi N a , Ravilly S b , Chabanon G c . a Service de Microbiologie, Paris, Hôpital Robert Debré, Paris, b Vaincre la Mucoviscidose, Paris, c Laboratoire de Bactériologie-Hygiène, France, Hôpital Rangueil, Toulouse, France Methicillin-resistant S. aureus (MRSA) is a major cause for epidemiological concern due to its spread through health-care settings, its increasing prevalence in the community, and the emergence of decreased susceptibility to glycopeptides. In patients with cystic fibrosis (CF), S. aureus (SA) is usually the first pathogen recovered from the respiratory tract, and the rate of MRSA has increased during the last decade. The respective prevalences of methicillin-susceptible SA (MSSA) and MRSA in the French CF population have been established at 54.6% and 10.9% in 2001 (Observatoire National de la Mucoviscidose). The present study was undertaken to assess the characteristics of the MRSA-colonised CF population and to analyse the antimicrobial susceptibilities and genetic relationships of isolates. One hundred and eleven MRSA colonised patients from 17 CF Centers in 11 regions were included. The mean age of acquisition is 13.7 years (<1-37); colonisation is chronic in 65% cases. Of 82 documented cases, 54 (66%) had been hospitalized during the prior year, whereas 28 (34%) had not; 40 (49%) received an antistaphylococcal antibiotic shortly (<30 days) after MRSA diagnosis, mainly cotrimoxazole (19 patients) or pristinamycin (11 patients); a glycopeptide has been used in five patients. Among 116 non-redundant isolates, most (88: 75.9%) were susceptible to gentamicin and resistant to tobramycin and amikacin. Pristinamycin, cotrimoxazole, fusidic acid and rifampicin were effective on 100%, 96.5%, 78.4% and 78.4% of isolates, respectively. Seven gentamicin resistant isolates exhibited a reduced susceptibility to glycopeptides. One hundred and fourteen isolates recovered from 109 patients were compared by use of pulse-field gel electrophoresis (PFGE), and classified in 41 types: 26/41 types were unique, whereas 15 included two to 27 isolates. Two types were predominant, involving 23 and 14 patients, in eight and six regions, respectively. In 8/17 CF Centres, several patients harboured the same type.

In conclusion, this analysis within the CF population shows the predominance of the gentamicin-susceptible/tobramycin resistant phenotype and the occurrence of reduced susceptibility to glycopeptides; it suggests that MRSA might be community-acquired and/or patient-to-patient transmitted.

Comparative evaluation of the VIUDAS HIV DUO ultra assay for the combined detection of HIV-1 antigen and antibodies to HIV Lyon, France, b Department of Microbiology, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France The aim of the present study was to evaluate the performances of the combined antigen and antibody HIV screening assay VIDAS HIV DUO Ultra (BioMérieux, Marcy l'Etoile, France) in comparison with two other combined tests: the former version of the same test (VIDAS HIV DUO, BioMérieux) and the AxSYM HIV Ag/Ab Combo assay (Abbott Laboratories, Rungis, France). A prospective study was performed on serum specimens received on a routine basis for HIV testing: 1443 blood samples were tested with the three assays. The sensitivity was 100% for the three tests. The specificity assessed on repeated false-positive samples was 99.86%, 99.03% and 99.65% for VIDAS HIV DUO Ultra, VIDAS HIV DUO and AxSYM HIV Ag/Ab Combo, respectively. In addition, 14 seroconversion panels were tested with the VIDAS DUO Ultra and AxSYM HIV Ag/Ab Combo assays. For four of these panels, a positive signal was detected one blood sampling point earlier with the VIDAS DUO Ultra assay. These results indicate that the VIDAS HIV DUO Ultra exhibits an improved specificity with comparison to the former version of this assay. In addition, given its excellent sensitivity and the availability of independent results for the antigen and the antibody assays, the test is appropriated to the early detection of HIV seroconversion.

Trak-c is a new diagnostic tool in the management of therapeutic follow-up of HIV/HCV co-infected patients treated for chronic hepatitis C Pivert A a , Payan C a , Lunel Fabiani F a , Morand P b . a Laboratoire de Virologie, CHU Angers, Angers, France, b Laboratoire de Virologie,CHU Grenoble, Grenoble, France Background: trak-C, developed by Ortho-Clinical Diagnostics TM , is an assay to quantitate total Hepatitis C Virus (HCV) core antigen in serum. The evaluation of trak-C assay was realised by comparison of the viral kinetics of both markers: total HCV core antigen (trak-C) and HCV viral load (Versant HCV RNA 3.0, Bayer Diagnostics). To evaluate this quantitative assay, we studied 204 patients from RIBAVIC protocol (approximately 1100 samples for each assay).

Methods: RIBAVIC is a therapeutic, multicenter, randomised trial comparing the efficacy of two treatments for chronic hepatitis C: Interferon a2b (IFN) 3 MU × 3 week and ribavirin 800 mg/day versus pegylated interferon (PEG-IFN) 1.5 g/kg/week and ribavirin 800 mg/day during 48 weeks, in co-infected HIV-HCV patients naïve of HCV treatment. Patients were tested at week (W) 0, 2, 4, 12, 24, 48 and 72. Sustained virological responders have a negative PCR 6 months after the end of treatment (W72).

Results: Correlation of core antigen quantitation by trak-C and RNA quantitation by HCV RNA v3.0 was excellent (r = 0.94, p < 0.01). We found a very good correlation between decrease of viral load and negativation of HCV core antigen under treatment: a 2 log IU/ml decline after W4 was significantly correlated with a negative HCV core antigen and sustained response (r = 0.64, p < 0,01). After W4, 69.5% of sustained responders had an RNA decrease >2 log IU/ml and 85.2% had a negative HCV core antigen (49.1% and 69% after W2). The positive and negative predictive values of response to the treatment at W4 were respectively, 57.7% and 85.4% for viral load reduction >2 log IU/ml, 56.5% and 91.1% for negative HCV core antigen, 88.9% and 79.1% for negative PCR (p < 0.0001). When we studied the delay of negativation under treatment, it appears that responders (delay = 36.7 weeks, n = 58) presents negative PCR for longer time than relapsers (delay = 28.6 weeks, n = 15) (p > 0.05). This result must be confirmed with more relapsers.

Conclusions: Total HCV Core Antigen appears to be a new tool for monitoring patients with HCV-HIV co-infection and an early predictor of response to the treatment.

Lebarbier C a , Williams V c , Garandeau C a , Bellaiche G b , Dény P c , Maisonneuve L a , Gordien E b . a Biologie Médicale, France, b Gastro-entérologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois, France, c Bactériologie, Virologie et Hygiène, Hôpital Avicenne, Bobigny, France Aims: To investigate HBV pre C-C mutant-chronic infection patterns according to the viral load (VL) level, using sensitive technique.

Patients and Methods: Forty-six patients chronically infected with HBV, HBsAg and anti-HBe Ab positive, were studied. HBV VL was determined using b-DNA assay 1.0 and 3.0 (Bayer HealthCare) with respective threshold of 7 × 10 5 and 2 × 10 3 copies/mL. Basal core promoter (BCP) and precore (PC) mutants were assessed with the Affigene ® HBV mutant VL assay (Sangtec Molecular Diagnostic).

Results: Eighteen out of 46 patients (39%) had a detectable VL ranging from 3.4 × 10 3 up to more than 10 8 copies/mL. Two patients (4.4%) had abnormal ALT value (2.5 and 8 N); VL values were 6.5 × 10 6 and 1.4 × 10 5 copies/mL, respectively. Pre-C-C mutants were found in 9 (60%) out of 15 tested patients: three having the G 1896 A and six the A 1762 T/G 1764 T mutations. Among patients having VL > 10 5 copies/mL (n = 7), five had normal ALT values and 4 (57%) had pre C-C mutants.

Discussion: Pre C-C mutant chronic infection usually associates positive HBs antigen and anti-HBe Ab, elevated serum ALT, VL > 10 5 copies/mL and detection of the mutations. A wide range (7 × 10 3 -10 8 copies /mL) of viral replication of pre C-C mutant strains, associated with normal ALT level raise the hypothesis that pre C-C mutant occurrence represents a step in the natural history of HBV chronic infection. Interestingly, two out of six patients with HBV VL > 10 5 copies/mL had no BCP or PC mutant viruses.

Conclusion: Our study highlights the complexity of the HBV pre-C-C mutant chronic infection. Large-scale prospective studies are needed to better define this clinical entity.

Gault E a,b , Le Gal F a,b , Gordien E a,b , Affolabi D a,b , Hanslik T c,d , Alloui C a,b , Dény P a,b . a Laboratoire de Bactériologie-Virologie-Hygiène, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, France, b EA3604, Université Paris 13, Bobigny, France, c Unité de Médecine Interne, Hôpital Ambroise Paré, Boulogne Billancourt, France, Versailles, France Background and aims: Hepatitis Delta Virus (HDV), in association with hepatitis B virus, is responsible for severe acute and chronic hepatitis. The treatment relies on long-term administration of high-doses of alphainterferon (IFN) and its efficiency is followed by the detection of anti-HDV IgM and HDV genome in serum. As for other chronic viral infections, HDV genome quantification in serum should be useful in the follow-up of infected patients. The aims of this study were to develop a quantitative assay to detect HDV of any type in the serum, and to evaluate the interest of HDV-RNA quantification in the follow-up of chronically infected patients receiving IFN.

Methods: A real-time RT-PCR assay was developed to quantify HDV-RNA load in serum. The assay efficacy was evaluated with 84 serum samples, and was used on 76 samples obtained from 11 chronically infected patients treated with pegylated IFN.

Results: The assay was sensitive enough to detect 100 copies/ml of serum, and was efficient to detect the genome of all HDV types including type 3 and the recently described types 5-7. Viral load determination in treated patients allowed to discriminate responders from non-responders to IFN therapy, with more accuracy than with the qualitative approach.

Conclusions: We have developed an assay, which is able to quantify HDV-RNA of all types in the serum of infected patients, improving their follow-up. The assay will help to understand the natural history of HDV infection and to define guidelines for the management of chronic delta hepatitis. Human herpesvirus-6 (HHV-6) is an ubiquitous and highly seroprevalent virus in the general population. Two variants A and B of the HHV-6 have been identified on the basis of genotypic and phenotypic differences, but many questions are pending concerning their specific epidemiological and pathogenic properties. Although both variants may infect human, HHV-6 variant B accounts for the majority of clinical manifestations during primary infection and reactivation (encephalitis, hematopoiesis disorders, febrile cutaneous rash), whereas the variant A has been occasionally associated to pathologies (fetal hydrops, encephalitis). Both variants may be detected in lymph nodes and lung tissue without clinical impact. The aim of our study was to develop a rapid, sensitive and specific method to identify HHV-6 variants in different types of biological samples, especially in case of mixed infection. We evaluated a technique adapted from the real-time quantitative method previously developed in our laboratory, which included the change of the consensual reverse primer into two variant-specific primers. Five different strains of HHV-6 variant A (GS, SIE, TAN) and variant B (HST, MAR) have been used either separately or mixed (variants A and B) in various proportions. For both variants, the sensitivity was 10 genomic copies. Regarding specificity, human DNA or other herpesvirus DNA (HSV, VZV, HCMV, EBV, HHV-7, HHV-8) were not amplified. In case of mixed infections, one variant (A or B) could be detected in the presence of more than 10 3 -fold more copies of the other one. Various biological samples including peripheral blood mononuclear cells, saliva, cerebrospinal fluid, tissue biopsies, bone marrow and oral mucosal swabs have been tested. For the samples for which a previous identification of HHV-6 variant was performed using a reference method, we obtained a total concordance. HHV-6 variant B was mainly identified and variant A or mixed infection could be evidenced. Of note, variant A infection was observed in case of neurological disorders. This new method constitutes a useful tool to identify HHV-6 variants in various biological samples, even in the case of mixed infections. We have also evidenced a neurological tropism of the variant A associated to encephalitis in infant or adult.

Vrioni G, Gartzonika C, Priavali T, Christaki C, Levidiotou S. Department of Microbiology, Medical School, University of Ioannina, Ioannina, Greece PCR is becoming the new standard for virological diagnosis of the infections of the central nervous system (CNS). Use of this test has been shown to have the impact on patient management as measured by shortened patient stays and reduction of empirical therapy administration. This study aimed at reporting our experience over the last years in the detection and management of herpesviruses and enteroviruses (EVs) induced CNS infections by using PCR assays. A total of 127 consecutive CSF specimens from patients hospitalized between April 2001 and August 2004 to the University Hospital of Ioannina with clinically suspected viral CNS infection were tested for the presence of the herpesvirus and EV genome using Herpes Consensus and Enterovirus Consensus assays (Argene Biosoft, France). The Herpes Consensus assay allowed the simultaneously amplification of the six major herpesviruses in a single PCR: herpes simplex virus 1 and 2 (HSV1, HSV2), varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6). The Enterovirus Consensus assay allowed the reverse transcription and amplification of all 64 prototypes of EVs. Amplified products were detected by microplate hybridization. The specificity and sensitivity of the assays were evaluated with samples from three external control proficiency panels. Overall, 42 (33%) of the CSF samples tested were positive in the PCR. HSV1 was detected in one adult (0.8%) with encephalitis, VZV was detected in one adult (0.8%) with meningitis, and EVs were detected in 40 children (31.5%) with meningitis and/or encephalitis. None of the specimens tested was positive for HSV2, CMV, EBV and HHV-6 genomes. From the 42 positive CSF specimens, none presented herpesvirus and EVs coinfection in the CNS The precise diagnosis of viral CNS infections was available within 24-48 h, which allowed for a better clinical management of the patients in terms of the duration of hospitalization and the specific therapeutic intervention. In conclusion the Consensus PCR methodology enabled the rapid detection of the herpesviruses and EVs in CSF and provided a reliable, noninvasive tool in the diagnosis of viral CNS infections.

Role of the mutator phenotype in experimental osteomyelitis due to Staphylococcus aureus and in antibiotic resistance Daurel C a,b , Prunier AL a , Garry L c , Chau F b , Leclercq R a , Fantin B b . a Microbiologie, Centre Hospitalier Universitaire, Caen, France, b E9933, Faculté Médecine Xavier Bichat, France, c 0339, INSERM, Paris, France To get further insights into the role of the mutator phenotype in the osteomyelitis physio-pathology due to Staphylococcus aureus and also in antibiotic resistance, we studied the behaviour of two strains of S. aureusonly differing by their mutation rate in a rat model of bacterial osteomyelitis of the tibia. Strains of S. aureus RN4220 and its mutator counterpart inactivated in the mutL gene by the insertion of a suicide plasmid were used. Mutation frequency determined on rifampicin containing medium was 45 times higher with the mutator strain. The behaviour of the two strains was studied separately in vitro and in rat model of osteomyelitis. Competition studies were performed in 50 rats co-infected with the two strains at a same ratio. Ten rats were sacrificed at five different times from 3 days to sixth weeks post-inoculation. A similar experiment was performed after a first in vivo passage for one derivate of each strain. To study the effect of the mutator phenotype in the emergence of antibiotic resistance, 20 rats were infected by each strain separately and treated with rifampicin sc 20 mg/kg bid for 5 days. Animals were sacrificed 48 h after the last antibiotic injection. No difference was observed between the separate growth of the two strains in vitro and in vivo indicating no fitness defect in the mutator strain. In contrast, competitive studies indicated that the mutator strain was clearly disadvantaged since it was found in all rats and all study times at lower bacterial titers (range 4.6 log cfu/bone versus 3 log cfu/bone, P < 0.05). In addition, this competitive loss of the mutator strain was amplified after a second passage in vivo, with a 100-fold difference in cfu counts between the two strains (P < 0.05). In animals treated with rifampicin, resistant mutant appeared in one from eight animals infected with the mutator strain, while no rifampicin resistant mutant was detected in rats infected with the wild strain. We concluded that, in a model of chronic bone infection due to S. aureus, the mutator phenotype was associated with a decreased fitness. However, under antibiotic selective pressure, this initial disadvantage could be compensated by the increased rate of emergence of antibiotic resistant mutant and may lead to competitive advantage.

Bert F b , Noussair L b , Lambert N b , Valla D a . a Hépatologie France, b Microbiologie, Hopital Beaujon, Clichy, France Objective: Spontaneous bacterial peritonitis (SBP) is a frequent complication in cirrhotic patients with ascites. Streptococci have been increasingly reported in SBP as a result of fluoroquinolone prophylaxis. The aim of this study was to determine the frequency and characteristics of episodes of SBP caused by streptococci, in particular viridans group streptococci (VGS) and to investigate a potential association between prophylaxis and the emergence of high level resistance to fluoroquinolones in these organisms.

Patients and methods: We investigated the microbiological data of 237 episodes of SBP and bacterascites over a 6-year period. The medical records of patients with a streptococcal infection were reviewed. MICs of ␤-lactam agents and fluoroquinolones were determined by the Mueller-Hinton agar dilution method.

Results: Eighty-four (35.4%) of the 237 episodes were caused by streptococci. VGS accounted for 73.8% of these isolates, preceding largely beta-haemolytic streptococci (10.7%), Streptococcus pneumoniae(8.3%) and Streptococcus bovis (7.1%). The most prevalent species belonged to the S. oralisgroup (n = 38) and the S. salivariusgroup (n = 12). The isolation of VGS was clinically relevant in 75.8% episodes and associated with asymptomatic bacterascites in the remaining 24.2% episodes. Most episodes were community-acquired. Only 29.8% of patients with VGS infection received norfloxacin prophylaxis. As compared to SBP caused by non-viridans streptococci, SBP caused by VGS was less frequently associated with fever, positive blood cultures and increased ascitic fluid polymorphonuclear neutrophil count. Eleven (13.1%) streptococcal isolates, including 10 VGS and 1 S. pneumoniae, had decreased susceptibility to penicillin. Four of these isolates exhibited high-level ␤-lactam resistance with MICs >4 mg/L. All VGS isolates, including those from patients with norfloxacin prophylaxis, remained susceptible to levofloxacin and moxifloxacin.

Conclusions: VGS are a major cause of SBP in cirrhotic patients with ascites. Long-term administration of norfloxacin is not associated with SBP caused by VGS expressing high level resistance to fluoroquinolones.

Outbreak of glycopepetid-resistant Enterococcus faecium in a French terciary care hospital: the end of the "French paradox"? Robin F d,e Introduction: Glycopeptid-resistant Enterococcus faecium (GREF) is one of the major cause of nosocomial infection in the USA but is still rare in Europe. We report the first outbreak of GREF which occurred in a hospital in Clermont-Ferrand, France.

Methods: A case-control study was performed in the Infectious Diseases and Haematology department. Cases were inpatients for whom GREF was isolated in faeces or other clinical cultures between the 1st of January and the 31 of July 2004. The control group was a randomized sample of inpatients during the same period and who did not acquire GREF. Each case was matched to three controls from the same specialty (infectious diseases or haematology).

Results: Sixteen cases of GREF carriage were identified in the department. GREF was cultured from the stools of all patients and, in addition, from urine in three and ascitis in one. The 6 month-cumulative incidence was 2.9% for that period compared to 0.4% during the same time in 2003 (p = 0.002). During the study period, GREF was isolated from 11 other inpatients from three other wards: abdominal surgery (four), gastroenterology (four), intensive care unit (three). Of these, GREF was cultured from urine in two, from Redivac ® discharge in three, from ascitis in one and from blood in three. Two patients with a GREF bacteraemia died as a direct consequence of the infection. Two strains were responsible for most of the colonizations. In multivariate analysis, controlling for time at risk and the Charlson Index of Comorbidity, the following variables found to be independently predictive for GREF carriage were prior exposure to third generation cephalosporin (OR = 10; 95% CI: 1.5-64; p = 0.02), antimicrobials regimen containing a beta lactamase inhibitor (OR = 5; 95% CI: 0.9-28; p = 0.07) and a urinary catheter in place during the period at risk (OR = 20; 95% CI: 1.3-291; p = 0.03).

Conclusion: This outbreak is likely to result from both multiantimicrobial pressure and patient to patient transmission. Isolation of the patients and enhancement of hygiene procedures have been implemented. This report might annunciate the end of what one could have called a "French (or a European) paradox" meaning a low rate of hospital colonization despite high antibiotic consumption and community reservoir of GREF.

Evaluation of a strategy of multiple-site screening of methicillinresistant Staphylococcus aureus at admission to a teaching hospital Eveillard M, Lancien E, Joly-guillou ML. Microbiologie-hygiène, CHU Louis Mourier, Colombes, France Objective: The carriage of methicillin-resistant Staphylococcus aureus (MRSA) is no longer confined to patients with known risk factors or to healthcare associated settings. To make up for performing screening cultures in an increasing amount of admitted patients, limiting the number of sampled sites could be an interesting alternative. Our objective was to determine the sensitivity of nasal cultures alone compared with the multiple-site screening undertaken in our hospital.

Methods: The study was performed during one year (2002) in a 600bed teaching hospital. For each MRSA carrier identified by multiple-site screening sample (nasal, axilla, rectal) on admission, MRSA-positive site combinations were recorded as follows: nasal alone (N), axilla alone (A), rectal alone (R), N + A, N + R, A + R, N + A, N + A + R. Concurrently, the cumulated number of days of hospitalisation, representing the number of theoretical isolation days (TID), was noted for MRSA carriers identified by screening. For the analysis, carriers were differentiated in nasal carriers (N or N + A or N + R or N + A + R) and other carriers (A, R, A + R). Intact skin and rectal carriers were identified by the same way.

Results: During the study, 123 MRSA carriers accounting for 1854 TID were identified among 1250 patients who underwent a multiple-site screening on admission. With nasal screening alone, 25.2% of MRSA carriers accounting for 530 TID (28.6%) would have been missed. Without rectal screening, 17.1% of carriers accounting for 431 TID (23.2%) would have been missed. Without axilla screening, only 8.1% of carriers accounting for 99 TID (5.4%) would have been missed. The proportion of carriers who would have not been identified with nasal screening alone was nearly twice higher among males than among females (36.5% versus 19.7%; P < 0.04).

Conclusion: Giving-up axilla cultures in non-ICU wards and carrying on rectal cultures would allow to screen 290 additional patients without extra-cost and should enable an higher sensitivity of the screening policy. Indeed, in the additional sampled population, a prevalence of MRSA carriage of 3.4% (10/290) would be sufficient to identify the number of carriers missed without axilla cultures.

Background: In order to follow the Sp serotypes and antibiotic resistance trends following the introduction of Prevenar ® (7-VPnC), a 5-year national surveillance network was set up since September 2001. Recommendations from Health Authorities were issued in March 2002 and reimbursement granted in December 2002.

Methods: Ninety French pediatricians were recruited to carry out 730 NP swabs per year in children (6-24 months of age) suffering from AOM with high fever and otalgia and not receiving antibiotic treatment within 7 days before enrolment.

Results: Over the 3-year survey (n = 1847), the % of 7-VPnC vaccinated children (≥1 dose) increased from 8.5% (1st year) to 19.9% (2nd year) and 59.3% (3rd year). Antibiotic usage in the last 3 months was reduced (p = 0.001), 51.5%, 44.5% and 42%, respectively, from year 1 to 3. Sp carriage of the third year (60.3%) is lower (p = 0.0001) than the previous years (69.9% the second year and 72.3% the 1st year). Among children with Sp carriage (n = 1228), the third year results confirm the decrease of serotypes included in the 7-VPnC : first year 61.6%, second year 59.9%, third year 47.9% (p = 0.0001). No relevant emerging non-vaccine serotype was identified. Among the vaccine serotypes, an increase was observed for 19F and 18C and a decrease for 6B, 23F and more dramatically for 14. The rate of highly penicillin resistant strains (MIC > 1 g/ml) substantially decreased (p = 0.0001), 21.3%, 14.8% and 8.9% respectively, from year 1 to 3. In vaccinated population (n = 526), Sp carriage is less important (57.8 % versus 71.2%, p = 0.0001) and vaccine serotypes are less carried (24.7% versus 44.5%) than in non-vaccinated population (n = 1312).

Conclusion: These results underline the need to continue the follow-up to assess the direct and indirect effect of vaccine on childrens' Sp colonization.

Papy E, Beaumesnil V, Wolff M, Lucet JC, Andremont A, Bouvet E, Certain A, Farinotti R, Fischelle A, Leport C. The Antibiotic Study Group, Bichat Claude Bernard hospital-Paris VII University, Paris, France Background and objectives: There are few data on antimicrobial prescribing in the ER. The objectives of this study were to describe antimicrobial prescribing and timing and patterns of modifications in the subset of patients admitted to the hospital.

Methods: Prospective study of patients who attended the ER during a 1-month period (November 2003) and who were prescribed antibiotic treatment (AT). ER and ward records information were used to complete a standardized case-report. The characteristics of AT were analysed at admission, on days 1, 3, 10 and at hospital discharge.

Results: A total of 5714 adults attended the ER, of whom 234 (4%) were prescribed AT. Of these 234 patients, 100 (43%) were discharged home (median age: 34 years), 39 (17%) were referred to another hospital, and 95 (40%) were admitted to the same hospital (median age: 71 years). The most common suspected diagnoses leading to an AT were respiratory tract infections (n = 62, including 51 pneumonias) and urinary tract infections (UTI) (n = 19). Patients with pneumonia received more frequently a third generation cephalosporin (3GC) or amoxycillin-clavulanate alone or associated with fluoroquinolones (FQ) (40/51, 79%) than amoxicillin alone or associated with a macrolide (6/51, 12%). UTI were treated with FQ (n = 7) or 3GC alone (n = 3) or associated with aminoglycosides (n = 5). During hospital stay, the mean modifications of AT were: day 1 (n = 33), days 1-3 (n = 46) and days 3-10 (n = 24): broadening (34%, 13% and 8%) or narrowing (27%, 15% and 8%) of antimicrobial spectrum and oral switch (18%, 41% and 54%), respectively. For 13/95 patients (14%), AT was stopped within a median delay of 4 days because there was no evidence of bacterial infection. Prescribing was considered inappropriate in 33% of the 27 patients with documented infection. The median duration of AT was 13 days and 16.5 days for pneumonia and UTI, respectively.

Conclusions: Antibiotic treatment is prescribed in 4% of all patients visiting a large teaching hospital. Most hospitalised patients are elderly patients with non-documented pneumonia who are usually treated with a long-course of broad-spectrum antibiotics. It is necessary to investigate the adequacy of these regimens to improve the targeted use of antibiotics.

A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolyzing oxacillinase oxa-58

Héritier C a , Dubouix A b , Poirel L a , Marty N b , Nordmann P a . a Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Service de Bactériologie-Virologie, Le Kremlin-Bicetre, France, b CHU Rangueil, Laboratoire de Bactériologie-Hygiène, Toulouse, France

Recently, we have characterized a carbapenem-hydrolyzing oxacillinase, OXA-58, that is a representant of a novel group of oxacillinases, from an A. baumanniiclinical isolate isolated in the burns unit at the Rangueil Hospital in Toulouse in 2003. OXA-58 was weakly related to other oxacillinases sharing 33%, 47% and 48% amino acid identity with OXA-10, OXA-24 and OXA-23, respectively. The aim of this study was to analyze the spread of this oxacillinase gene as source of carbapenem-resistance in A. baumannii in that hospital. From August 2003 to March 2004, seven carbapenem-resistant A. baumannii isolates were collected. Six were from six patients from the burns unit and one was an environmental isolate, collected in the surgery block during systematic air sampling. PCR experiments using primers specific for the bla OXA-58 gene gave positive results for the seven carbapenem-resistant A. baumannii isolates. These carbapenem-resistant A. baumannii isolates had the same bla OXA-58 -positive plasmid of ca. 30 kb after plasmid extraction and hybridization with the bla OXA-58 probe. Genotypic comparison was performed for evaluating clonality of the isolates. Pulsed-field gel electrophoresis (PFGE) was realized after digestion of whole-cell DNAs with ApaI restriction enzymes. PFGE analysis showed that the six carbapenem-resistant isolates from patients corresponded likely to a single clone, whereas the isolate from the environment, that was also bla OXA-58 positive, was of a different genotype. Identification of the same bla OXA-58 -positive plasmid in two different clones of A. baumannii indicated the spread of this plasmid. This study constitutes the second description of an outbreak of carbapenem-resistant A. baumannii producing a plasmid-encoded carbapenem-hydrolyzing oxacillinase, after that of OXA-23-producing A. baumanniistrains in Brazil. As observed for the other carbapenem-hydrolyzing oxacillinase genes, bla OXA-58 was not present in the form of a gene cassette in a class 1 integron, but associated with insertion sequences. Thus, spread of a novel ␤-lactamase-mediated resistance mechanism was identified, underlying emergence of novel carbapenem-hydrolyzing enzymes in A. baumannii.

Fillaux J a , Dubouix A a , Daude S a , Archambaud M a , Segonds C a , Conil C c , Laguerre J b , Marty N a . a Bactériologie-Hygiène, France, b Brulés, France, c Réanimation, CHU RANGUEIL, Toulouse, France Introduction: Acinetobacter baumannii is essentially a skin commensal which can turn into an opportunistic pathogen responsible for real outbreaks, particularly in intensive care units. In the recent past, multi-resistant A. baumannii strains have been described. During 2003 summer, an A. baumanni outbreak resulting in colonisation and infection was observed in our hospital. Amongst the isolated strains, none displayed the "national epidemic" clone producing the VEB-1 extended spectrum betalactamase (ESBL). The multiresistant strains we observed had thus two characteristic antibiotypes: in the intensive care unit, strains were exclusively susceptible to imipenem, tobramycin and amikacin while in the Burn unit, strains were only susceptible to amikacin.

Objectives: The aim of this work was to investigate whether the multiresistant strains had been already present in our hospital previously to the 2003 outbreak.

Methods: We listed all the clinical samples that had been positive for A. baumannii between 1 January 2000 and 31 December 2003. The multiresistant strains were then submitted to pulse-field gel electrophoresis after digestion by Sma I and Apa I enzymes and clinical characteristics were noted. Statistical analysis was performed using chi squrae test and Fischer's exact test.

Results: Amongst the 793 clinical isolates found, 149 (18.8%) corresponded to the following multi-resistance criteria: (1) susceptibility to imipenem, tobramycin and amikacin, (2) exclusive susceptibility to amikacin, (3) exclusive susceptibility to imipenem, (4) resistant to all antibiotics tested. The resistant strains were more likely isolated in the intensive care unit (60%). However, clinical samples were from various origins: non protected respiratory samples (43%) as well as blood cultures (5%). Simultaneous analysis of pulsotypes and antibiotypes was able to highlight that the outbreak observed in the intensive care unit could be linked to an initially endemic clone that had been isolated from 2001 and was responsible for the four previously mentioned antibiotypes. In the same manner, a second clone responsible for an ESBL phenotype was sporadically present in our institution. However, the strains isolated in the Burn unit were also genetically related one to each other, but the specific clone responsible appeared only in 2003.

Conclusion: This study allowed us to put in evidence the existence that several multi-resistant clones can endemically co-exist during several years and can only be detected thanks to acute survey of epidemic sources.

Honoré S a , Lascols C a , Legrand P a , Soussy CJ a , Cambau E a,b . a Bactériologie-Virologie-Hygiène, France, CHU Henri Mondor APHP, Créteil, France, b Bactériologie-Hygiène, France, CHU Pitié Salpêtrière APHP, Université De Paris, France

Plasmid-mediated resistance to quinolones was recently described in Klebsiella pneumoniae and Escherichia coli and is due to the QNR protein that protects DNA gyrase from quinolone inhibition. Prevalence of qnr is between 2% and 11%, referring first studies in China, Spain and USA, and is unknown in France. The strains harbouring qnr gene are usually producing plasmid-mediated AmpC-type-␤-lactamase (PCase) or extended spectrum ␤-lactamase (ESBL). We have screened 478 nalidixic acid (Nal) resistant enterobacterial strains isolated in Henri Mondor hospital between 2002 and 2004 (316 Escherichia coli,100 Klebsiella pneumoniae, 28 Enterobacter spp., 20 Citrobacter freundii, 9Serratia marcescens, 3 Proteus and 2 Providencia) for the presence of qnr gene by PCR using specific primers amplifying an intragenic 543 bp fragment. Among them, 58 had a phenotype in concordance with a ESBL and three with a PCase. Nal-S strains (n = 20) were tested as negative controls. Positive control was the original strain K. pneumoniae UAB1. Each strain for which the PCR was positive was tested with two other couples of primers generating a 627 or a 661 bp intragenic fragment of qnr. PCR products when obtained were sequenced. Among the 478 strains, 441 were PCR negative, 33 were PCR positive with the first couple of primers, three of them were PCR positive with two couples of primers, and only one strain was positive with the three couples of primers. For all the strains except the latter one, PCR products did not have the expected size and sequences were different from qnr. For the only strain that was positive with the three couples of primers, the sequence of the PCR products was identical to qnr excepted one base, resulting in a silent mutation. This strain was an Enterobacter cloacae with a high level of resistance to ciprofloxacin and had a ESBL phenotype. We described the first strain ofEnterobacter cloacae that harbours the qnr gene known to mediate plasmid-borne quinolone resistance. This was the only strain among 478 enterobacterial strains tested, resulting in a prevalence of 0.2% in this serie. Large scale survey among hospitals with investigation of all the enterobacterial species will be necessary to confirm this low prevalence rate of qnr in France.

Mammeri H a , Van De Loo M a , Poirel L a , Martinez-martinez L b , Nordmann P a . a Service de Bactériologie-Virologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France, b Department of Microbiology, University Hospital Marquès de Valdecilla, Santander, Spain Objectives: Although quinolone resistance results mostly from chromosomal mutations, recent surveys indicated that such resistance may be mediated by a plasmid-encoded qnr gene in Enterobacteriaceae. Thus, 297 nalidixic-acid resistant Escherichia coli clinical isolates (out of a total of 2700 E. coli isolates) that had been isolated at the Bicêtre hospital (France) were screened for qnr by PCR.

Results: A single E. coli isolate was identified that carried a ca. 180 kb conjugative plasmid pQR1 harboring a qnr determinant. It conferred lowlevel resistance to quinolones and was associated with a chromosomal mutation in the subunit A of the topoisomerase II gene. The qnr gene was located on a sul1-type class 1 integron just downstream of a CR1 element comprising the Orf513 recombinase. Promoter sequences for qnr expression overlapped the extremity of CR1, thus indicating the role of CR1 in expression of antibiotic resistance genes. This sul1-type integron was different from other qnr-positive sul1-type integrons identified in American and Chinese enterobacterial isolates. In addition, plasmid pQR1 carried another class 1 integron that was identical to In53 from E. coli. In53 possessed a series of gene cassettes including those coding for the extended-spectrum ␤lactamase VEB-1, the rifampin ADP ribosyltransferase ARR-2, and several aminoglycoside resistance markers.

Conclusion: This is the first report of plasmid-mediated quinolone resistance in Europe that was associated with an unknown level of plasmid-mediated multiresistance in Enterobacteriaceae.

Type II topoisomerase genotype of quinolone-resistant clinical isolates of Escherichia coli isolated in France Lascols C a , Attalah L a , Soussy CJ a , Cambau E a,b . a Bactériologie-Virologie-Hygiène, CHU Henri Mondor APHP, Créteil, France, b Bactériologie-Hygiène, CHU Pitié Salpêtrière APHP, Université De Paris, France

The aim of the study was to seek for mutations of the DNA gyrase and topoisomerase IV genes involved in quinolone resistance in clinical strains of Escherichia coli isolated from multicenter studies. The strains studied were 74 clinical isolates including 33 nalidixic acid (Nal)-resistant (R) and ciprofloxacin (Cip) R, one NalR Cip-intermediate (I), 40 NalR Cipsusceptible (S). Mutations in the quinolone-resistance-determining region (QRDR) of the four topoisomerase genes (gyrA, gyrB, parC and parE) were assessed by PCR sequencing.

Mutations known to be associated with quinolone resistance were shown in all the strains but one. gyrA mutations were Ser83Leu (n = 68) or Ser83Ala (n = 2), Asp87Asn (n = 31), Asp87Tyr (n = 4) or Asp87Gly (n = 3); parC mutations were Ser80Ile (n = 28) or Ser80Arg (n = 5), Glu84Lys (n = 7) or Glu84Gly (n = 1). parE mutation (Leu445His) was found in two isolates whereas no isolate harboured mutations usually described in gyrB. Among the 34 NalR CipR strains (geometric mean MIC [MICg] Cip = 19.3 mg/L), 31 strains (91.2%) had three QRDR mutations (two gyrA + one parC) (MICg Cip = 19.6 mg/L), one strain had four mutations (two gyrA + one parC + one parE) (MIC Cip = 16 mg/L), and one strain had two mutations (one gyrA + one parC) (MIC Cip = 16 mg/L). Among the 40 NalR CipS strains (MICg Cip = 0.19 mg/L), 31 strains (77.5%) (MICg Cip = 0.15 mg/L) had one mutation in gyrA, six strains (MICg Cip = 0.6 mg/L) had two mutations (one gyrA + one parC) and two strains (MICg Cip = 0.25 mg/L) had three mutations (two gyrA + one parC). No mutation in the QRDRs was observed for only one strain (MIC Cip = 0.25 mg/L). Unknown mutations were also observed ingyrB (Ser492Asn for nine NalR CipR and three NalR CipS strains), in parC (Ser57Thr for two NalR CipR and one NalR CipS strains) and in parE (Leu416Phe for three NalR CipR strains). This study showed that NalR clinical isolates of E. coli, either CipS or CipR, harboured at least one mutation in the topoisomerase genes (gyrA, gyrB, parC and parE) and that NalR CipR isolates harboured the association of mutations in two or three of these genes. Whereas we did not find any gyrB mutant, we described the first clinical isolate harbouring the parE mutation Leu445His. Unknown mutations observed in gyrB, parC and parE should be investigated for their involvement in quinolone resistance. Travellers in tropical countries import in France more than 5000 P. falciparum (Pf) isolates annually from which 10-15% are sent to us for typing. Isolates from symptomatic patients without previous drug intake (HPLC measurement) are selected for drug susceptibility testing with in vitro tests (1993-2004, n = 1100) and with molecular markers (1996-2004, n = 2900) . Characteristics of corresponding patients are similar over the years, including: African natives (71%); living in France (86%); travelling in Africa (98,9%); returning either from Cameroon, Cote d'Ivoire, Senegal, Mali or Comoros (68%); mean age (32 years); children under 15 years of age (14%); and sex ratio (M:F = 1.78). Among these, prevalence of Pf chloroquine resistance (in vitro IC 50 > 100 nM) is 0.41 in 1993-2002, and 0.55 in 2003-2004 ; prevalence of Pf cycloguanil resistance (in vitro IC 50 > 500 nM or DHFR mutation S108N) is 0.28 in 1993-1996, 0.51 in 1997-2002, and 0.62 in 2003-2004 . Foot-step increase of Pf resistance was observed for the two antimalarials. These results are used on an annual basis to adjust prophylactic recommendations for travellers to each endemic country (invs.sante.fr/beh/). Following WHO guidelines for use of antimalarials, we consider now a prevalence of 0.25 of resistance to chloroquine plus cycloguanil in Pf from an endemic country as the upper limit for recommending prophylactic use of the association (countries with Pf resistance of group 2): Togo and Benin exceeded this limit in 1996 -1997 and Senegal in 2003 -2004 . Prevalence of Pf resistance to mefloquine, atovaquone-proguanil or doxycycline is still under 0.25 in all endemic countries and are recommended for prophylaxis in countries with chloroquine plus cycloguanil Pf resistance >0.25 (countries of group three). Indirect evidence for efficiency of these recommendations is gained from the figure of 15 travellers among 728 Pf attack analysed by CNRCP in 2003 having correctly followed them (2%). Since the 1999 French consensus, chloroquine or sulphadoxine-pyrimethamine are no longer used for Pf treatment. Quinine resistance has only been detected in this period in few Pf isolates from Asia and no chloroquine failure was suspected in imported Plasmodium vivax, ovale or malariae.

Musset L, Massias L, Matheron S, Bouchaud O, Le Bras J, Corresponding Group. Hôpital Bichat-Claude Bernard, CNR Chimiosensibilité du Paludisme, Laboratoire de Parasitologie, Paris, France

In 1999, marketing of atovaquone-proguanil (Malarone ® ) expanded the very limited range of antimalarial drugs with low falciparum resistance. The combination is indicated for malaria prophylaxis in areas with chloroquine resistance and for treatment of uncomplicated P. falciparum malaria. Since 2002, both indications gained increased favour of French physicians and travellers, owing to it is good tolerance. From the beginning of prescription in Europe and North America, six therapeutic failures were published yet, one early therapeutic failure (ETF) and five late one (LTF). In three cases, failure was confirmed by blood drug dosage. A unique mutated codon (268) on the parasite target of atovaquone, cytochrome b, was present in 4/6. Association between therapeutic failure and cytochrome b mutation needs further confirmation. This last two years, we were informed of 251 atovaquone-proguanil treatments in travellers contamined mostly in West Africa and Comoros. From 148 cases with clinical follow up files, five failures were recorded, three ETF and two LTF. Isolates were analysed by dosing d 3 residual drugs in plasma, measuring in vitro atovaquone susceptibility and sequencing d 0 and d fail cytochrome b gene. In two cases, bad observance and/or poor absorption is the likely failure explanation. Two out of three isolates from true therapeutic failure presented with a single mutation causing amino acid change, respectively: M116I and Y268S. This compare to a series of 85 isolates, without known failures, in which only one mutation (codon 314) was identified. These results confirm high conservation of the Plasmodium cytochrome b house keeping gene. Three other failure cases require more analysis to conclude. In spite of fast resistance emergence when atovaquone was used alone, its combination with proguanil exhibited satisfactory efficacy, tolerance and safety. Drug resistance associated with mutations on the cytochrome b gene leading to therapeutic failures of P. falciparum are yet rarely encountered with atovaquone-proguanil.

Illnesses in travellers returning from the tropics: a prospective study of 622 patients Objectives: Each year about 50 million people travel from industrialised countries to developing countries. Although between 8% and 19% of travellers consult a doctor after returning from the tropics, the full spectrum of health complaints is unknown.

Methods:We analysed the relative frequency of travel-associated health complaints in all travellers (immigrants, expatriates, business travellers and tourists) consulting our department between November 2002 and May 2003.

Results: A total of 622 patients were studied [256 women, 366 men; median age 38 years; 282 tourists (45.3%), 210 immigrants (33.8%), 88 expatriates (14.1%), 42 business travellers (6.7%)]. The median duration of travel was 36.9 days. The main destinations were Africa (57.6%) and Asia (26.4%). A total of 637 diseases were diagnosed, distributed as follows: skin diseases (23.4%), gastrointestinal infections (19.1%), respiratory tract infections (11.5%), malaria (8.8%), viral hepatitis (4.1%), urinary tract infections (3.4%), sexually transmitted infections (3.4%), dengue fever (2.5%), tuberculosis (2.7%), and others (13.8%). 257 travellers consulted for fever. Malaria and intestinal tract infections accounted for 21% and 23% of diagnoses in these patients, respectively. Malaria was associated with travel in Africa (p = 0.001) and immigrant status (p < 10-4), while respiratory and urinary tract infections were associated with tourist status (p < 10-4 and =0.02 respectively) and dengue fever with travel in Asia (p = 10-3). Overall, 230 diagnoses (36.1%) corresponded to imported tropical diseases, the main imported diseases being malaria, schistosomiasis, amebiasis, gastrointestinal disorders caused by intestinal nematodes, and dengue fever.

Conclusions. Tropical diseases are not the leading cause of consultation in travellers returning from the tropics. With the noteworthy exception of dengue fever and invasive schistosomiasis, immigrants visiting their home countries are the travellers most at risk of common tropical diseases.

A post-marketing study (PMS) to confirm the cardiac safety profile of IZILOX ® Veyssier P b , Voiriot P c , Bégaud B a , Brentano CF d , a Unité de Pharmaco-Epidémiologie, Université Victor Segalen, Bordeaux, France, b Service de Médecine Interne, Centre Hospitalier, Compiègne, France, c Unité de Pharmaco-Epidémiologie, Vandoeuvre Les Nancy, Nancy, France, d Service de Pharmacologie Clinique, Hôpital Saint Antoine, Paris, France Background: As mentioned in the Summary of Product Characteristics (SPC), ECG analysis done in clinical trials showed that PO moxifloxacin (Izilox ® ) resulted in QT prolongation in some subjects (mean: 6 ms ± 26, 1.4% relative to initial value). To confirm the Izilox ® cardiac safety profile, we carried out a PMS study.

Methods: Prospective observational study in infected adults treated with Izilox ® in usual medical practice. The subject observation period included the treatment duration with Izilox ® + a 3-day follow-up after end of therapy (EOT). To assess the Izilox ® cardiac safety profile, type and incidence of critical adverse events (AE) were analyzed by an independent Expert Committee (EC). These events were defined as any clinical event potentially surrogate of ventricular rhythm disorder consequent to QT prolongation. They were assessed as events of documented cardiac origin (confirmed by additional exams/ECG), not documented cardiac origin (strong clinical presumption but no additional exam/ ECG) or extra-cardiac origin. After the initial visit, all subjects (subj.) were followed for any AE occurrence up to 3 days after EOT.

Results: Of 13,578 ITT subjects (mean age 51 ± 17, females 49%) 54%, 37% and 8% were treated for acute sinusitis, acute exacerbation of chronic bronchitis and community acquired pneumonia respectively. A total of 1046 AE (678 subj., 5%), mainly gastro-intestinal disorders, was reported. 854 AE (564 subj., 4.15%) were assessed as drug-related. Of the 1046 AE, 189 were considered to be critical events (159 subj., 1.2%) by the EC. An extra cardiac origin was assessed for 154 AE, a documented cardiac origin was assessed for 1 AE (not drug-related), and a not documented cardiac origin was assessed for 34 AE (28 subj., 0.21%). Of those 34 AE, 25 (19 subj., 0.14%) were considered drug-related: palpitations (n = 13) tachycardia (n = 4) malaise (n = 4) vertigo (n = 3) pallor (n = 1). Nineteen (13 subj., 0.10%) of these 25 AE led to Izilox ® discontinuation; all the 25 AE resolved.

Conclusions: This PMS study indicates that Izilox ® clinical safety profile was similar to that previously known with no unexpected adverse effects identified and was consistent with the current SPC. No clinically severe drug-related adverse event of cardiac origin was observed. Methods: The consumption of antibacterials using ATC/DDD classification (WHO version 2004) was expressed in DDD/1000 inhabitants per day (DID). The number of packages of antibiotics was provided by the Institute of Public Health of the Republic of Slovenia. Published articles including the key words "antibiotic drugs" and "bacterial resistance" in proceedings of annual national scientific meetings (five), national medical journals (four), national newspapers and magazines (six), one TV station and Slovenian website were included in analysis from 1996 to 2003. In 1999 the Health Insurance Institute of Slovenia which covers healthcare costs for over 99% of population introduced restrictive measures for prescription of amoxicillin/clavulanic acid and fluoroquinolones.

Results: The total outpatient consumption of antibacterials increased from 15.21 DID in 1996 to 20.08 DID in 1999, falling to 16. 33 DID in 2002 and again increasing to 16.97 DID in 2003 . The consumption of nonrestricted antibiotics increased from 10.87 DID in 1996 to 12.78 DID in 1999, falling to 10.75 DID in 2002 and increasing to 11.72 in 2003. The consumption of restricted antibiotics has been decreasing continuously from 7.29 DID in 1999 to 5.25 DID in 2003. The total number of published articles in professional journals and newspapers was 84 and 67, respectively. There were 35 TV communications and 1866 websites found. On a year-to-year basis there was a strong correlation between the number of newspaper articles and the total antibiotic consumption (r = 92).

Conclusion: Restriction of antibiotic prescription was followed by a decrease in the consumption of restricted antibiotics. The non-restricted antibiotic consumption has also been decreasing for 3 years with an increase in the fourth year. There was a correlation between paper media coverage and total antibiotic consumption.

Targeted surveillance of antibiotic prescription-a clinical governance design Northwick Park Hospital, Harrow, Middlesex, UK, b Pharmacy and Microbiology, Peterborough District Hospital, Peterborough, UK Introduction: This is the contribution of a busy District General Hospital to the national fight against misuse of broad spectrum antibiotics. We re-alised that targeting a few key intravenous broad spectrum antibiotics-viz. meropenem, ceftazidime, ciprofloxacine, amikacin, piperacillin, vancomycin and teicoplanin-would produce significant impact on clinical prescription and cost without resulting in excessive workload. The programme should be clinically driven as a guarantee that the anticipated reduction of antibiotics would not harm the patients.

Methods: The study is action research intended to change prescription culture over time. The seven selected antibiotics count for 40% of the hospital intravenous antibiotic expenditures. The WHO principles of Clinical Governance are used to measure programme outcomes: Professional performance: compliance with programme by reducing empiric antibiotic therapy Resource use: reduction of antibiotic expenditures. Risk management: prevalence of resistant micro-organisms Patients satisfaction: no increase in mortality The concept of the programme was introduced in 1998 and a formal programme was launched in 2001.

Results: Due to excellent compliance the prescription culture was changed towards antibiogram guided prescriptions.The cost reduction was beyond the most optimistic predictions. Actually, the cost in 2002 was reduced to the same level as in 1996. The estimated savings are about £ 1 million. The prevalence of resistant organisms-Staphylococcus aureus, Enterococci, Pseudomonas, Enterobacteria and yeast-were remarkable unchanged in contrast to the all over increase from 1996 through 1998. The same trend was seen regarding specific antibiotic resistance against gentamicin, ciprofloxacin, piperacillin, ceftazidime, teicoplanin and vancomycin.

No increase in mortality was detected except for neutropenic patients. It may be related to a change of the prophylactic antibiotic protocol.

Conclusion: A simple antibiotic programme targeting seven selected broad spectrum antibiotics has changed prescription culture and provided significant financial savings. The hospital flora was unchanged and no harm to patients were seen. Neutropenic patients showed an increase in mortality. It may be unrelated to the programme.

Besnier JM e , Rodon P a , Bastides F e , Prazuck T b , De Jong W e , Michelet C d , Raffi F c , Autret-leca E e , Paintaud G e , Choutet P e , Le Guellec C e . a Hôpital, Blois, France, b Hôpital Universitaire, Nantes, France, c Hôpital, Orléans, France, d Rennes, France, e Hôpital Universitaire, Tours, France Background: Adequate NFV plasma level is required to maintain maximal HIV suppression. However, because of variable food-effects, evening trough concentrations (C 0 ) can be lower than morning C 0 . We developed a pharmacokinetic (PK) model to predict evening trough concentration from morning one.

Methods: Fifty-two pts receiving NFV bid or tid for ≥3 months were prospectively studied. The composition of the meal before last drug intake and of the breakfast on the day of the study was graded according to the nature and the amount of food. Two blood samples were taken just before the morning dose (morning C 0 ) and at a second randomly selected time after drug intake (from 1 to 12 h post-dose). Serum NFV concentrations were measured by HPLC. Individual concentrations (posthoc, NONMEM) were first fitted using population PK parameters from published studies without covariates. To test wether meal composition or morning/evening intake could explain the difference between observed and predicted concentrations, we evaluated additional models in which bioavailability for each drug intake was set at different values based on published description of the impact of these factors on NFV PK.

Results: Median morning C 0 was 1.48 mg/L (0.04-5.53). The other concentrations measured at various times after the morning dose ranged from 0.05 to 6.02 mg/L. The model including the combined impact of meal and diurnal factor [bioavailability set to 1 (evening/rich meal), 0.8 (evening/light or no meal), 0.6 (morning/rich breakfast) or 0.4 (morning/light or no breakfast)] provided the best description of individual PK, thus enabling estimation of concentration-time course over the dosing interval. Using this model, median estimated evening C 0 was 0.62 mg/L (0.10-3.50), or 60% (7-130) of morning C 0. From the 41 pts (79%) whose morning C 0 was above the target concentration (1 mg/L), only 16 (31%) were still above it at the time of the evening dose.

Conclusions: Using a model which takes into account the composition of meals, evening C 0 can be predicted with only two blood samples, of which a morning C 0 , thus providing the basis for medical advice about optimal NFV intake or dosage modification when the predicted evening trough concentration is <1 mg/L despite adequate morning C 0 .

Single intravenous application of 500 mg levofloxacin results in high liver tissue concentrations Weinrich M a , Scheingraber S a , Stremovskaia T b , Schilling MK a , Kees F c , Pistorius GA a . a Department of General, Visceral and Vascular Surgery, Germany, b Institute of General and Special Pathology, University Hospital of the Saarland, Homburg/Saar, Germany, c Institute of Pharmacology, University of Regensburg, Regensburg, Germany Introduction: A broad spectrum potency on gram-positive and -negative germs is characteristic of levofloxacin. High levels of levofloxacin in tissue and body fluids, including the gallbladder and bile have been repeatedly reported. Yet there are no studies on penetration of levofloxacin into human liver tissue.

Patients: From May to November 2003, 28 patients (13 f/15 m) were given a prophylactic intravenous antibiotic treatment with 500 mg levofloxacin (Tavanic ® ) during induction of general anesthesia for liver resection. Levofloxacin blood levels were determined approximately 60 min after infusion and after liver resection. A sample was also derived from healthy liver tissue of the resected specimen. In addition to this the tissue was examined histopathologically to determine the grade of cirrhosis (Ishak score) and steatosis.

Results: Levofloxacin levels in the liver tissue were 18.1 ± 5.4 g/g (mean ± standard deviation) with corresponding serum levels of 6.6 ± 1.7 g/ml 71 ± 14 min after infusion and 4.8 ± 1.4 g/ml after resection (159 ± 51 min after infusion). The tissue/serum ratio of 3.8 at the time of resection proves that good liver tissue penetration takes place. The tissue concentration showed a significant correlation to serum levels and BMI as well as inversely to the grade of steatosis. Without exception the determined levels were above the MIC of common germs found in liver abcess and bilary tract infections. Infectious postoperative complications were not observed.

Conclusion: Levofloxacin penetrates liver tissue exceptionally well and is therefore an optimal agent for the treatment of hepato-bilary infections caused by levofloxacin sensible germs. Oral application of levofloxacin reduces costs drastically but not the effect because intravenous and oral application are equally bioavailable.

The aim of this study was to investigate imipenem distribution in muscle and lung interstitial fluids by microdialysis in rats, and to compare free tissue concentrations with free concentrations in blood. Microdialysis probes were inserted into jugular vein, hind leg muscle and lung. Imipenem recoveries in these three media were determined in each rat by retrodialysis by drug before drug administration. Imipenem was infused intravenously at a dose of 120 mg/kg over 30 min and microdialysis samples were collected during 150 min. The whole study was conducted under isoflurane anaesthesia in non hydrated rats (n = 4) and hydrated rats (n = 6). Decay of free concentrations in blood, muscle and lung with time were monoexponential and concentrations profiles in these three media were virtually superimposed in both groups. Accordingly, AUC tissue (muscle or lung) to blood ratios were always virtually equal to 1. Compared to values previously determined in awake rats, clearance was respectively reduced by 2 and 1.5 in non-hydrated and hydrated rats, but volume of distribution was unchanged. Imipenem distribution in rats was investigated with success using microdialysis in tissues associated with intravascular microdialysis. Free concentrations in both tissues were equivalent and could be predicted from free blood concentrations.

Boisson K, Hocquet D, Patry I, Plesiat P, GESPA Group. Bacteriologie, CHU, Besancon, France Background: Combination therapy is recommended in serious Pseudomonas aeruginosa infections in order to rapidly clear bacterial inoculums and to prevent the emergence of resistance.

However, assessment of drug interactions by standard methods (checkerboard, killing curves) is time consuming and operator-dependent. Here, we report a simple E-test method for the study of drug combinations on bacteremic P. aeruginosa.

Methods: Synergism between (i) piperacillin/tazobactam (TZP) or ceftazidime (CAZ) and (ii) amikacin (AN) or ciprofloxacin (CIP) was tested on 110 genotypically distinct bacteremic P. aeruginosa isolates from six French university hospitals (GESPA participants). E-test strips were set side by side (TZP/AN, TZP/CIP, CAZ/AN, CAZ/CIP), MIC against MIC, onto Mueller Hinton agar plates inoculated with standardized incoculums. After 1 h at room temperature, the AN and the CIP strips were removed and the plates were incubated 24 h at 37 • C. Synergism was defined as a decrease of ©¬−lactam MIC ≥ 2 dilutions in the presence of 1 MIC of AN or CIP. Drug combinations found strongly synergistic with the E-Test method were reevaluated with the checkerboard technique.

Results: Drug interactions were synergistic, indifferent/additive, or antagonistic in 40 (36.3%), 70 (63.7%), and 0 strains, respectively. Overall, the ©¬−-lactam/AN combinations were more often synergistic (30%) than the ©¬−-lactam/CIP combinations (11.8%). The synergistic rates were 29.2% for TZP/AN, 16.9% for CAZ/AN, 10.4% for TZP/CIP and 7.5% for CAZ/CIP. Synergism occurred essentially in strains resistant to both of the paired antibiotics compared with fully susceptible strains: 100% versus 7% for CAZ/AN, 58.5% versus 15.3% for TZP/AN, 26.6% versus 3% for CAZ/CIP, and 20% versus 4.5% for TZP/CIP. The results of the E-test method for detecting synergism appeared to agree fairly well with those from the checkerboard technique (17/20 strains).

Conclusion: The side-by-side E-test method offers many advantages for routine determination of drug interactions on P. aeruginsoa. It is easy to perform and provides reliable, reproducible results within 48 h. Our study confirms that interactions are synergistic mostly on strains resistant to the combined drugs.

Change of susceptibility rates with time or location: how does it impact on predictive values of disk diffusion susceptibility testing reports? Introduction: Antimicrobial disk diffusion susceptibility testing is devoted in a clinical context to predict whether an antibiotic regimen will be effective. Test performance should be evaluated through predictive values of a report, i.e. the test ability to predict true-S, true-I, true-R isolates. This approach implies that variation of susceptibility prevalence (frequency of susceptible, intermediate and resistant isolates) affects the predictive value of a result, simply because the level of discrepancies will vary with the prevalence of S, I, R categories. The prevalence effect is traditionally taken into account through positive and negative predictive values, but has never been evaluated with three-class result tests such as agar diffusion based susceptibility testing.

Aim: This study presents two simulated examples (co-amoxiclav and lomefloxacin) to illustrate the impact the susceptibility prevalence variation may have on the performance of the disk diffusion method.

Methods: We developed tools for evaluating quality prediction of a result and we quantified the influence of the susceptibility prevalence variation on the disk diffusion method performance through a modelling approach. For each antimicrobial agent, simulations based on a resampling procedure were performed from minimum inhibitory concentration/diameter experimental datasets. Experimental variability on minimum inhibitory concentration and diameters was taken into account in the simulations.

Results: The results show that prevalence impacts on the disk diffusion method performance and may be quantitatively noteworthy for some antimicrobial agents considering the prevalence variations recorded with time, location and type of species.

Conclusions: Consequences of these results on zone diameter breakpoint determination policy are raised. This implies the following should be considered (i) take into account more rigorously the susceptibility prevalence in studies dealing with zone diameter breakpoint determination and performance evaluation, (ii) re-evaluate disk diffusion breakpoint consistency when the weight of prevalence variation is noteworthy, (iii) estimate consequences of a breakpoint international consensus on prediction quality and appropriate patient management.

Giannitsioti E, Vorou R, Galani I, German V, Koratzanis E, Souli M, Orlandou K, Greka G, Giamarellou H. University General Hospital ATTIKON¨, 4th Department of Internal Medicine, University of Athens, Athens, Greece Objectives: To evaluate the sensitivity of disk diffusion test with cefoxitin (30 mcg) in the detection of methicillin resistant CNS compared with minimal inhibitory concentration test (MIC) since during the last decade CNS emerged as significant clinical pathogens in serious infections.

Methods: Susceptibility tests were performed after determining MIC test according to NCCLS guidelines and cefoxitin disc of 30 gr (Kirby Bauer, BD sensi-disc; Becton Dickinson) in 35 • C. An inhibition zone diameter ≤24 mm indicated methicillin resistance whereas>24 mm indicated methicillin sensitivity according to NCCLS guidelines. All strains with MIC 0.5-1 g/ml were investigated for the presence of mecA gene with PCR using mec A1(5 -AAATCGATGGTAAAGGTTGGC-3 ) and mec A2 (5 -AGTTCTGCAGTACCGGATTTGC-3 ) primers.

Results: From a total of 380 CNS isolates, 128 (33%) were methicillin sensitive (MIC ≤ 0.25 g/ml) and 205 (53%) methicillin resistant (MIC ≥ 2 g/ml) while 47 (14%) presented with a range of 0.25 g/ml < MIC <2 g/ml. In 137 isolates with MIC ≥ 2 or MIC ≤ 0.25, cefoxitin disc (30 g) inhibition zone diameter and MIC were correlated as follows: Nocardiosis is an infection associated with severe morbid conditions especially in immunocompromised patients. The diagnosis, presently based on direct examination and conventional cultures, is difficult, time consuming and often delayed or prevented due to the relatively slow growth of these bacteria, and the empiric therapeutic decision before sampling. The objective of this study was to develop a PCR-based assay for the rapid detection of Nocardia directly from human clinical samples. The technique consisted in a 16S-specific amplification combined with a chemiluminescent hybridization. The probe was obtained by PCR from DNA of the type strain Nocardia asteroidesATCC 19247 T . DNA extraction and amplification from specimens (bronchoalveolar liquid, skin biopsy and cerebral abscess) seeded with serial dilutions of Nocardia asteroides ATCC 19247 T allowed the evaluation of the analytical sensitivity of the assay which reached 10 3 CFU/reaction after agarose gel electrophoresis and 1 CFU/reaction after transfer and hybridization. The applicability of the PCR assay to diagnose human nocardiosis was evaluated by investigating eighteen clinical human samples. For patients with nocardiosis confirmed by conventional cultures, clinical specimens were positive with a sharp chemiluminescent signal after hybridization. No amplification was observed for 20 clinical samples from patients with confirmed tuberculosis used as a negative control. These results highlighted the high specificity and sensibility of the PCR protocol presented in this study. It appeared useful in the rapid diagnosis of nocardiosis directly from clinical samples without culture, resulting in timely and appropriate clinical management that can amount to significant savings for patients. and this technique became current in routine. We tested hybridization protected ARNr or HPA (Gen-Probe) compared to standards techniques (direct immunofluorescence) (Direct IFD) for C. trachomatis, examination and culture for N. gonorrhoae). The doubtful or conflicting tests were confirmed by a technique of competition (PCA). We studied 208 patients (144 endo-cervical samples and 64 urethral samples). Our results were analysed statistically. In woman, 21 cases of C. trachomatis were diagnosed (14.58%) and two cases of N. gonorrhoae (1.38%). In man, 10 cases of C. trachomatis were diagnosed (15.62%) and five cases of N. gonorrhoae (7.81%). In conclusion, the technique of HPA enabled us to improve the diagnosis of these two types of bacteria, which could be underestimated by the standards methods. Objective: Rapid appropriate antibacterial treatment is important to improve the prognosis of methicillin-resistant Staphylococccus aureus (MRSA) bacteremia. RT-PCR can identify S. aureus (Sa) and detect methicillin resistance. We used it directly in positive blood culture (BC) bottles with Gram positive cocci (GPC) upon direct smear examination (DSE) to provide clinicians with fast and accurate results and evaluate the impact of these results on treatment changes and appropriateness.

Methods: Between March and August 2004, we analysed the first positive BC bottle in all the 415 patients with staphylococci bacteremia. DNA was extracted when positivity with GPC was detected upon DSE using a quick and cheap 10 min procedure. Extracts were used as templates for a new triplex RT-PCR targeting fem, mecA and 16S rRNA genes. PCR inhibitors such as charcoal were eliminated. Overall turnout of the assay was 90 min. Results of PCR were not transmitted to the clinicians but results obtained in parallel by standard bacteriological techniques were transmitted following usual procedures. All antibiotic treatment changes at time of BC positiveness and 48 h thereafter were recorded.

Results: 32 BC were positive for MRSA and 66 for methicillinsusceptible Sa (MSSA), 1 for MRSA and MSSA, 188 for MR coagulase negative staphylococci (CNS), 116 for MS-CNS, 4 for MR-CNS and MS-CNS, 7 for Micrococcus sp. Sensitivity and specificity of RT-PCR for the diagnosis of MRSA, and MSSA was 100%. Detection of GPC in BC upon DSE in 387 patients induced immediate treatment changes in 22.5% of the 187 that were already treated, and initiation of therapy in 25.5% of the 200 that were not treated. Upon results of cultures 48 h later, treatments were further changed in 14.5% patients. Among the patients with Sa positive BC 9.9% were not treated at time of DSE, 4.4% were inefficiently treated (oxacillin for MRSA), and 11% inappropriately (glycopeptide for MSSA).

Conclusions: Early availability of RT-PCR results may dramatically increase treatment adequacy in a fair proportion of patients with BC positive for GPC upon DSE.

Fluoroquinolone use and subsequent multidrug-resistant bacteria emergence in the intensive care unit Background: Staphylococcus aureus is the main cause of early-onset infection after liver transplantation (LT). The risk of infection is strongly associated with preoperative nasal carriage, particularly for methicillin-resistant S. aureus (MRSA). However, since MRSA carriers often have more advanced liver disease than non-carriers, a multivariate analysis is required to investigate whether nasal carriage is an independent risk factor for infection. The aim of this study was to identify independent predictors of early S. aureus infection in liver transplant recipients using a multiple logistic regression model.

Methods: We conducted a retrospective cohort study of 323 consecutive LT recipients. All patients were screened for S. aureus nasal carriage before surgery. Medical records were reviewed for preoperative and perioperative variables. Strains were typed by pulsed-field gel electrophoresis (PFGE). Univariate statistical analysis followed by stepwise logistic regression was performed.

Results (22 cases) were the most common out-patient specialties. 23.6% of in-patients were receiving intensive care, whereas PICU accounts for only 8% of hospital beds. Only 11(16.2%) of 68 cases of MRSA in out-patients since 2000 had not previously attended BCH in the preceding year. 41 episodes of MRSA bacteraemia occurred in 37 children (all in-patients when MRSA colonisation first documented). Overall, the risk of bacteraemia in in-patients colonised with MRSA was 13.9%. The risk was highest in the 2-5 years (19.0%) and 6-10 years (20.0%) age groups, and lowest in children aged >10 years (3.7%). The mean interval from first isolation of MRSA to onset of bacteraemia was 91.2 d (median 8 d; range 0-831 d). Intravascular devices accounted for 21 (51.2%) of bacteraemias. Overall, MRSA accounted for 15.0% of all Staphylococcus aureus bacteraemias, and for 30.2% of S. aureus bacteraemias on PICU. The mortality rate from MRSA bacteraemia was 7.3%, compared with 1.7% from MSSA bacteraemia (p = 0.07; Fisher's exact test).

Conclusions: Contrary to reports from other centres, we found no evidence that MRSA is becoming more common. Few cases were seen in children without a history of recent hospital attendance, suggesting that MRSA is not endemic in the community. Around one in seven children who acquire MRSA in hospital subsequently develop bacteraemia. Recognition that hospital acquisition of MRSA is most common in certain specialties can facilitate targeting of control measures.

Emergence of a new highly epidemic methicillin-resistant Staphylococcus aureus clone producing the toxic shock syndrome toxin, responsible either for hospital-acquired and community-acquired infections in France Two categories of methicillin-resistant Staphylococcus aureus (MRSA) clones harbouring the mecA gene can be detected in the community: (i) those that are considered as health-care associated and correspond to hospital clones; these MRSA strains are detected in patients with risk factors such as recent hospitalisation or contacts with health-care workers; (ii) those that have truly emerged in the community; these MRSA strains infect unusually younger patients without established risk factors for MRSA and share usually a Panton-Valentine leukocidin. We have characterized an emerging MRSA clone responsible either for hospital-acquired infections and communityacquired infections and containing the tst gene encoding the toxic shock syndrome toxin (TSST-1). One hundred and three strains of tst + S. aureus were collected from 42 cities by the French Reference Center for Staphylococci between 2002 and 2003 and were characterized by phenotypic and genotypic methods. Most of mecA + tst + strains (n = 25) harboured the accessory gene regulator (agr) two allele and only two strains had an agr 3 allele. A contrario most of mecA − tst + strains (n = 70) had an agr 3 allele and only five strains had an agr 2 allele. The clonal origin of all of the mecA + tst + agr 2 strains was demonstrated by determining the pulsotype, the sequence type (ST5), the antibiotic resistance profile, the type of staphylococcal chromosome cassette mec (SCCmec IV) and the toxinic profile. These strains were responsible of infections that occurred predominantly among children (median age = 3.3 years), either in hospitals and in the community. This clone may have arisen de novo through insertion of mecA gene into the mecA − tst+ agr 2 clone as demonstrating by comparing the pulsedfield gel electrophoresis types that differed by a single band shift due to insertion of the SCCmec IV. Our findings suggested that this MRSA clone probably did not emerge from the others pandemic MRSA clones ST5 such as New York/ Japan Clone.

In conclusion, a new highly epidemic MRSA clone producing TSST-1, responsible for nosocomial and community-acquired infections, has emerged by horizontal transfer of SCCmec type IV into a methicillinsusceptible clone and has spread all over France.

Halwani MH, Slack RS, Grundmann HG. Division of Microbiology & Infectious Diseases, University Hospital of Nottingham, Nottingham, UK Objective: To determine the incidence and the risk factors for endemic (non-outbreak situations) respiratory tract infection (RTI) in an Adult Intensive Care Unit (AICU).

Design: Prospective longitudinal study using daily surveillance and identification of bacterial isolates.

Setting: A 16 bed AICU of 1500-bed tertiary teaching hospital. Patients: All patients who stayed 48 h or more in AICU from January 2000 to April 2001. RTI was defined using Centre for Disease Control criteria (CDC).

Results: A total of 397 patients were eligible for the study and followed for 2889 patient days with a median length stay of 6 days. Forty-seven episodes of RTI were identified in 41 patients with an overall rate of 12% and an incidence (first incidence) of 14 per 1000 patient-days, respectively. The median length of stay to acquire the first episode was 5 days (range 2-86). Staphylococcus aureus 26 (63.4%) of which 21 (81%) were methicillin resistant (MRSA) and E.coli 5 (12%) were the most predominant pathogens involved. Logistic regression analysis identified four independent risk factors for endemic RTI. Those were exposures to ventilation [P < 0.001 OR 5.5 CI 2.4-13] and arterial lines [P = 0.03 OR 4.6 CI 1.14-19] throughout the patient's stay, bronchoscopy [P < 0.001 OR 3.2 CI 1.4-7.2] and ciprofloxacin [P < 0.001 OR 3.2 CI 1.5-11.5].

Conclusion: Prevention of RTI in AICU may depend on efforts to minimise these risk factors especially with regard to quinolone use and bronchoscopy.

Monclús D, Buendía B, Girón RM, Pérez de Ayala A, García-Peñuela E, López-Brea M. Microbiology, H.U. de la Princesa, Madrid, Spain Objectives: To evaluate the prevalence of infection and/or air way colonisation by MRSA from 2000 to 2004, in cystic fibrosis (CF) diagnosed patients, and to determine the susceptibility in respiratory isolates.

Methods: 42 patients with cystic fibrosis, 21 male and 21 female, with media age: 26.60 ± 6.69 years. 78.6% with pancreatic insufficiency. The patients came from the monographic unit of adults with CF. The sputum samples were cultured following standard microbiological procedures. Colonies quantification in OFPBL agar, saboureaud chloranphenicol agar, blood agar, chocolate agar, chocolate agar with bacitracin, MacConkey agar, mannitol salt agar and Gram stain was performed. Isolates were identified by conventional test and a automated system (Micro-scan, Dade-Behring) The antimicrobial susceptibility was determined by an automatic system (Micro-scan) and disk diffusion method according to NCCLS recommendations.

Results: The prevalence of infection by MRSA was 21.42%. It was isolated in nine patients, five females and four males, with a media age of 30.67 ± 9.15 years, and 88.9% with pancreatic insufficiency. The number of MRSA isolated in the nine patients during the study period was 42. 55.6% of patients were also colonizated by P. aeruginosa, 44.4% by S. aureus methicillin sensitive, and 22.2% by A. xilosoxidans. The antimicrobial susceptibility obtained is shown in the (100) Conclusions: A high frequency of MRSA colonisation was found in patients with cystic fibrosis. The 100% of MRSA strains were susceptible to glycopeptides and linezolid in vitro. The highest resistance rate was showed by ciprofloxacin and macrolides. Objective: Epidemiological studies done in the United States have demonstrated high hospitalisation and outpatient rates attributable to influenza in children between the ages of 6-23 months; rates being comparable to those seen in children with high risk conditions has led to recommendations for immunization in this age group. Due to The paucity of epidemiological studies on Influenza in children in Europe our prospective study seeks to determine the hospitalisation and outpatient influenza incidence rates in children under 6 years old presenting to the Royal London Hospital UK over two winter seasons 2002/2003 and 2003/2004. Design/Methods: We recruited children under the age of 6 years old in the hospital presenting with acute influenza-like illnesses. A structured electronic questionnaire was administered and nasopharyngeal aspirates were performed and sent for viral immunofluorescence and PCR. Influenza rates were stratified by age and by clinical diagnoses. Influenza incidences were also estimated from a predictive clinical diagnoses models generated from the data collected in the first season i.e. 2002/2003. Results: During the two seasons 977 children were recruited and the influenza A attack rate was 5.9%. Over the two seasons the average influenza A hospitalisation incidence rate was 26.1 per 10,000 person-months whereas the influenza A accident and emergency outpatient rate was 15.4 per 10,000 person-months. The highest age specific influenza hospitalisation incidence rate was in children aged 24-35 months old which was 61 per 10,000 person-months whereas the 6-23 month olds had an age specific influenza hospitalisation incidence rate of 4.6 per 10,000 person-months. The highest age specific influenza AE outpatient incidence rate was in children aged 6-23 months old and was 19.8 per 10,000 person-months whereas the 24-35 months had an age specific influenza AE outpatient incidence rate of 8.45 per 10,000 person-months. An influenza predictive model based on clinical diagnoses parameters was generated from the first season's data and consisted of five variables: upper respiratory infection, tonsillitis, pneumonia and the incidences of otitis media and non specific febrile illnesses under the graph. The estimated influenza incidence rate in all the 4628 eligible children under 6 years old recruited in the first seasons study was 29.1-35.4 per 10,000 person-months. Influenza rates were highest in children presenting with pharyngotonsillitis, febrile seizures and otitis media.

Conclusion: Influenza infections in children generate hospitalisations, AE and GP outpatient visits in the UK even during low intensity influenza transmission seasons. Children between the ages of 24-35 months had the highest rates of influenza infection and the highest rates of influenza were seen in children presenting with pharyngotonsillitis. The predictive clinical diagnoses model had a good fit for the 2003/2004 season and can be used to estimate influenza incidences. These findings can be used to inform influenza immunization policy in the UK.

Use of respiratory syncitial virus rapid diagnostic test (RSV-RDT) to predict the occurrence of bronchiolitis in children under 3 months of age suffering from acute viral rhinitis Background: During the first few weeks of life, particularly among preterm infants, infection with RSV could lead to severe symptoms as lethargy, apneic episodes, or respiratory failure. Rhinitis and cough precede for few days the lower respiratory signs and symptoms. Acute viral rhinitis due to other respiratory viruses is a frequent situation in this setting. The aim of the study is to evaluate the interest of RSV-RDT in nasopharyngeal specimens for children under 3 months of age suffering from rhinitis with cough, to predict the occurrence of bronchiolitis and hospitalisations.

Methods: From 2001 to 2004, 13 pediatricians performed RSV-RDT for children (from birth to 3 months) suffering from acute viral rhinitis with cough (without wheezing or respiratory distress). Information collected included duration of breast-feeding, presence of gastro-oesophageal reflux, type of cough, respiratory frequency, prematurely birth, risk factors, tobacco, result of test, initial decision, short-term evolution (bronchiolitis, hospitalisation) and treatment.

Results Human metapneumovirus is a recently discovered virus that causes respiratory disease in children and in adults. hMPV infection has clinical characteristics similar to those of respiratory syncytial virus (RSV) infection, ranging from mild upper respiratory tract infection to bronchiolitis and pneumonia. HMPV is genetically related to avian pneumovirus C but does not replicate in turkeys or chickens. It has been shown to replicate in primates and small animals such as guinea pigs, mice and Syrian golden hamsters. This study was undertaken to evaluate the suitability of BALB/c mice as models for hMPV infection. hMPV is not a natural pathogen of mice. However, we showed that intranasal inoculation of BALB/c mice with hMPV led to a productive infection with significant morbidity. Indeed, hMPV induced overt clinical disease in mice, with a significant weight loss on day 2. Lung viral replication occurred from days 3 to 5. hMPV elicited high levels of IgG-specific antibody response in sera with a strong increase in both IgG1 and IgG2a levels suggesting that hMPV induced a systemic Th1/Th2-like response. This mixed Th1/Th2-like profile is in accordance with the fact that both IFN-gamma (Th1) and IL-4 (Th2) were produced in bronchoalveolar lavage (BAL). Acute infection with hMPV elicited a rapid and sustained pulmonary inflammatory response without eosinophilia. Airway obstruction measured by plethysmography, and airway hyperresponsiveness after metacholine challenge were significantly increased in hMPV-infected mice compared to controls. In summary, we present an animal model that enables the investigation of immunodeterminants of protection and recovery from hMPV infection.

HHV-6 as a causative agent of fulminant hepatic failure in young children Among young children, a rising number of cases of fulminant hepatic failures (FHF) remains of undetermined cause. Human herpesvirus 6 (HHV-6), a betaherpesvirus, is able to infect hepatocytes in vitro, and has been associated with FHF and acute liver injury. The aim of this study was to evaluate the incidence of HHV-6 infection in a group of pediatric patients harbouring various acute liver diseases, in comparison with a control group of children with stable chronic liver diseases. Twenty-three children (median age: 24 months; range: 7-61) with different types of liver injuries underwent liver transplantation: 6 FHF with undetermined cause, three FHF with an etiologic cause (hepatitis A virus (HAV) infection, Wilson disease, autoimmune hepatitis), three acute decompensations of chronic liver diseases (ADCLD), and 11 stable chronic liver diseases (biliary cirrhosis). HHV-6 DNA was detected and quantified in explanted livers and peripheral blood mononuclear cells (PBMCs) at the time of tranplantation. Among children with FHF of undetermined cause and ADCLD, HHV-6 DNA was detected in 100% of liver specimens and 50% of PBMC specimens, with HHV-6 median load higher in liver biopsies (1070 copies/10 6 cells) than in PBMCs (29 copies/10 6 cells). These results are in favour of viral replication in hepatic tissue. Conversely, among children with stable chronic liver diseases, only one had HHV-6 positive detection in liver and PBMCs, with low HHV-6 loads (26 and 323 copies/10 6 cells, respectively). HHV-6 was not detected in the patient with HAV hepatitis, and HHV-6 loads were quite low in both liver biopsy and PBMCs (125 and 168 copies/10 6 cells, respectively) from the one with Wilson disease. Of note, HHV-6 loads were high for the patient with autoimuune hepatitis (13,768 and 10,000 copies/10 6 cells, in liver and PBMCs, respectively). All the HHV-6 identified were variant B. Our results suggest that HHV-6 may play a significant role in the occurrence of FHF and ADCLD. Moreover, HHV-6 may act as a triggering factor in the development of autoimmune fulminant hepatitis. Nevertheless, the viral mechanisms of liver injury remain to be elucidated. Results: During studied period 1977 cases of varicella were hospitalized in CR. In 10 selected departments of infectious diseases were hospitalized 1317 (66.6%) patients. Seventy nine percent of patients were children below 18 years of age, 21% were adults. The average duration of hospitalisation was 8.1 days, median duration 7 days. In 147 (11.2%) children were registered with risk factors, 78 patients were on immunosuppressive treatment. Complications were observed in 851 (64.6%) patients: in 282 (21.4%) patients local and in 569 systemic. Systemic complications were observed in 42.4 of children and in 46.4 of adults (RR = 1.18; p = 0.23). There was no significant difference in occurrence of complications between groups with or without risk factors: the occurrence of local complications in the group with risk factors was 29.3% compared with 29.6% in non-risk group (RR = 0.99; p = 0.98). Incidence of systemic complications in risk group was 33.3%. Significantly higher incidence of systemic complications-44.4% was among adult patients (RR = 0.75; p = 0.01). Altogether 569 primary complications were observed-104 cases of encephalitis, 156 cases of liver involvement and in 21 patients was diagnosed atypical pneumonia (average age 26.9 years). One hundred and forty one patients were treated in intensive care units and three patients required reanimation care. The average duration of stay in intensive care unit was 6.0 days (median 5 days). Only 17 patients had a history with risk factors. Five hundred twenty seven patients were treated with aciclovir.

Conclusions: 1. There was no significant difference in occurrence of complications between immunocompromised and immunocompetent patients, higher incidence of complications was observed in adults. 2. Most frequent complications were liver involvement and encephalitis and in adults atypical pneumonia. 3. The course of the disease was significantly influenced by administration of aciclovir. 4. Vaccination against varicella is recommendable for immunosuppressed children and adults and immunocompetent non-immune adults.

High protection rates against bacterial and viral diseases in children and teenagers needs a constant awareness of parents and pediatricians. In Germany a mandatory health check, which usually takes place at the age of six, before enrolment in primary school is performed by the Public Children and Youth Health Service Centre (PCYHS). At this visit the parents receive additional information about vaccines, which their children had not yet obtained. In order to increase vaccination rates a vaccination register in the city of Essen/Germany was established. At the first check of vaccination cards of 6th graders (n = 4 568) only 15% of the students had the complete vaccination set they needed at their age. These low rates led to the implementation of an active vaccination counselling program throughout the city of Essen for these students. Following the check of vaccination cards the students received a vaccination information brochure and were also asked to have their paediatrician complete the missing vaccinations.

The following year the previous collected vaccination cards were collected again and the increase of protection rate was investigated. The overall protection rate increased by 16% (Measles, Mumps and Rubella from 43% to 59%, Hepatitis B from 24% to 40%). In an additional project videos about Hepatitis B/MMR were shown before the individual counselling. This extended information increased the protection rate for another 15% for MMR to 74% and 40% for Hepatitis B to 80%. A similar vaccination counselling programme was established for kindergarten children. Only 44% of the 3-4 year old children investigated (n = 2909) had a complete vaccination status. After the counselling 88% of the children showed complete vaccination status 3 months later. These results indicate that vaccination counselling of children by the PCYHS may help dramatically to increase the coverage rate of vaccinations. This was achieved by setting up a vaccination register, a one-time individual vaccination counselling and additional information by videos. This increase was only possible by the close cooperation of kindergarten, schools, and the PCYHS. This model of counselling may help to increase coverage of vaccinations in the german population at low costs.

Almuneef M, Memish Z, Balkhy H, Alotaibi B, Helmy M. Departments of Infection Prevention and Control, Pediatrics, and Internal Medicine, King Abdulaziz Medical City-King Fahad National Guard Hospital, Riyadh, Saudi Arabia Introduction: Varicella Zoster infection (Chickenpox) is a common and benign disease of childhood. The predominance of the uncomplicated cases in children tends to over shadow the morbidity associated with severe cases and the resultant hospitalisation.

Objective: To establish the complication rate of chickenpox in the Saudi National Guard population over a 2 years and 6 months period.

Methods: All reported cases of chickenpox at the King Abdulaziz Medical City, Riyadh (KAMC-R) were prospectively followed for development of complications during the period between June 2001 and December 30, 2003.

Results: A total of 3802 cases of Chickenpox were reported and followed during their acute illness. The majority of the cases, 2984 (79%), occurred in children <15 years of age. Among all Chickenpox cases, 78 (2.1%) required hospitalisation, and 50 patients developed 58 (1.5%) complications. Skin and soft tissue infections were the most common complications 20 (34%), followed by pneumonia in 16 (28%), bacteremia in 6 (10%), encephalitis in 4 (7%) and necrotizing fascitis in 4 (7%). Complications were less common in children (36/2984, 1.2%) as compared to adults (14/818, 1.7%) (P = 0.26).

Pneumonia (P = 0.03) and hospitalisation (P = 0.004) were more common in adults compared to children. The overall fatality rate 0.05%; two patients died aged 2 months and 28 years with a rate of 5.3/10,000.

Conclusion: These data provide a baseline for morbidity and mortality from Chickenpox, and further support the inclusion of Varicella Vaccine in the routine childhood immunization program in Saudi Arabia. Results: Out of the 92 patients, 12 pediatric cases were noted. The mean age was 38 ± 21 years and the male to female ratio was 0.84. The disease was acute in 62 (67%), subacute in 28 (30%) and chronic in 2. The main presenting symptoms were fever, sweating, easy fatigability and diffuse aches. Fever, vomiting and adenopathies were significantly more frequent in the acute form (97% versus 75% for fever; p < 0.001. 18% versus 7% for vomiting; p < 0.05. Eighteen percent versus 3% for adenopathies; p < 0.01). Spenomegaly was more frequent in children than adults (50% versus 19% chez les adultes; p < 0.03). Osteoarticular involvement was the most prevalent complication (28%) and spondylitis was seen in 46% of these cases. Meningoencephalitis was the most frequent neurological manifestation. Among the haematological tests, relative lymphocytosis was significantly more frequent in children than adults (75% versus 19%; p < 0.001) and in the acute form than the subacute (36% versus 7%; p < 0.001) whereas leucocytosis was more frequent in the subacute form (21% versus 7%; p < 0.01). Sixty patients were treated with doxycycline-rifampicin and 21 with cotrimoxazole-rifampicin for 6 weeks to 3 months, with good results in all cases. Surgical treatment was needed in 4 cases.

Conclusion: Brucellosis is still an endemic disease in Lebanon and should be routinely considered in the case of prolonged fever, articular and neurological manifestations. Purpose: This prospective study in the Greek population investigates the incidence of elevated antibody titers against Chlamydia (Cp) in patients with restenosis or without, within the first semester after PTCA, in a series of 110 patients. IgG, IgA and IgM antibodies against Chlamydia pneumoniae were measured at the time of PTCA and 6 months later, when the patients were examined for restenosis. Patients were divided into two groups: group A (n = 23) with restenosis and group B (n = 87) without restenosis.

Methods: In the microimmunofluorescence method used, elementary bodies of TWAR-183 Chlamydia pneumoniae served as antigen. Titers of IgG > 1/40 and IgA > 1/40 were considered as positive, indicating the IgG past infection and the IgA chronic infection. IgM was found in all tests negative and IgG ≤ 1/320, consequently none of our patients suffered from acute chlamydial infection. In the presence of angina or a positive treadmill testing the patients underwent an angiogram. In the absence of both the above mentioned, an exercise test with myocardium perfusion imaging with TL 201 was performed.

Results: The univariate analysis chi-square for sex, age, diabetes mellitus, hypertension, hyperlipidaemia, stent implantation, smoking and the univariate t-test for age did not show any statistically significant correlation of them with restenosis. In the multiple logistic regression analysis patients with restenosis had 3.57 times (OR = 3.57) more frequently IgG > 1/40 (P = 0.06) and 3.63 times (OR = 3.63) more frequently IgA > 1/40 (P = 0.03) than patients without restenosis.

Conclusion: Patients with restenosis had 3.57 times more frequently IgG > 1/40 and 3.63 times more frequently IgA > 1/40 than patients without restenosis, a finding indicating that elevated IgG and IgA antibodies against Cp could be prognostic factors for restenosis. Also this supports the need for further studies to clarify the real role of Cp chronic infection in restenosis of coronary arteries post PTCA. BK virus infection was prospectively studied during the first year post renal transplantation. Infection was assessed by the detection and quantification of viral DNA in urine and plasma, to determine the frequency and the risk factors for BKv active infection and disease. One hundred four unselected and consecutive patients who underwent renal allograft transplantation in 2002 at Nantes Hospital were enrolled. Urine and plasma samples were collected at 1, 2, 3, 6, 9 and 12 months post transplantation and evaluated for viral DNA by a home-made real time PCR. All positive samples were quantified using a plasmid standard curve and NCCR region of 31 BKv urine strains was sequenced. Virological datas were then analysed according to demographic, clinical and biological parameters. A total of 451 blood and 421 urine samples were collected (median of four urine and four plasma per patient). Positive DNAuria and/or DNAemia were observed in 57% and 29% of patients, respectively. We defined three groups of patients: no infection (gr1, 45 pts), positive urines (gr2, 29 pts), positive plasma (gr3, 30 pts). DNAuria became positive within the first 3 months in 80% of patients. Urine viral loads ranged from <3.6 to 11.6 log cop/ml (median 6.4) and were higher in gr3 than in gr2 (p = 0.0008). Positive DNAuria was significantly associated with the use of FK506 as maintenance therapy (OR 3.2, p = 0.05) and cold ischemia duration >24 h (OR 4.6, p = 0.008) and viral loads were significantly higher in patients receiving FK 506 (p = 0.03). Comparison of the 31 NCCR sequences with archetype WW NCCR sequence, found ponctual mutations. They were not associated with any of the parameters analysed. Viral loads in plasma ranged from <3.2 to 7.8 log cop/ml (median 3.7). Positive DNAemia was closely associated to positive DNAuria (RR = 7.8, p < 0.001). Our prospective data highlight the high frequency of active BKv infection after renal transplantation, which is favoured by FK 506 therapy and local ischemia. Despite the observation of high viral load in some of patients, none developed BKv nephropathy. A systematic follow-up of BKv infection is thus not required after renal transplantation.

Seaton RA, Bell E, Gourlay Y, Semple L. Gartnavel General Hospital, Glasgow, UK Purpose of study: To evaluate a protocol for the community management of moderately severe cellulitis.

Methods: A protocol detailing indications for IV therapy, IV-oral switch, hospital admission and indications for medical review was developed and approved for nurse specialists working in our outpatient and home parenteral antibiotic therapy service. Clinical outcomes post-intervention (07/03-07/04) were compared with data collected prior to the intervention (01/02-07/03).

Results: 230/339 (68%) of patients referred for outpatient management were suitable for the protocol (prior to its introduction). 112/148 patients seen prospectively were suitable for the protocol. Median age was 49 and 50 years with 52 and 61% male. Thiry nine percent and 47% were referred from emergency departments. Median duration of outpatient IV therapy was reduced from 4 to 3 days (p = 0.01). Readmission rates were 6% and 7% and cure/improvement rates were 99% and 97%. Twenty (19%) of patients post-intervention required medical review (100% prior to intervention).

Conclusions: Moderately severe cellulitis may be effectively and efficiently managed in the community by trained nursing staff using a suitable management protocol. This approach may be associated with reduced duration of IV therapy. Background: Guillain-Barré syndrome (GBS) is the most common cause of acute flaccid paralysis in developed countries. Campylobacter jejuni (CJ) and cytomegalovirus (CMV) are the two main infectious agents incriminated as triggers, but their role in GBS occurring in France remains poorly documented.

Methods: We studied 265 patients with GBS from the Greater Paris admitted between January 1996 and December 2001 to the medical intensive care unit of the Raymond Poincaré hospital. Serum antibodies to CJ were tested by a complement fixation test (Institut Virion, Würzburg, Germany). IgM and IgG serum antibodies to CMV were tested with the miniVIDAS system (BioMérieux, Marcy l'Etoile, France); the IgG avidity was measured in samples with positive IgM.

Results and Conclusion: Serological evidence of recent infection by CJ was present in 58 (21.9%) and by CMV in 40 (15.1%) of the 265 patients; one patient had evidence of infection by both CJ and CMV. GBS cases involving CJ developed a mean of 9.6 days after the infectious event, mostly a gastrointestinal illness (51.7%), occurred majoritarily in males over 50 years (mean [S.D.] age, 51.3 [19.1] years; sex ratio, 0.63), and were associated with a severe (mechanical ventilation, 39.7%) pure motor form (56.9%) and with serum IgG antibodies to the ganglioside GM1 (37.5%). GBS cases involving CMV were also severe (mechanical ventilation, 37.5%), but developed a mean of 12.2 days after the infectious event, mostly a upper respiratory tract infection (22.5%) or an influenza-like syndrome (15%), occurred in younger patients (mean [SD] age, 35.9 [12] years), predominantly females (sex ratio 0.45), and were associated with severe sensory loss (72.5%) and with IgM antibodies to the ganglioside GM2 (37%).

Karpov I a , Kachanka A b , Kishkurno E a . a Infectious Diseases Hospital, Medical University, Belarus, b Infectious Diseases, President's Hospital, Minsk, Belarus Bacterial meningitis is a very serious problem in the Republic of Belarus and has considerable mortality, although the morbidity is comparatively low. According to official statistics of the Infectious Diseases Hospital now we have change of etiology of the purulent meningitis among adults in the Republic of Belarus. The most common agent is Str. pneumonia, causing approximately 50% the purulent meningitis. N. meningitis causes approximately 25% the bacterial meningitis. L. monocytogenes is a very common agent of meningitis in patients over 55 years, who have some chronic diseases, for example diabetic or alcoholism. As a rule, the drug users have the bacterial meningitis, caused by S. aureus. In these cases the meningitis is the first manifestation of the bacterial endocarditis. Rare cases of bacterial meningitis caused by H. influenzae have the particular interest. Nowadays taking into consideration the considerable increase of resistance of Str. pneumoniae to penicillin in countries of Eastern Europe, we use cephalosporins of the third generation as the first line of therapy. The ideal antibiotics for these patients are ceftriaxone or high doses of cefotaxime. As a rule both the immunosuppressive patients and the old patients received the combination of ceftriaxone/cefotaxime plus ampicillin (16-24 g/day). The etiologic therapy of the bacterial meningitis, caused by S. aureus, includes cephalosporins of the third generation or meropenem. Meropenem is used by patients with neutropenia or other immunosuppressive states. We add vancomycin to the first line of therapy only when we suspect hospital-acquired meningitis. When we prescribe antibacterial therapy, we pay attention to the basic pathology, age of patients and initial localization of infection. Aims: To study the prevalence and determine the factors that could be associated with hepatic steatosis in HCV-HIV co-infected patients.

Methods: 148 HCV-HIV co-infected patients from the Aquitaine Cohort (95 males, median age: 39 years; median CD4 count: 499/l) were included. All patients were eligible for HCV antiviral therapy and their alcohol intake was < 50 g/day. Data collected at the time of liver biopsy included: type of HAART (protease inhibitors, non nucleoside reverse transcriptase inhibitors: NNRTI, nucleoside reverse transcriptase inhibitors), CDC stage of HIV infection, HIV plasma viral load, BMI, glycemia, total cholesterol, triglycerides, transaminases and HCV genotype. Histological activity and fibrosis were graded according to the Metavir scoring system. Steatosis was classified as: none, minimal (≤10% hepatocytes), mild-to-moderate (11%-30%), or severe (>30%).

Results: Overall, steatosis was present in 99 patients (67%) (minimal N = 44, mild-to-moderate N = 28, severe N = 17) and was considered as microvesicular in 7%, macrovesicular in 40% and mixed in 53%. For statistical analyses, steatosis was defined as an outcome when its degree was at least mild-to-moderate. In univariate analyses, steatosis was significantly associated with BMI > 25 (p = 0.02), HCV genotype 3 (p = 0.02), the use of NNRTI (p = 0.047), aspartate aminotransferase (p = 0.04) and severe histological activity (p = 0.002). The association with severe fibrosis (F3-F4) was close to significance (p = 0.07). In multivariate analysis, the only factor that remained significantly associated with steatosis was histological activity (p < 0.03), and BMI > 25 was close to significance (p = 0.09). Examination of magnitude of coefficients changes makes histological activity appear as a confounder or an intermediate factor for the occurrence of steatosis. Indeed, when histological activity was not included in the regression model, BMI was associated to steatosis (p = 0.03) and the association between steatosis and HCV genotype 3 was very close to statistical significance (p = 0.06).

Conclusion: Steatosis is a common histological finding in HCV-HIV co-infected patients. Factors associated with steatosis in these patients appear to be similar to those reported in HCV-infected patients, however the association between steatosis and histological activity should be further investigated.

Persistence of HCV-RNA in mononuclear cells after HCV elimination from the serum during interferon therapy Identification of HCV-RNA in blood serum is crucial for hepatitis C diagnosis and for appropriate treatment. Detection of HCV-RNA in blood serum is used for therapy monitoring of patients with hepatitis C. Despite of HCV-RNA elimination from blood serum during treatment in some patients HCV viremia appears again after completion of therapy. The aim of the study was to assess HCV-RNA in peripheral blood leukocytes of hepatitis C patients in relation to HCV-RNA and antibodies to HCV in the serum. The study involved 40 patients undergoing anti-viral therapy (interferon + ribavirin). RNA isolated from serum and peripheral blood leukocytes (by Qiagen kits for genomic or viral RNA) was examined for the presence of HCV-RNA by RT-PCR technique using specific oligonucleotide primers or by comercially available kits (Amplicor, ROCHE). In order to show possible presence of HCV sequence in peripheral blood leukocytes, molecular DNA probes was constructed with PCR amplicon and biotin labelled by nick translation. HCV sequences was detected by FISH and also on chromatin fibers by extended chromatin fibers in situ hybridization (ECFs-FISH). Twenty two patients out of 40 eliminated HCV-RNA from the serum and 18 remained HCV-positive. In the serum negative group HCV-RNA was detected in mononuclear cells of 10 patients. The presence of HCV-RNA in mononuclear cells was confirmed by FISH technique. In ECFs-FISH procedure no signal was found in all examined patients. Our data suggest that leukocytes infected with HCV can serve as virus reservuare. HCV-RNA serum negative patients after completion of anti-viral therapy having HCV-RNA in their leukocytes would be at greater risk of hepatitis C recurrence. These HCV-RNA serum negative but leukocyte positive patients would be a potential source of spreading HCV infection. This work was supported by KBN grant nr 3PO5E10124.

The implications of lamivudine therapy in acute viral hepatitis with HAV-B Objectives: To assess the efficiency of Lamivudine in acute viral hepatitis B (HAV-B) with prolonged high ALT levels and the implications on immune response.

Methods: 22 patients with HAV-B with prolonged high ALT levels (ALT> N, 6-8 weeks after onset) admitted at our hospital between January 2000 and September 2003 received LAM 100 mg/day for 3 months (9 patients) and for 6 months (13 patients). They were followed up every month by biochemical (ALT) and serologic (HBe and HBs seroconversion) tests. We followed up the dinamics of HBsAb at 6 months.

Results: The ALT levels were rapidly normalized (median levels 1150 IU/ml) within 1 month in 17/22 patients, after 2 month in 3/22 patients and after 3 month in last 2 patients. HBeAg seroconversion was observed in all patients: after 4 weeks (14/22 patients) and after 20 weeks (8/22 patients). One patient became VHB carrier. The loss of HBsAg was observed in 21/22 patients: after 4 weeks-1 patient; after 16 weeks in 13/21 patients; after 24 weeks in 7/21 patients. HBsAb were found in 19/21 cases: at 3 months (10/19 patients) and at 6 months (9/19 patients). HBsAb never appeared in 2 patients. At the end of therapy only in 5/19 cases, the HBsAb titers were protective. After 6 months from arresting Lamivudine, the HBsAb titers were decreased and 2 patients had the HBsAb undetectabile.

Conclusions: Lamivudine may be a solution to prevent chronic hepatitis B. However, we observed an HBsAb levels decreasing, probably due to influence of the immune response.

Maillard A b , Chapplain JM a , Arvieux C a , Tattevin P a , Souala F a , Dupont M a , Neveu C b , Guist'hau O b , Michelet C a , Ruffault A b . a Maladies Infectieuses, France, b Virologie, CHU Pontchaillou, Rennes, France Objectives: In clinical practice, some HIV-infected patients with discordant immunological/virological outcome are maintained under a protease inhibitor (PI)-based regimen despite persistent viral replication. We investigated the kinetics of resistance mutations emergence under selection pressure in these patients, and the impact on future drug regimen.

Methods: We enrolled nine patients remaining on their initial PI-based therapy during at least 2 years, despite detectable plasma viremia. Genotypic resistance testing was performed by population-based sequencing on pre-PItreatment plasma, first available sample after virological failure (VF = viral load > 400 copies/ml), then yearly until treatment modification or discontinuation. The following protease gene codons were analysed according to 46, 48, 50, 82, 84, 90 (key mutations), 10, 20, 24, 32, 33, 36, 47, 53, 54, 63, 71, 73, 77, 88 .

Results: PI-treatment, initiated between May 1996 and July 2000, consisted in indinavir (n = 5), nelfinavir (n = 2), saquinavir (n = 1), or saquinavir + ritonavir (n = 1). Median follow-up was 53 months (range, 25-81). Baseline median VL and CD4 cell counts were 4.96 log 10 /ml and 206 cells/l, respectively. VF was observed at a median of 5 months (range, 2-12) with VL and CD4 values of 3.85 and 294, respectively. Median VL and CD4 changes were −1.12 and +143 between baseline and last genotype and −0.10 and +57 between VF and last genotype. At baseline, six patients had one to three mutations in the protease gene but no key mutations. Three to six NRTI mutations were found in all NRTIs experienced patients (n = 7). Zero to two key protease mutations were detected at VF and one to three on the 1-year genotype. Median total numbers of protease resistance mutations were: 3 (range, 0-5) at VF, 5 (range, 3-8) at the 1-year genotype, 6 (range, 4-8) at the 2-year, 3-year (n = 6) and 4-year genotype (n = 5). Six patients acquired resistance to lopinavir and amprenavir. No evolution was observed in RT gene except for the 2 NRTI-naive patients.

Conclusion: Accumulation of PI-mutations was slow after emergence of key mutations. However, these mutations led to the acquisition of whole class resistance in six of nine discordant patients during long-term VF and thus could compromise future treatment options.

Coste-Burel M c , Besse B c , Papy K c , Lopes P b , Laboisse C a , Imbertmarcille BM c . a Anatomie Pathologique, France, b Gynécologie Obstétrique, c Virologie, CHU Nantes, Nantes, France Cervical cancer is associated with high-risk types of human genital papillomavirus (HR-HPV), notably with the genotype 16 which is the most common in all countries (>50%). The oncogenic potential of the HR-HPV mainly depends on the expression of the viral oncoproteins E6 and E7 and some data suggested that particular viral variants of E6/E7 genes may be more oncogenic. To evaluate this particular point in our local population, we analysed retrospectively 89 HPV-16 positive cervical samples obtained from 78 women consulting the gynaecological unit of Nantes university hospital. 20.3% of samples had a normal cytology, whereas the others showed a cervical intraneoplasia grade 1 (20.3%) or grades 2-3 (66.3%). 84 E6 genes and 88 E7 genes were successfully amplified by specific PCR. Variants were analysed by direct nucleotide sequencing and multiple sequence alignments of the full length E6 and E7 gene were performed with Mega program. Phylogenetic trees were constructed. No insertions or deletions in the sequenced fragments were observed. Only 31.3% of the HPV-16 E6/E7 genes were identical to the prototype sequence (T350). The previously described T350G mutation in E6 gene was present in 57.1% of HPV-16. A total of 15 (5 non-published, 10 non-synonymous) and 5 mutations (1 non-published and 2 non-synonymous) were identified in E6 and E7 gene, respectively. Four samples contained multiple nucleotide changes typical of non-European variants. No significant associations were observed between variants and the different cytological classes, but interestingly, the four multiple variant samples were all associated with cervical intraepithelial neoplasia (3 high-grade, 1 low grade). Since the risk of high grade cervical neoplasia seems to increase in patients infected with certain HPV-16 variants, the knowledge of their local prevalence is of interest. Furthermore, the determination of E6/E7 variants may be useful in the perspective of HPV antiviral treatment and vaccine. Background: Neonatal BM have a poor prognosis with a mortality rate of 15-25% and 20-50% significant sequelae. Incidenceand bacterial epidemiology were not known in France.

Methods: Allcases of BM from birth to 18 years, in France were recorded prospectively by a clinical-259 pediatric wards-and microbiological network which covers 68% of pediatric departments. Specific neonatal results from January 2001 to January 2003 are presented.

Results: 201 (sex ratio M/F 1.2) cases are reported by 114 departments. Group B Streptococcus (GBS) represents 56.2% of cases, E. coli29.8%, N. meningitidis 3.5%, S. pneumoniae 1.5% and miscellaneous 9%. In early onset BM (0-4 days, n = 72), GBS is largely predominant (83.3% versus 11.1% for E. coli). In late onset BM (5-28 days, n = 129), GBS and E. coli rates are similar (respectively 41.1% and 40.3%). Among preterm (gestational age < 37 weeks, n = 38), GBS (26.3%) is lower than E. coli (50%). In full-term (n = 156), GBS is higher (64.1%) than E. coli (25%). Serotype III GBS is isolated in 86% and E. coli K 1 in 93.7%; E. coli ampicillin resistance rate is 34.5%. Third generation cephalosporins are used in 76.6% of cases for GBS and 85.2% for E. coli. Case fatality rate, 13.2%, is higher in preterm 26.3% versus 9.8% (p = 0.007). Conclusion: Prognosis of BM in newborn is poor with a high mortality rate. GBS remains the most common pathogen but E. coli is increasing especially in LO meningitis. Methods: Since January 2001-January 2003, 259 French pediatric wards (68% of pediatric departments) working with 168 microbiologic departments enrolled all children with bacterial meningitis. Information collected included risk factors, signs and symptoms, cerebrospinal fluid (CSF) analysis, treatments and short-term evolution for SpM.

Results: 140 centers reported 368 SpM (sex ratio M/F 1.3), 69.7% of children were less than 2 years old, median age 0.8 years (peak of incidence at 5 months). Before 2 years of age, day care attendance modalities were home 61.8%, day care center 19.6% and child minders 18.6%. Underlying conditions were reported in 10.6% of cases. CSF control at day 2 was sterile in 95.3%. The percent of penicillin non-susceptible strains was 53.8% (46.6% intermediate and 7.2% resistant). Antibiotic combination (vancomycin plus third-generation cephalosporin) was prescribed in 96.5% of cases and steroids in 39% of cases. Case fatality rate was 11.1%, related neither to age nor to antibiotic susceptibility, nor to steroids use. For children less than 2 years, vaccine serotypes accounted for 60.1% of cases. In addition with serotype 6A and serotype 19A, pneumococcal conjugate vaccine (7-VPnC) coverage reached 72.8%. For older patients vaccine serotypes accounted for 53.2% and 66.1% with serotypes 6A and 19A. Among five children vaccinated by 7-VPnC, one (5 months old, 2 doses) had serotype 6B in CSF culture, the four others had non-vaccine serotype.

Conclusion: These results will represent a baseline to monitor SpM changes, future serotypes and resistance evolution after extended use of the 7-VPnC, recommended in France for routine use in infants since January 2003.

Joram N b , Loubersac V a , Winer N c , Roze JC b , Gras-le Guen C b . a Laboratoire de biochimie, CHU Nantes, France, b Réanimation Pédiatrique et Néonatalel, France, c Service de Gynecologie-Obstétrique, Hopital Mère Enfant, CHU Nantes, Nantes, France Background: Bacterial materno-foetal infection is one of the most frequent causes of neonatal morbidity and mortality. Its prognosis is closely related to early diagnosis and treatment. In this context, paediatricians frequently initiate early antibiotherapy in newborns with infectious risks factors, exposing those non infected to unnecessary treatment. The aim of our work was to evaluate the value of procalcitonin (PCT) dosage in umbilical cord as an early and specific marker of perinatal bacterial sepsis.

Methods: A prospective study was conducted in 160 neonates with suspected materno-foetale infection. Thirty neonates without any risk factor constituted the control group. Serum procalcitonin and C-Reactive protein concentrations were measured simultaneously in umbilical cord blood and in maternal blood. According to clinical and bacteriological course, three groups were defined: group 1, infected (n = 20); group 2, colonized (n = 20); group 3, non-infected and non-colonized neonates (NINC) (n = 120).

Results: A statistically higher serum procalcitonin concentration was found in the infected group versus controls and colonized (p < 0.05). A PCT value greater or equal to 0.5 ng/ml was observed in 18/20 infected newborns and in 2/120 non infected newborns. The CRP dosage was >10 mg/l in 10/20 infected newborns. The sensitivity, specificity, negative and positive predict-ing values were respectively 90%, 99%, 99% and 90% for PCT, and 50%, 100%, 94% and 100% for CRP. Maternal PCT serum level was negative in all cases.

Conclusions: Although maternal PCT dosage does not seem to be informative, serum procalcitonin in cord blood seems to be a useful and early marker of antenatal infection.

Infectious complications in paediatric acute myeloid leukaemia: low incidence of bacteraemia due to viridans streptococci in a 10-year retrospective study Brunet AS b,c , Ploton a,c , Galambrun C b,c , Pondarre C b,c , Pages MP c , Bleyzac N c , Freydière AM a,c , Barbé G a,c , Bertrand Y b,c . a Bactériologie, France, b Immuno-Hématologie et transplantation de moelle osseuse, France, c Hopital Debrousse, Lyon, France Objectives: Infection remains an important cause of morbidity and mortality in children with acute myeloid leukemia (AML). Viridans streptococci (VS) are the main cause of severe sepsis, with profound neutropenia and high dose cytarabine as predisposing factors. The aim of the study was to evaluate, between 1993 and 2003, in children with AML, frequency and characteristics of infectious complications (IC), incidence of VS sepsis, interest of preventive decontamination and value of cytarabine dosage on occurrence of IC (18, 24 or 36 g/m 2 in first intensification).

Patients and methods: Medical charts of 78 children, treated according to the EORTC 58921 clinical trial, were retrospectively analysed including 264 chemotherapy courses. For prevention of infection, patients were isolated in laminar air flow rooms, received gut decontamination (per os aminoglycoside and amphotericin B), gum decontamination (vancomycin mouth washing), and trimethoprim-sulfamethoxazole. Efficiency of decontamination was evaluated weekly. IC were categorized as microbiologically documented infections (MDI), clinically documented infections (CDI) and fever of unknown origin (FUO).

Results: Overall, 268 IC occurred: 154 FUO (57.5%), 23 CDI (8.6%) and 91 MDI (33.9%) out of which 58 bloodstream infections (59 pathogens) (table). Five patients died of infectious-associated complications (6.4%). No child died from bacterial infections and no patient with VS sepsis required management in intensive care unit. Invasive fungal infections were proven in four patients. According to condition of gum ant gut decontamination, number of IC per patient was significantly different. According to dose of cytarabine during first intensification, prevalence of IC was significantly different. No resistant strains were detected in spite of use of local antibiotics Streptococcus pneumoniae is the most common cause of bacterial pneumonia in young children. Pleural empyema is a rare complication of bacterial pneumonia, associated with a severe morbidity. We recently observed an increase in the incidence of pneumococcal pleural empyema in children admitted at the Necker hospital. The diagnosis of pneumococcal empyema infection, based on the culture of blood or pleural fluid, is frequently negative due to previous administration of antibiotics. Rapid pneumococcal capsular antigen (PAC) detection by latex agglutination has been used for several years, but its diagnostic value is not clearly established. In this work, we evaluated retrospectively the accuracy of PAC in the diagnosis of S. pneumoniae empyema compared to culture in blood and pleural fluid and molecular biology in pleural fluid. We tested for PAC, 55 pleural empyema cases collected over a 4-year period (2000) (2001) (2002) (2003) , according to criteria of Light. Microbiological documentation of causal pathogen, by culture or PCR rRNA16S and sequencing, were found in 30 cases including 21 cases with S. pneumoniae. The other bacteria were S. aureus (4) and S. pyogenes (5), all found with a negative PAC in pleural fluid. Among the 21 pneumococcal empyema, PAC were positive in 18 cases providing a sensitivity of 84%. PAC were positive in seven cases, while bacterial cultures of pleural empyema were sterile. In five of these seven cases, the diagnosis of pneumococcal empyema was confirmed by PCR (4) when it was performed, or with positive culture of other clinical sample (1). In two cases, the positive PAC were not confirmed despite a positive microscopic examination in one case. The discrepancy between culture and PAC could be explained, according to clinical history of the patients, by previous administration of antibiotics. PAC detection in pleural fluid is a useful test in diagnosis strategy of pneumococcal empyema in children with a high predictive positive value (94%). The low predictive negative value (77%) does make it impossible to rule out the diagnosis of pneumococcal empyema. Therefore, the detection of PAC provides an additional and rapid response in children with pneumococcal empyema, including those having received previous antibiotic therapy.

The secretion in significant amounts of staphylococcal bicomponent leukotoxin LukE-LukD has been associated with antibiotic-associated diarrhoea (+enterotoxin A), and with bullous impetigo (+epidermolysins). Secretion of the toxin is observed for about 35% of routine isolates whereas the corresponding gene is present in more than 85% of these isolates. We analysed 19 independent isolates both for the presence of the LukE-LukD operon and for the toxin production, and tentatively developed a PCR test that detected a deleterious mutation in given isolates. Furthermore, gene expression was assessed by using a competitive RT-PCR test to verify the role of an inserted sequence in the promoter, and sequences corresponding to the secreted toxins were cloned and expressed in E. coli to assess their biological function compared to a control toxin. On the 19 isolates, only 16 (84%) carried the LukE-LukD operon and 8 (42%) secreted the leucotoxin. The operon sequence of four of the isolates revealed numerous mutations that may affect the protein structure, but the three expression-deficient strains showed the deletion of one basis just after the initiation codon. This deletion made impossible any functional translation, despite corresponding mRNAs were synthesized at levels comparable to the control. Four isolates were estimated to carry this deletion among the 19 studied. When proteins were expressed in E. coli some mutations were identified as able to inactivate the leucotoxin. Taken together, this study evidences the extreme variability of the LukE-LukD operon and the lack of toxin expression/function of the toxin for about half of the isolates even genes are present. This illustrates the discrepancy between gene presence that might be detected by genotyping tests and the effective production of a functional toxin. Thus, phenotyping methods remains indicated for the detection of such a leucotoxin to avoid false-positive data, and previous clinical associations remain significant.

This work was co-supported by the Stawars project for CNR-Provincia Autonoma Trentino.

Loulergue P, Lina G, Tristan A, Bes M, Etienne J, Vandenesch F.

Staphylococcal infections are frequent and represent a major public health issue. Although resistance to methicillin used to be an exclusivity restrained to hospitals for years, a worldwide emergence of communityacquired methicillin-resistant S. aureus(CAMRSA) clones has been noticed. The inter-human skin-to-skin transmission is the postulated cause of the rapid epidemic spreading of these clones. CAMRSA strains have three common characteristics: a type IV SCCmec cassette (staphylococcal cassette chromosome), a type 3 agrallele (accessory gene regulator) and a phage (phiSLT) carrying the Panton Valentine leukocidin (PVL) gene. The combination of these elements appears to provide to the strains a selective advantage with an increased epidemic potential. We hypothesized that the insertion of the phage phiSLT is a determinant of dysregulation in the staphylococcal proteome, by modulation of the expression of protein A, one of the major surface protein of S. aureus. We analysed the expression of protein A in eleven isogenic couples of S. aureus strains before and after transduction of the phiSLT phage. Each strain had been inactivated for a major regulation system of the virulence of S. aureus: two upregulating systems Rot and SarS, and three downregulating systems SarA, Agr and ArlRS. The expression of protein A was analysed by Northern and Western blots. We observed that the acquisition of phage phiSLT induced an overexpression of protein A in several isogenic strains, notably in rot and arl-insertion mutants. The up-regulation of protein A was more prominent at the protein level rather than at the transcriptional level. These results confirm that the presence of phiSLT not only brings a major cytolytic toxin (i.e. the PVL) but also induces an over-expression of protein A and potentially of other virulence factors, that may enhance the colonizing and/or invasing capacities of S. aureus. Twelve isolates were cutaneous samples, and the others were taken from urinary site (n = 2), pulmonary site (n = 3) or blood culture (n = 1). The patients were hospitalised in different departments (8 in medicine, 6 in surgery, 4 in intensive care, 2 in long term care units and 1 in emergency unit). Three patients were transferred from another hospital, the other were coming from home (n = 13) or long term care units (n = 3). Their mean age was 54.9 years (4 d to 95 years), sex ratio: 0.69. Half of them had an history of previous hospitalisation in the last 18 months. 7/11 patients had received broad-spectrum antiobiotics (4 (-lactam-(-lactamase combination and 3 other (-lactam antibiotics) before MRSA isolation. 15/22 MRSA-s were hospital-acquired colonisations or infections (mean time of acquisition: 23.2 d), 7 others were community-acquired. Eight patients were infected, 11 colonized and for two patients, status was unknown. For all the strains, we performed a PCR multiplex analysis of nucA, mecA and 16S rRNA genes. PFGE analysis of genomic DNA from these strains revealed different pulsotypes.

Conclusions: Our results show that the emergence of these MRSA-s strains is not related to an epidemic spread. Therefore, the rational of the isolation of these patients has to be discussed.

Grohs P b , Veil D a , Kac G c . a Société I2a, Montpellier, France, b Microbiologie, France, c Unite d'Hygiène, Hopital Européen Georges Pompidou, Paris, France Objective: Monitoring methicillin-resistant Staphylococcus aureus (MRSA) rates is crucial in hospital settings, but its calculation is hampered by variations according to duplicate isolates. The aim of this study was to assess the impact of applying different methods for duplicate isolate removal on the MRSA rates by using a specifically designed software.

Materials and methods: Trends in S. aureus resistance were analysed by using the Sirscan 2000 computer system, from isolates collected in a 750-bed university hospital (Hopital Européen Georges Pompidou) during a 4-year period. Reference duplicate (RD) criteria were defined as one major and three minor differences in antibiotic patterns and a 30-day time period between two isolates. Variations in antibiotic patterns, time period between two isolates and number of antibiotics tested were studied and compared to the RD criteria. NCCLS recommendations based upon results from the first isolate of a species per patient per analysis period irrespective of body site, anti-microbial susceptibility profile or other phenotypic characteristics were evaluated. In addition, exclusion of outpatients and screening specimens was also studied.

Results: From 1st July 2000 to 30th June 2004, the MRSA rate was 31.1% when using RD with 20 antibiotics tested. When duplicates were not eliminated, the MRSA rate significantly increased to 34.0% (p = 0.002). When using NCCLS recommendations, the MRSA rate significantly decreased to 27.6% (p = 0.002). When no difference was tolerated in antibiotic pattern and when the time period was set at five days, the MRSA rate significantly increased to 34.3% and 34.2% respectively (p = 0.003 for each). The same trend was observed when testing 10 antibiotics. When considering exclusion of outpatients and screening specimens, the MRSA rate varied slightly but not significantly.

Conclusions: To assess accurate MRSA trends, these results suggest that criteria used to remove duplicates should be carefully selected and described in scientific reports to allow meaningful comparison between hospitals.

Direct screening of MRSA from swab specimens using duplex real-time PCR assay: implication for antibiotic prophylaxis Desbouchages L a , Serazin V b , Leneveu M a , Rast G a , Giudicelli Y a,b , Merrer J c . a UF Bactériologie, b UF Biologie Moléculaire, c Unité d'Hygiène,

Aim: Methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage is a potential source of infection in orthopaedic surgery. Rapid identification of MRSA in clinical specimens is important both for antibiotic prophylaxis and isolation of colonized patients. Currently, screening patients for MRSA using culture methods requires 1-3 days for detection and identification. We developed a duplex real-time PCR, targeting the mecA (specific of methicillin resistance) and nuc (specific of S. aureus) genes, without previous isolation and enrichment. We compare the results of this method with those of conventional culture in a group of surgical patients with high risk of MRSA carriage for which vancomycin prophylaxis is usually recommended.

Materials and methods: Nasal swabs were collected on admission during 5 months in 122 elderly patients admitted with a femoral neck fracture. All samples were processed in parallel by selective plating method (Mueller Hinton + ofloxacin 4 (g/ml) and by duplex real-time PCR. SYBR green was used for amplicon detection.

Results: Results of PCR screening were obtained within 2 h. Swab samples were negative by both methods in 99 patients (81.2%), 11 were positive by both methods (9.0%), 1 was positive by culture only (0.8%) and 11 were positive by duplex real-time PCR only (9.0%). In the latter group, all samples were a mixture of methicillin-sensitive Staphylococcus aureus and methicillin-resistant coagulase negative Staphylococcus. Conclusion: This duplex real-time PCR is a rapid, cost-effective and valuable method to rule out MRSA nasal carriage. Therefore, vancomycin prophylaxis could be safely avoided for these patients free of MRSA nasal carriage.

Hill R, Levey M. R&D, Pharmaceutica, Worcester, UK Evolution of bacterial cell walls that resist the action of beta-lactam antibiotics, continues to pose unique challenges to the treatment of infection. An emerging technology of 'bacterial transforming agents (BTA) identifies molecules that reverse cell wall resistance primarily to beta-lactams and related agents, by therapeutically targeting moieties involved in the binding of muropeptide tails to cell wall cross-links. Moieties that mimic those in the pentaglycine cross-links of S. aureus, including methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, can result in peptidoglycan muropeptides terminating with a d-Ala-X, instead of d-Ala-d-Ala. BTAs similarly interact with muropeptide tail-cross-links assemblies to hypersensitise the cell wall, transforming MRSA into MSSA, without eliminating PBP2. As a basic test of the technology in vitro, a glycine benzyl ester at 0.2% ww/v, reduced the MICs of 20 MRSA (including UK Epidemic MRSAs-1, 15, 16 and 17) from >256 mg/l to 2-4 mg/l. Other BTAs increase potency by 10-100 times, such that their co-formulation with betalactamase-resistant anti-staphylococcal beta-lactams or related antimicrobial for topical treatment becomes immediately possible. In addition, MICs of vancomycin for MRSA with reduced glycopeptide-sensitivity, were reduced from 4.0 to <0.5 mg/l. There is also some activity against vancomycinresistant Enterococcus faecium. None of these substances have antimicrobial activity in their own right and MRSA are only transformed into MSSA in the presence of a BTA. A specific agent with established pharmaco-kinetics and toxicity data, that reduces MICs of methicillin from >256 to >4.0 mg/l, in the presence of serum, is a 'bench-mark' coformulant with antimicrobials such as flucloxacillin and cloxacillin for in vivo study.

By coformulation, BTAs could restore the activity of some well known anti-staphylococcal antimicrobials only active against MSSA, to produce new therapeutic entities. radiography) and bacteriological investigations. Furthermore, between January 2003 and september 2004, a systematic comparison of all the Mycobacterium tuberculosis strains isolated in the hospital was conduced by a molecular typing method in order to access an eventual transmission. Sixty two strains were compared by spoligotyping according to Kamerbeek et al. Spoligotyping is a typing method based on DNA polymorphism present at one particular chromosomal locus, the "direct repeat" (DR), which is only present in M.tuberculosis complex bacteria. The number of DR elements in the cluster can vary between strains of the species. These 36 bp DRs are interspersed by non-repetitive DNA spacers of 36-41 bp. Forty three spacers representative of the M. tuberculosis complex strains are synthesized as oligonucleotides and immobilized on a nylon membrane. Isolates are strain-typed on the basis of detecting the presence, or the absence, of specific spacers using PCR and a reverse-line hybridization technique. The nursing auxiliary'strain clearly showed a distinct spoligotype from the others investigated strains. Interestingly, this spoligotype was unique in the spoligotype database of the Centre de Référence des Mycobactéries de l'Institut Pasteur. In this large epidemiological survey of a suspected nosocomial case of tuberculosis, spoligotyping appeared as an interesting, easy to perform and rapid method of molecular typing. It allowed to demonstrate that the nursing auxiliary tuberculosis was unrelated to the others cases of tuberculosis diagnosed in the hospital during this period. However this investigation is actually prolonged for a recommended period of 18 months. Introduction: Despite a widespread perception that the epidemiology of pulmonary tuberculosis (TB) in Athens has changed recently, in part due to the influx of immigrants during the past 15 years, this has not been investigated properly. Our aim was therefore to conduct an epidemiological survey collecting relevant data from patients diagnosed at the two largest Pulmonary Hospitals of the city.

Methods: All TB patients diagnosed at Sotiria and Sismanoglion Hospitals during an 18-month period were prospectively enrolled. Strain isolation and identification was performed according to standard procedures. The agar proportion method and MGIT (Becton Dickinson, USA) were used for susceptibility testing to isoniazid (INH), rifampin (RIF), ethambutol (EMB), streptomycin (SM) and pyrazinamide (PZA). Demographic, clinical and laboratory data were collected through a review of medical records and interviews with patients.

Results: A total of 234 TB cases were confirmed. The majority were men (77%) and lived in Athens (68%). Most patients (71%) were native Greeks. There were 69 foreigners, of whom 54% emigrated from Eastern Europe. Their mean age was 31.6 years compared to 53.9 years among Greeks. Pulmonary TB was diagnosed in most (96%) and disseminated disease in 11 patients (5%). Immunodeficiency was recognized in 17 patients (7%), 61 patients (26%) reported other chronic disease and 11 (5%) were intravenous drug users. Community exposure was reported by 15 persons (6%), while an institutional transmission involving five inpatients of a Psychiatric Clinic was strongly suspected. Twenty-two individuals (9%), of whom 10 were immigrants had documented prior TB treatment. Acid fast stains were positive in 66% of cases. Resistance prevalence was 14% for INH, 5% for RIF and EMB, 2% for PZA and 24% for SM. Resistance to two, three, four and five drugs was 8%, 3%, 1% and 1%, respectively. Eleven strains (5%) were resistant to both INH and RIF; three of these originated from immigrants.

Conclusions: Pulmonary TB in Athens affects primarily males with immigrants representing a third of this population. The prevalence of multidrug-resistance is 5%. Objective: To outline the clinical and epidemiological features of tuberculosis (TB) of the central nervous system (CNS) parenchyma along with the optimal duration of anti-TB therapy.

Methods: This is a retrospective case survey of patients admitted to Lariboisière Hospital between 1995 and 2004 with a diagnosis of CNS parenchymal TB. Demographic, clinical, laboratory, radiological data along with duration of and response to anti-TB therapy were collected. Diagnostic criteria were either proven presence of mycobacteria in the CNS parenchyma or bacteriologically proven TB elswhere and radiological images of CNS TB along with clinical and radiological improvement after antituberculous therapy.

Results: 23 patients fulfilled the aforementioned diagnostic criteria. Most of them were aged 40-49 (40%) and of male sex (69.6%). Fifty two were African, 14.7% from the Indian subcontinent; the others were Asian, European and Caribbean natives. 34.7% were HIV infected. The main clinical symptoms were: headache (74%), weight loss (69.6%) and fever (60.9%). Cerebrospinal fluid (CSF) was pathologic in 69% of the patients; acid-fast bacilli were seen on direct examination in only one patient and cultured in 5/23 patients (21.7%). CNS mycobacteria were identified by direct examination, culture or PCR in 7/23 patients (30.4%). CT scan showed parenchymal mass lesions in 90% and MRI in 100% of the patients that underwent the examinations. In patients that underwent a complete course of anti-TB therapy the induction phase used a 4-drug regimen: isoniazid + rifampin + pyrazinamid + ethambutol in 82.6% of the patients and a 3-drug regimen in 17.4%; consolidation therapy used mostly isoniazid + rifampin (43.75% of patients). 87.5% of these patients had a total duration of treatment of at least 12 months; none of those needed additional therapy.

Conclusions: CNS parenchymal TB is more frequent in middle-aged adults. Its diagnosis is based on an association of clinical, laboratory and radiological arguments as well as on response to anti-TB therapy. In our opinion treatment for this form of TB requires a 2-month course of a 4-drug regimen followed by bi-therapy for a total duration of at least 12 month.

Key words: tuberculosis, CNS, parenchyma, tuberculoma, demography, anti-tuberculous therapy

The diagnosis of lymph node tuberculosis in Tunisia

Lymph node tuberculosis (LNTB) is the common form of extra pulmonary tuberculosis. In clinical practice histological and cytological study of the lymph node material mostly permits the diagnosis.

Objectives: Description of the diagnostic approaches to LNTB. Methods: Retrospective study of cases of LNTB who were hospitalized in the department of infectious diseases in Rabta's hospital in Tunis during ten years, from 1990 to 1999.

Results: 63 cases of LNTB were studied, 34 men and 29 women with mean age of 35 years. Twenty four patients were immunocompromised, 18 were co infected by HIV.

Diagnosis was suggested by the perception of peripheral lymphadenopathy at the first clinical examination of 42 patients (67%). Tuberculin skin test was positive in 79% of cases. Twenty nine patients (46%) were abdominal or thoracic tuberculous lymph nodes were visualised by Doppler sonography and tomodensitometry. In our patients, diagnosis of lymph node tuberculosis was confirmed by cytological and histological exams of the lymph nodes in 56 patients (89%) and seven patients were treated on basis of the clinical observation.

Conclusions: Confirmation of LNTB is not easy, clinical observation, histology, cytology and radiology must be combined for establishing the diagnosis.

Magira E, Gounaris TH, Tsopra O, Gounari P, Arsenoglou TH, Sioula E.

We present a 22-year-old patient from Ethiopia who admitted to our hospital because of high fever and malaise. The clinical examination reveals enlarged lymph nodes at her upperclavicular space and the axillaries, high body temperature and loss of weight. Her liver was palpable. Her medical record was unremarkable and she mentioned a healthy life before she gets sick. The laboratory values were consisted with anemia and hypoalbuminaemia. Abdominal ultrasound revealed enlarged lymph nodes. Excision of the lymph nodes in the upperclavicular space was performed and massive white material was produced and the microscopic examination showed Mycobacterium tuberculosis infection. Chest X-ray was consistent with miliary Tb. 48 h after her admission to the hospital the patient's condition was deteriorated; her blood pressure was decreased her pulse rate was 120/min and the temperature was 39 • C. The HIV antibody test turned to be positive and coinfection with M. tuberculosis was recognized. The patient was placed on anti HIV and anti-Tb therapy as well, but 36 h later she succumbs. This is fulminant Tb sepsis case in the setting of human immunodeficiency virus infection in a patient that was previously remained free of symptoms.

Tuberculosis treatment in France: from guidelines to practices Tattevin P f , Chapplain JM f , Lesprit PH b , Billy CH c , Roblot F e , Alfandari S g , Rouveix E a , Bouvet E d . a Ambroise Paré, Boulogne, France, b Henri Mondor, Créteil, France, c François Quesnay, Mantes-La-Jolie, France, d Bichat-Claude Bernard, Paris, France, e La Milétrie, Poitiers, France, f Pontchaillou, Rennes, France, g Gustave Dron, Tourcoing, France Background: Guidelines for the treatment of tuberculosis (TB) have been updated in 2003 in USA (Centers for Disease Control and prevention, American Thoracic Society, Infectious Diseases Society of America) and France (Conseil Supérieur d'Hygiène Publique). Both are mainly evidence based and agree on most points. They recommend a treatment duration of 6 months for pulmonary TB, whether or not the patient is HIV-infected, and for any extra-pulmonary TB except in case of neuro-meningeal involvement where a 9-12 months course may be preferred. Corticosteroids are recommended at the initiation of TB treatment in case of pericarditis or neuro-meningeal TB.

Objectives: To assess whether practices in France are in agreement with those guidelines.

Methods: Using the French infectious diseases socitey net, we performed an anonymous audit of practices focusing on TB treatment duration and corticosteroids use according to the TB presentation. In May 2004, 375 members of the Société de Pathologie Infectieuse de Langue Française (SPILF) were asked to complete a short form about what they consider arestandard of carefor the treatment of TB in their department. Data were analysed using Epi Info 2000, 3.01 (CDC, Atlanta).

Results: 66 complete forms were analysed. The most frequently reported standard treatment duration was 6 months for pulmonary TB in non HIV-infected patients (reported as the usual duration for 91% of responders) and for miliary TB (45% of responders), 9 months for pulmonary TB in HIV-infected patients (42%) and for TB lymphadenitis (57%), and 12 months for meningeal TB (79%) and osteo-articular TB (65%). Corticosteroids were mainly prescribed during the treatment of TB meningitis (systematic use for 80% of responders), pericarditis (65%), pleurisy (20%), lymphadenitis (14%) and miliary (14%).

Clinical significance of efflux-mediated resistance to FQs in Pseudomonas aeruginosa evaluated by Monte-Carlo simulation Dupont P a , Hocquet D a , Patry I a , Chavanet P b , Plésiat P a . a Laboratoire de Bactériologie, CHU Jean Minjoz, Besançon, France, b Service des Maladies Infectieuses, CHU du Bocage, Dijon, France Objectives: Eight fluoroquinolones (FQs) (pefloxacin, norfloxacin, ofloxacin, moxifloxacin, levofloxacin, ciprofloxacin, trovafloxacin, and grepafloxacin) were assessed for their bacteriostatic and bactericidal activities against FQ-resistant mutants of P. aeruginosa overproducing the active efflux systems MexAB-OprM or MexXY. To gain an insight into the clinical significance of the resistance conferred by these mechanisms, a Monte Carlo simulation was conducted with various FQ regimens.

Methods: Seven and eleven clinical strains were found to overproduce MexAB-OprM or MexXY efflux systems, respectively, by immunoblot and qRT-PCR experiments. Gene sequencing revealed no mutation in the QR-DRs (gyrA, gyrB, parC and parE) of these isolates. MICs were determined by microbroth dilution assay and MBCs were assessed by the killing curve method. PK/PD parameters were calculated by using a Monte-Carlo simulation conducted with various FQ regimens on 1000 patients. We chose an AUC 0-24 /MIC ≥ 125 and a Cmax/MIC ≥ 10 as the pharmacodynamic targets predicting clinical outcome.

Results: Overexpression of MexAB-OprM or MexXY increased the MICs of all the FQs two-to eight-fold. For example, ciprofloxacin MICs reached 0.5-1 g/mL when the pumps were overexpressed. In addition, MBCs were two-to four-fold higher than the MICs for all the FQs tested. Monte-Carlo simulation showed that the PK/PD parameter attainment rates decreased dramatically as a result of efflux-mediated resistance. Success rates were as low as 4% even with simulation of aggressive treatment (IV ciprofloxacin 800 mg tid) when ciprofloxacin MIC reached 0.5 g/mL.

Conclusion: FQs exhibit decreased bacteriostatic activities but remain bactericidal on efflux-overexpressing mutants. The low resistance levels conferred by efflux mechanisms are however predicted to result in poor clinical outcomes. Overall, these data strongly suggest that while modest, active efflux provides P. aeruginosa with a resistance that may be sufficient to impair the efficacy of single therapy by FQs.

The objectives were to study the role of the multidrug efflux system AcrAB-TolC in resistance of multidrug-resistant Salmonella Typhimurium DT104 and DT204 strains to detergents and bile salts, and also to evaluate the role of the components AcrB and TolC in the colonisation of these strains in chicks. acrB and tolC mutant strains were constructed by insertional inactivation or deletion of the genes, respectively. MICs of detergent (SDS) and bile salts were determined for the wild-type strains, the acrB, and the tolC mutants. The effect of sodium choleate (CHOL) on the in vitro growth of these strains was also evaluated. The LD50 s of the strains were measured in a day old chicken model, inoculated with several doses (3-9 log 10 cfu) per os, at 7 days post-inoculation. The colonisation levels were assessed at the sublethal dose 7 days post-inoculation by determining the number of CFU of Salmonella in the faeces, caeca, spleen, and liver. In the case of the acrB mutants, the MIC values of SDS, sodium deoxycholate (DOC) and CHOL decreased 64-128-fold, 2-8-fold and not significantly, respectively, relative to those of the wild type strains. For the tolC mutants, MICs of SDS, DOC and CHOL decreased 1024-2048-fold, 512-fold, and 256-fold, respectively. Thus, the decrease in resistance levels to SDS and bile salts was much more important for the tolC than for the acrB mutants. CHOL did not affect the in vitro growth of the wild-type strains or the acrB mutants but inhibited that of the tolC mutants. The LD50s were 6 log 10 and 7 log 10 cfu for one wild type DT104 strain and the acrB mutant, respectively, and were not calculable for the tolC mutants or the DT204 strains because of a too small number of dead chicks. In contrast to the acrB mutants, the tolC mutants were unable to colonise the organs, and were not detected in the faeces of most chicks. The colonisation levels of the acrB mutants were the same as those of the wild-type strains. Thus, TolC but not AcrB appears to be essential for multidrug-resistant S. Typhimurium DT104 and DT204 colonisation of chicks, which correlate well with their respective roles in resistance to detergents and bile salts. TolC could therefore be a better target than AcrB for the development of efflux system inhibitors.

Cagliero C, Cloix L, Payot S, Cloeckaert A. UR086 BioAgresseurs, Santé, Environnement, Institut National de la Recherche Agronomique, Tours-Nouzilly, France Campylobacter, one of the leading cause of human gastroenteritis, is reported worldwide to be increasingly resistant to antibiotics. Apart from target mutations, an efflux mechanism (CmeABC efflux system) has been described. By sequencing the whole operon of a resistant strain, we found that, in contrast to CmeA and CmeC, the CmeB sequence greatly differs (22%) from that of the NCTC 11168 strain. The objectives of this work were to design a PCR-RFLP method to study the diversity of this multidrug transporter in several representative strains of Campylobacter jejuni and Campylobacter coli (isolated from human, poultry or pig) and to examine its utility as a typing method. Twenty-three strains were included in the analysis. The entire cmeB gene was amplified by PCR and digested by eight restriction enzymes. A comparison of the restriction patterns was made to determine the diversity of the transporter sequence (at the nucleotide and protein levels). Eighteen different overall patterns were obtained. The same discrimination could be obtained by associating only half of the enzymes. A single HinfI-HaeII digestion was sufficient to discriminate two-third of the strains. Three pairs of identical patterns (including one human and one poultry grouping together) were observed. Overall, the strains showed 79-97% of homology except one poultry strain with less than 30% of homology. Differences were localized all over the sequence and also concern the characteristic functional motifs of the transporter. Of the twenty-eight potential restriction sites, two and five were respectively conserved in all or all except one of the strains. In conclusion, in contrast to its Salmonella and Escherichia coli AcrB homolog, a high diversity was observed in the cmeB multidrug transporter gene of both Campylobacter jejuni and Campylobacter coli. This could be of importance in targeting this pump to combat resistance. Furthermore, the PCR-RFLP designed in this work could be a cheap and easy-to-perform method to compare isolates of these bacterial species. In addition, protein modifications that could have a functional significance (in the characteristic motifs involved in substrate recognition and energizing) were also observed.

Vidaillac C a,b , Guillon J a , Arpin C b , Grellet J c , Jarry C a , Quentin C b . a EA 2962, Laboratoire de Pharmacochimie, Université de Bordeaux 2, Bordeaux, France, b EA 525, Laboratoire de Microbiologie, Université de Bordeaux 2, Bordeaux, France, c EA 525, Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Université de Bordeaux 2, Bordeaux, France

The discovery of efflux pumps inhibitors (EPIs) capable to restore the antibiotic susceptibility of bacterial mutants overexpressing efflux, in particular multidrug resistance (MDR) systems, would be of major interest providing that they are devoided of toxicity at therapeutic levels. Among currently available EPIs, benzimidazole derivatives such as omeprazole are safely used since years as inhibitors of the eukaryotic proton pump in the treatment of gastric ulcers, but exhibit a moderate activity against bacteria. In this study, a series of new potential inhibitors was synthesized, based on some common features shared by different EPIs. In this series, five molecules (1a-1e), showing structural analogies with the benzimidazole proton pump inhibitors, were examined. Then, published methods investigating the bacterial efflux systems and their inhibition were tested, in order to delineate a strategy for EPI evaluation, using the following model: Staphylococcus aureus strain SA 1199B, overexpressing the MDR efflux pump NorA, as germ-test; norfloxacin as preferential substrate; and omeprazole as reference EPI. Antibiograms by the diffusion method in agar supplemented with the EPI at MIC/4, subsequent checkerboard assays combining the antibiotic and the EPIs, and finally HPLC measurements of antibiotic intracellular accumulation with or without EPIs were found to be a useful approach. Products 1a-1d appeared to be efficient by the diffusion test and the checkerboard technique ( FIC = 0.25, for optimal concentrations of 8 mg/l of norfloxacin and 64 mg/l of EPI). At these concentrations; the most promising molecule 1c increased the intracellular level of norfloxacin from 3 to 8 × 10 −9 ng/10 −6 cells; compound 1e gave poorer results. In comparison, omeprazole yieded to a FIC = 0.25, and increased the norfloxacin intracellular accumulation up to 12 × 10 −9 ng/10 −6 cells. Thus, our products actually acted as EPIs on the MDR efflux pump NorA, but further research is needed to obtain drugs more effective than omeprazole. However, our data allowed structure-activity relationship analysis that will help us to modify the design of our synthesis and throw some light on the mechanism of action of these inhibitors on bacterial efflux pumps.

De Mouy D a , Fabre R b , Cavallo JD b , Arzouni JP a , Baynat M a , Bicart-see A a , Doeschler T a , Gavinet AM a , Galinier JL a , Garrabé E b , Gontier P a , Grillet N a , Larribet G a , Lepargneur JP a , Naepels I a , Payro G a . a AFORCOPI-BIO, Paris, France, b HIA Bégin, Saint-Mandé, France

The aim of this study was to determine the distribution and the antibiotic susceptibility patterns of the strains isolated from 15 to 65 years old females with community-acquired urinary tract infections. From October to December 2003, 10 French private laboratories consecutively collected 420 clinical strains with medical informations from an interview with the patient: fever, pregnancy, associated diseases, history of urinary-tract abnormalities, re-infection (3 months), previous antibiotic treatment or hospitalization (6 months). Escherichia coli was the most prevalent pathogen (80%) followed by Proteus mirabilis (4%), Klebsiella spp. (2%), other Enterobacteriaceae (4%), Enterococcus spp. (3%), Staphylococcus aureus (2%), Staphylococcus saprophyticus (2%) and Streptococcus agalactiae (2%). S. aureus was more often isolated in diabetic's patients. Susceptibility to antibiotics was studied for E. coli using determination of minimal inhibitory concentrations by the agar dilution method in a coordinating center. Results were interpreted according to the recommendations of the Comité de l'Antibiogramme de la Société Française de Microbiologie. The susceptiblity was 61% for amoxicillin (AMX), 93% for nalidixic acid (NAL), 97% for norfloxacin (NOR) and ciprofloxacin (CIP), 77% for cotrimoxazole (SXT), 99% for fosfomycin, gentamicin and cefotaxime. The susceptibility of E. coli was lower in case of previous treatment with ␤-lactam antibiotics for AMX (84% versus 95%, p = 0.02) et SXT (62% versus 81%, p = 0.02). In the same way, previous treatment with quinolones was associated with decreased susceptibility for NAL (84% versus 95%, p = 0.02) and SXT (62% versus 81%, p = 0.02). For the treatment of these urinary tract infections, fluoroquinolones represented 53% of the prescribed antibiotics, followed by ␤-lactam antibiotics (24%), fosfomycin (14%), cotrimoxazole (4%), furanes (4%) and nalidixic acid (1%). Single-dose treatment, three days and seven days or more treatments were respectively prescribed in 16, 12 and 73% of the cases. Urinary tract infections (UTI) acquired in the community, seldom complicated, are very frequent and require an empiric treatment protocol based in the antimicrobial susceptibility pattern to etiologic agents. Uropathogenic Escherichia coli are the more frequent bacteria causing UTI and a marker for to predict the evolution of resistance in the community. We have studied the isolation of E. coli and your antimicrobial susceptibility pattern in our area during the last 5 years. We identified 4685 strains from urine samples with significant counts using conventional methods and broth dilution for to establish MIC from several antimicrobials (Microscan, Dade Behring). We have evaluated the sensitivity to ampicillin (AM), amoxicillin-clavulanic acid (AC), nalidixic acid ( (75.1-73.9 ). Strains with decreased sensitivity to CIP (1ìgr/ml) are more frequent now (2.1% versus 1.3% in 2000). Also, is relevant the proportion of strains with MIC of 0.5ìgr/ml (10.8%). One thousand and ten strains were resistant to fluoroquinolones (23.6%). In this group the percentages of sensitivity to other antimicrobials were substantially lesser: 16.3 (AM), 63.3 (AC), 39.2 (TMP/SXT), 90.1 (FOS), 74.9 (FD) and 75.1 (GM), presenting cross-resistance in several strains. As conclusions is remarked the recovery in susceptibility of some antimicrobials recommended in ambulatory therapy, perhaps due to an antimicrobial policy established from few years in the community healthcare. Nevertheless is disturbing the constant increased in the resistance of quinolones group, according to uncontrolled and inappropriate use due to the good image of activity and tolerability.

Ronco E a , Denys P c , Laffont I c , Bernède C d , Martel P d , Guillemot D d , Salomon J b , Dizien O c , Bussel B c , Perronne C b , Gaillard JL a . Background: Urinary tract infection (UTI) is the most common medical complication in patients with spinal cord injury (SCI). However, the relevant biological criteria remain unclear because of repeated catheterization and common asymptomatic bacteriuria and/or pyuria.

Methods: We measured the colony forming unit (CFU) and white blood cell (WBC) counts in two groups of urine samples collected prospectively from SCI male patients under intermittent catheterization (IC): 344 urine samples from 184 patients with clinical evidence of UTI and 256 samples from 212 asymptomatic controls.

Results: Between 69% and 87% of urine samples from symptomatic patients, and between 55% and 74% of control samples were considered as positive according to the following classical criteria: (i) ≥10 2 cfu/ml; (ii) ≥10 5 cfu/mL; (iii) ≥10 5 cfu/mL and ≥10 4 wbc/mL. We evaluated various CFU and WBC tresholds, alone and in combination for their ability to discriminate between the two groups. Overall, combining both criteria of bacteriuria and of pyuria was the most discriminating. The best treshold combination was 10 4 cfu/ml and 5 × 10 4 wbc/mL (OR = 3.86 versus around 2 with the classical criteria). This combination provided a sensitivity of 74% and a specificity of 55.1%, while the classical criteria were more sensitive but much less specific (sensitivity/specificity in %: 100/25.8 [≥10 2 cfu/mL], 87.7/37.5 [≥10 5 cfu/mL] and 79.7/45.3 [≥10 5 cfu/mL and ≥10 4 wbc/mL]).

Conclusion: In summary: (i) biological criteria are overall weakly discriminating in SCI patients under IC; (ii) combining criteria of bacteriuria and pyuria provides better sensitivity/specificity ratios; (iii) the optimal tresholds are 10 4 cfu/mL and 5 × 10 4 wbc/mL. Very few data have been published on the microbiology of acute prostatitis. Most of the microbiological studies on urinary tract infections (UTI) either do not specify the site of infection, or focus on cystitis or pyelonephritis. For prostatitis, data are available mainly for chronic forms.

Objectives: To describe and compare microbiological data (species and antibiotic-resistance profiles) of community-acquired or nosocomial acute prostatitis.

Methods: Retrospective study of all acute prostatitis cases with available uroculture, hospitalized from 1998 to 2002 in two French university teaching hospitals (either in urology, medicine or infectious diseases sections).

Results:

Microbiological data Acquisition mode 

The bacterial strains responsible for acute prostatitis appear very similar to those of other UTI sites. Nosocomial prostatitis, including patients with indwelling catheters, should be of major concern, regarding to its specific bacteriology (including an over-representation of Pseudomonas aeruginosa), to the major differences in antibiotic resistance profiles, and to the restricted number of antibiotic diffusing into the prostate, conditions that may lead to treatment failure or chronic evolution.

Aetiology of chronic prostatitis syndrome Skerk V a , Krhen I b , Schonwald S a , Cajic V a , Markovinovic L a , Roglic S a , Zekan S a , Skerk V c , Tambic A total of 1442 patients with symptoms of chronic prostatitis were examined over a 4-year period at the Outpatient Department for Urogenital Infections, University Hospital for Infectious Diseases "Dr. Fran Mihaljevic", Zagreb, Croatia. An infectious aetiology was determined in 1070 (74.21%) patients. In 561 (52.4%) of 1070 patients the inflammatory finding (>10 WBCs/hpf) was found in EPS or VB 3 . Normal, <10 WBCs/hpf was found in 362 (67.54%) of 536 patients with symptoms of chronic prostatitis in whom C. trachomatis was detected in EPS or VB 3 , in 51 (33.77%) out of 151 patients with isolated Trichomonas vaginalis and in 40 (55.56%) out of 72 patients with isolated Ureaplasma urealyticum. Escherichia coli was the causative pathogen in 95, Enterococcus in 68, Proteus mirabilis in 37, Klebsiella pneumoniae in 16, Streptococcus agalactiae in 19, and Pseudomonas aeruginosa in three patients with chronic prostatitis. Other patients had a mixed infection. In patients with chronic bacterial prostatitis caused by E. coli, P. mirabilis, Kl. pneumoniae, Enterococcus or Streptococcus agalactiae, an inflammatory finding was regularly found in EPS or VB 3 .

Bonnal C, Mion M, Baune B, Armand-lefevre L, Lucet JC, Wolmark Y.

Purpose: The management of UTI in patients (Pts) in extended-care facilities is challenging, because of the high prevalence of bacteriuria, difficulties in diagnosing symptomatic UTI, and evidence that antibiotic treatment (AT) of asymptomatic bacteriuria (AB) is rarely beneficial. This study aimed to (i) identify UTI and AB, and (ii) to evaluate the impact of an antibiotic management program.

Methods: From July, 2003 to June, 2004, all positive urine cultures (PUC) obtained from patients hospitalized in a geriatric hospital (180 beds) were included. AB and UTI were diagnosed, according to McGeer criteria (Am J Infect Control, 1991; 19:1-71) . AT instituted for UTI or AB were prospectively assessed, and suggestions for alternative AT were made, if needed, according to standard recommendations.

Results: 181 patients (254 PUC) were included (mean age, 85 ± 9 y). In 128 PUC (50%), clinical signs of UTI were present: fever (32%), painful urination (15%), other signs (1-4% each). Other 126 PUC were considered AB. AT was initiated in 98 Pts: 69/128 with UTI (54%) and 29/126 (23%) with AB (p < 0.001). The white blood count was significantly higher in Pts receiving AT (8.9 ± 3.4 versus 7.7 ± 3.3 G/l, p < 0.01). No other criteria differed between the two groups. Of the 98 Pts with AT, 55 (57%) initially received a fluoroquinolone, 11 (11%) ceftriaxone, 11 (11%) amoxicilline, 11 (11%) cotrimoxazole and 10 (10%) other drugs. Before intervention, AT was correctly given according to susceptibility results in 79/98 Pts (81%); ordered AT durations corresponded to recommendations (5-7 d for UTI and 10-14 d for pyelonephritis) in 70/98 (71%) AT. The ordered AT duration was less often appropriate during the first 6 months of the study (29/48 [60%] versus 41/50 [82%], p < 0.02). After intervention, the actual number of ATdays was 19% lower than that initially ordered (153/807 d), with a higher reduction during the 6 first months (99/400 [25%] versus 54/407 [13%] d, p < 0.0001).

Conclusion: AT of bacteriuria in institutionalized Pts does not always correlate with presence of signs of UTI, underlining difficulties in diagnosing UTI in these Pts. After timely intervention to improve appropriateness of AT, a global 19% reduction was observed, with possible improved prescriptions by clinicians over time. Purpose: To assess the pharmacodynamic activity of azithromycin simulating clinically achievable serum and epithelial lining fluid (ELF) concentrations after a 500 mg intravenous dose against macrolide-resistant and susceptible S. pneumoniae.

Methods: A full computer controlled device derived from the original two-compartment kinetic model proposed by Blaser et al. (Antimicrob Agents Chemother 1985; 27:343-9 ) was used. The pharmacokinetic profile of azithromycin obtained in human serum and ELF after intravenous administration of a 500 mg dose was evaluated. Four S. pneumoniae clinical isolates were used: one macrolide-susceptible strain (MIC = 0.5 mg/L), low-level resistant strain (MIC = 2 mg/L), intermediate (MIC = 8 mg/L) and high-level macrolide-resistant strain (MIC = 256 mg/L). Initial inocula were in the range of 7 × 10 6 to 6 × 10 7 cfu/mL. Colony counts from samples from the peripheral compartment were determined over 24 h.

Results: Against the macrolide-susceptible strain no differences were found between both concentrations with ≥3 log 10 reduction at 24 h. Against the low level macrolide-resistant strain, only the ELF concentration achieved this bactericidal activity at the same time period. 

The high ELF concentrations obtained clinically with azithromycin showed a high bactericidal activity against low-level macrolide-resistant S. pneumoniae (CMI = 2 mg/L) and bacteriostatic activity against macrolide-resistant S. pneumoniae. This fact may explain the lack of clinical failures against S. pneumoniae with MIC ¡Ý 2 mg/ Purpose: To explore the pharmacodynamic need for continuous versus intermittent (tid) administration of ceftazidime, based on the in vitro susceptibility of the Pseudomonas aeruginosa isolate.

Methods: A full computer controlled device derived from the original two-compartment kinetic model proposed by Blaser et al. (Antimicrob Agents Chemother 1985; 27:343-9 ) was used. The pharmacokinetic profile of ceftazidime obtained in human serum after intermittent administration of a 6 g daily dose (2 g tid) or 6 g/day continuous infusion, producing similar AUC 0-24 h (approximately 950 g h/ml) for both regimens, was simulated. Four P. aeruginosa clinical isolates were used: one susceptible (MIC = 8 g/ml), two intermediate (MIC = 16 g/ml) and one resistant strain (MIC = 32 g/ml). Initial inocula were in the range of 2 × 10 7 to 1 × 10 8 cfu/ml. C max /MIC was 5, 2.5 and 1.3 for the continuous infusion and 15, 7.5 and 3.8 for the intermittent administration, and T > MIC was 100% for the continuous infusion and 99.8, 69 and 47.6% for the intermittent administration against the susceptible, intermediate and resistant strains, respectively. Colony counts from samples from the peripheral compartment were determined over 24 h. Reduction of initial inocula over time was calculated.

Results: Against the susceptible and intermediate strains, no differences were found between both regimens with ≥3 log 10 reduction from 8 to 24 h. Against the resistant strain, only the continuous infusion achieved this bactericidal activity at the same time period, minimising the differences between resistant and susceptible strains found with the intermittent administration.

Conclusion: Local prevalence of P. aeruginosa resistant strains with MIC = 32 g/ml of ceftazidime justify, from the pharmacodynamic point of view, the need for continuous versus intermittent administration.

Cousson J c , Hoizey G b , Floch T c , Raclot P c , Petit JS c , Vernet-garnier V a , Lamiable D b , Leon A c . a Laboratoire de Bactériologie, b Laboratoire de Pharmacologie, c Réanimation Polyvalente, CHU Reims, Reims, France Background: It is well known today that the main determinant of betalactam antibiotics efficacy is the duration of the time that concentrations remain in excess of the minimum inhibitory concentration (MIC) of susceptible organism over the course of therapy. This prospective study aimed to evaluate the efficacy, in term of pharmacodynamic profile, of continuous infusion versus intermittent administration of ceftazidime in intensive care unit patients with severe nosocomial pneumonia.

Methods: 16 patients under mechanical ventilation with nosocomial pneumonia were randomised to receive either 60 mg/kg/day ceftazidime by constant rate infusion following a 20 mg/kg loading dose (Group A) or 20 mg/kg every 8 h by intravenous bolus injection (Group B). Patients with renal dysfunction were not eligible. In both groups, serial blood samples were collected during 48 h (11 and 17 samples in Group A and B, respectively) after the start of drug administration. Plasma concentrations of ceftazidime were measured by high performance liquid chromatography. Based on our local bacteriological conditions, the pharmacodynamic profile of ceftazidime was assessed as the duration of time the plasma concentration remained above a desired target concentration of 20 mg/L for each regimen.

Results: The mean time for which plasma ceftazidime concentrations decreased below 20 mg/L was 0 min for the continuous infusion group (Group A) and 8.5 ± 1.1 h per day for the bolus group (Group B).

Conclusion: These findings show that ceftazidime administered by continuous infusion in critically ill patients under mechanical ventilation with nosocomial pneumonia appears to substantially improve the pharmacodynamic profile of this beta-lactam compared to the intermittent regimen.

Firsov AA a , Lubenko I a , Vostrov SV a , Alferova IV a , Smirnova M a , Zinner SH b . a Department Pharmacokinetics & Pharmacodynamics, Gause Institution of New Antibiotics, Moscow, Russia, b Harvard Medical School, Mount Auburn Hospital, Cambridge, United States Objective: To compare the pharmacodynamics of daptomycin (DAP) and vancomycin (VAN), killing kinetics of differentially susceptible S. aureus were studied at widely ranged AUC/MIC ratios.

Methods: Two clinical isolates, S. aureus 866 (MIC DAP 0.35 mg/L and MIC VAN 0.70 mg/L) and S. aureus 10 (MIC DAP 1.1 mg/L and MIC VAN 2.2 mg/L) were exposed to DAP (as a single dose) and VAN (as two 12 h doses). Mono-exponential concentration decay was simulated with half-lives of 9 h (DAP) and 6 h (VAN) and AUC/MIC ratio varied from 33 to 970 h.

Results: Anti-staphylococcal effects of DAP and VAN depended on the simulated AUC/MICs: the higher the AUC/MIC, the lower numbers of surviving organisms and the later regrowth. Despite pronounced variability of the time-kill curves, AUC/MIC relationships of the intensity of the antimicrobial effect (I E ) were specific for DAP and VAN but independent of bacterial strain. An E max model fits these relationships with r 2 0.90 (DAP) and 0.82 (VAN). Based on the I E -AUC/MIC relationships, the effects of DAP (4 mg/kg-proposed therapeutic dose) on S. aureus 866 (AUC/MIC 1100 h) and 10 (AUC/MIC 350 h) may be 3.4 and 2 times greater, respectively, than those of two 1-g doses of VAN given with a 12 h interval (AUC/MIC 570 and 180 h, respectively).

Conclusion: These findings predict greater anti-staphylococcal effects of clinically achievable AUC/MICs of DAP relative to VAN. 

Meynard JL c , Lacombe K c , Poirier JM d , Massot O c , Lefebvre B c , Bouchaud O a , Guiard-schmidt JB e , Vertsuyft C d , Benlian P b , Girard PM c . a Maladies Infectieuses, Hôpital Avicenne, France, b Biochimie, Hôpital Saint-Antoine, France, c Maladies Infectieuses, Hôpital Saint-Antoine, France, d Pharmacologie, Hôpital Saint-Antoine, France, e Maladies Infectieuses, Hôpital Tenon, Paris, France Background: LPV/r use is frequently associated with a significant increase of lipids parameters but the impact of LPV/c concentrations on these lipids changes remains discussed.

Objectives: To assess (1) the incidence of lipids changes during treatment with LPV/r; (2) correlation between total cholesterol (TC), HDL-C, LDL-C, triglycerides (TG), and drug plasma concentration (C min , C max ) of LPV.

Methods: Prospective study in naive and PI pretreated (<2 PI-containing regimen) patients with measurements of TC, LDL-C, HDL-C, TG, LPV C min , C max at W2, W12 and W24. Changes in lipids levels were analysed by paired-samples T-test. Correlations between parameters were studied by Pearson or Spearman correlation tests.

Results: Fifty-eight patients (23 naive, 35 pretreated) were included. Mean age was 41 years with 39 males/19 females. Baseline characteristics were: median CD4 cell count = 150/mm 3 (1-553), HIV viral load (VL) = 4.76 log copies/ml (1.7-5.7). Mean values (mmol/l) were: CT = 4.5; LDL-C = 3.4; HDL C = 0.8; TG = 1.24. CD4 cell count and HDL C were significantly lower in naive patients than in pretreated (117/204 and 0.65/0.95) (p < 0.05). There was a significant increase (p < 0.0001) of CT (4.5 versus 5.1), LDL-C (3.3 versus 3.7), HDL-C (0.8 versus 1) and TG (1.24 versus 1.8) between W0 and W24. No correlations were found between all lipid levels changes and LPV C min and C max (mg/l) at W2 (6577; 10,000), W12 (5405; 8550) , W24 (5264; 7730) . Drug intervention for correction of LDL-C value (>4.9 mmole/l) according to the guidelines for dyslipidemia in HIV infected patients (IDSA) was indicated in 6.9% (W0), 6.9% (W2), 12.1% (W12) and 8.6% (W24) of patients (ns).

Conclusion: Treatment by LPV/r is associated with a significant increase of lipids levels. These changes in lipidic parameters are not influenced by LPV plasma levels. Indication of drug intervention for correction of lipids abnormalities remained low (8.6% at W24). Conclusions: TM and CIP showed the lowest values of MPCs against P.a. However, whatever the antibiotic tested, (i) MPCs were high as compared to MICs, (ii) none of the C max /MPC ratio was >1, (iii) T MSW were high for all the tested regimens. Although these antipseudomonal treatments are associated with improved clinical outcome (mortality), as a whole, these results can explain the high frequency of resistant mutants in vivo and suggest that higher doses and/or combination therapy may be necessary to achieve optimal pharmacodynamic indices when using aminoglycosides or fluoroquinolones.

Hepatitis B virus genotypes a, c, d are responsible for a more severe hepatic disease than genotype b and e in chronically infected-patients Gordien E a , Ganne N b , Williams V a , Thar T b , Kaddouri H a , Alloui C a , Dziri Mendil S a , Hawajri A a , Trinchet JC b , Deny P a , Beaugrand M b . a Laboratoire de Bacteriologie Virologie, Hopital Avicenne, Bobigny, France, b Hépato-gastro-entérologie, Hopital Jean Verdier, Bondy, France Aims: To analyze hepatitis B virus (HBV) genotype distribution and clinical significance in patients from Paris suburban area.

Patients and methods: HBV genotyping and basal core promoter (CP) and precore (PC) mutants were determined in 109 chronically infected patients, respectively by a pre-S1 restriction length fragment polymorphism method and/or direct sequencing with the TRUGENE TM HBV genotyping kit (Bayer Health Care) and by the Affigene ® kit (Sangtec Molecular diagnostic).

Results: Genotypes a (26.6), b (12.8%), c (18.3%), d (18.3%) and e (14.6%) were found. Patients were originated from Asia (30.3%), Europe (28.4%), Sub-Saharan Africa (23.9%), Caribbean (10.1%), and North Africa (5.5%). Genotypes a and d (HBV/A and /D) infected all subgroups except Asian patients, whereas HBV/B or /C were found in 97% of Asian patients. HBV/E infected only Sub-Saharan African and Caribbean patients. Baseline serum HBV-DNA level was lower in HBV/B and/D (P =0.01). Anti-HBe seroconversion occurred in 57 patients (52.3%), mainly in HBV/D infected patients (P =0.01). HBV/A and /D infected-patients had higher serum alanine aminotransferase levels (P <0.05). CP and PC mutants found in 86.6% of anti-HBe positive patients, were associated with genotype D (P =0.04) and severe liver fibrosis (F3/F4 METAVIR classification) (P =0.002). Severe liver fibrosis was also related to HBV/A, /C and /D (P =0.02). However, No difference in occurrence of hepatocellular carcinoma or failure to treatment was observed.

Conclusions: HBV genotypes a, b, c, d, and e circulate in our area reflecting geographical origin of patients. HBV/A, /C and /D might be responsible for more severe hepatic disease.

Lada O, Benhamou Y, Poynard T, Thibault V. Hôpital Pitié-Salpêtrière, Paris, France Objectives: in chronic hepatitis B (CHB), persistence of HBs Ag is sometimes associated with antibodies (Ab) to hepatitis B surface antigen (anti-HBs). The reason for the presence of both Ag and Ab might be the selection of HBs Ag immune escape variants. To assess this hypothesis, variability of HBV S gene and protein from CHB patients was compared between patients carrying both HBs Ag and anti-HBs antibodies and patients solely positive for HBsAg. Among 864 CHB patients, 77 (8.9%) carried both HBs Ag and Ab on a same sample. We selected 14 patients who presented both markers (group I) on several consecutive samples and four control patients positive for HBs Ag only (group II).

Methods: Whole HBV genome from each patient's serum was PCRamplified and cloned. The S region of 15-19 clones per patient was sequenced and analysed. In group I, mean anti-HBs titre was 135 UI/L (range 38-434). The overall rate of co-infection with different HBV genotypes assessed by clonal analysis (265 clones) reached 22% (co-infection A and G n = 2, A and C n = 2).

Results: Comparative analysis of the a-determinant region (aa124-147) showed an increased variability of the nucleotide (p = 0.03, Mann-Whitney test) and the protein (p = 0.04) sequences from group I patients compared to control patients. Indeed, 10 (71%) patients from group I presented at least two clones carrying 1 or more residue change within the a-determinant; among them eight patients carried more than one substitution. In comparison, only one patient from group II presented a unique substitution in this region. Interestingly, the most frequent changes observed in group I patients, were located at position s145 (21%), s129 (9%) and s126 (22%) the most described mutations in immune escape variants.

Conclusion: Persistence of HBsAg despite production of detectable amount of HBs Ab is associated with an increase of the a-determinant variability. Progressive selection of HBV immune escape mutants during chronic carriage may explain the coexistence of HBs Ag and antibodies. Objective: Greece is a country of intermediate and low endemicity of hepatitis B (HBV) and hepatitis C virus (HCV) infections, respectively. A downward trend for HBV infection has been noted during the last years contrasting to the very high infection rates among immigrants, however, recent epidemiology data on these infections are lacking. The "Attikon" is a new University hospital located in western Attica, an area with low socio-economic status inhabitants and many immigrants. Our purpose is to determine the epidemiology of HBV and HCV infections among patients presenting to this hospital and present here our preliminary findings.

Methods: HBV and HCV serology results were obtained from all consecutive patients examined during a 6-month period (1/02/04 to 31/07/04) and analyzed retrospectively. The detection of HBsAg, anti-HBs, anti-HBc, anti-HBe and anti-HCV in serum was performed by the Microparticle Enzyme Immunoassay (AXSYM, Abbott, Greece).

Results Conclusions: In this population, the prevalence of seronegativity for any HBV infection marker was 61.2%. The low rates of anti-HBc(−)/anti-HBs(+) detection (13%) possibly indicate a low incidence of vaccination, however, these data need to be correlated with patient age. HCV infection rates appear to be low (2%), similarly to previous studies from our area. The analysis of these results in correlation with patient demographic data will define the epidemiology of hepatitis virus infections among this population.

Maïga I c , Mahot S b , Muller S b , Le Faou A a , Venard V a . a Laboratoire de virologie, Faculté de Médecine and CHU de Nancy, Vandoeuvre Lès Nancy, France, b Département d'Immunologie, Laboratoire National de Santé, Luxembourg, Luxembourg, c Laboratoire de biologie médicale, Hôpital du point G, Bamako, Mali Sub-Saharan Africa is a region of high endemicity of hepatitis B virus. A survey of 152 medical students from Mali has shown that 128 (84%) have had a previous contact with HBV of which 56% were Ag-HBs (+) and/or ADN (+) [two patients were Ag-HBS (−)/ADN (+)]. Such a high prevalence, which is more than two times the one estimated in the general population is puzzling and deserves further investigations. In this population, 110 clinical and epidemiological data were obtained. No relation has been observed between region of Mali patients come from and HBV infection prevalence. Of these students, 92 gave a written agreement for HIV serology. In this selected cohort, the HIV seropositivity was 9% while the overall prevalence in Mali is of 1.7%. The high prevalence of these two infections in a population of student who live promiscuously on the campus of the Faculty of Medicine (Point G, Bamako) isolated from the city, suggest a sexual transmission.

We have determined the genotype (PreS1/PreS2/S) of 33 HBV strains from patients with circulating DNA. All but 4 were of genotype E. These four strains were classified as genotype A but differed widely from reference strains. In order to further characterize these strains, the sequencing of PreC/C region was undertaken. A strong analogy of these sequences with the one of "classical strains" suggests a co-infection in these patients which explains the apparent skewness. Such a hypothesis has been confirmed by restriction fragment length polymorphism. This study confirms the high prevalence of genotype E in Sub-Saharan Western Africa (M. Mulders et al., J Inf Dis 2004; 190:400) . It points out also the high prevalence of sexually transmitted infections in selected populations. However these results have to be confirmed for preventive measures to be taken.

Noel V c , Emmanuelli J b , Breton G a , Longuet P a , Macrez A a , Rigolli B b , Vilde JL a , Leport C a . a Maladies Infectieuses et Tropicales, CHU Bichat-Claude Bernard, France, b Institut de Veille Sanitaire, Paris, c Orthopédie, Centre Hospitalier, Reims, France Between March 16 and April 30, 2003 , 90 patients were hospitalized (>24 h) in a reference Infectious Diseases Department for suspicion of SARS, based on epidemiological and clinical data. Diagnosis was difficult owing to the non-specific presentation: cough in 70%, fever in 46%, other respiratory, in 18%, or digestive symptoms, in 7%. Thirty-six percent patients had lymphopenia, 10%, thrombopenia, and 8% increased transaminases levels. Because of isolation, chest X-ray was done at bedside in 86 patients, and showed abnormalities in 17%. All patients with pneumopathy were given amoxicillin and roxithromycin. In the absence of confirmed SARS, alternative diagnoses were looked for in order to exclude its suspicion, allowing to stop the isolation, and introduce appropriate treatment. An alternative diagnosis was recognized in 17 (19%) patients. A variety of community acquired diseases was identified in 16 patients, by isolation of the causative organism from nasopharyngeal/respiratory secretions: metapneumovirus infection, n = 1, influenza A or B, n = 4, pneumococcal pneumonia, n = 4, tuberculosis, n = 1, by blood or urine cultures: infective endocarditis, n = 1, pyelonephritis, n = 1, Salmonella sp. enterocolitis, n = 1, or by other diagnostic means: Mycoplasma pneumoniae pneumopathy, n = 1, (serology), maxillary sinusitis, n = 1. An Asian acquired-infection was diagnosed in one patient: Burkholderia pseudomallei, n = 1. No SARS coronavirus was isolated. All pts were cured. The initial evaluation of each patient, performed concomitantly by clinicians and epidemiologists, was discordant in 35 (39%) pts on epidemiological data (n = 24) or clinico-biological data (n = 11). At the final evaluation all pts were considered as "excluded" cases for epidemiologists, while 47 (54%) were considered as "possible" or "doubtful" cases for clinicians. Whether these cases were a minor form of coronavirus infection, with spontaneous healing, remains hypothetical. Improvement of virological methods to isolate and identify both coronaviruses and other potential respiratory infections-associated viruses, in combination with serological tests, would be useful to assess this hypothesis retrospectively in these patients, and in case of a new outbreak. The occurrence of influenza infections during hospital stay is responsible for severe consequences in immunocompromised and debilitated patients. The virus can be introduced in the medical setting by patients, visitors and health care workers (HCWs). The best way to prevent the diffusion of influenza virus by HCWs is to recommend their annual vaccination. However, the vaccine coverage of HCWs against influenza is weak. The aim of this study was to evaluate the perception of influenza vaccination by HCWs and their knowledge of the risks linked to influenza in hospitals. A self-administered questionnaire including 24 short items was proposed to the HCWs of two French University Hospitals (Hôpital Edouard Herriot in Lyons and CHU de Saint-Etienne) by the hygiene referent nurses of each ward, by the Departments of Occupational Medicine and by electronic mail. From a total of 7973 questionnaires that were distributed, 2763 responses (34.6%) were obtained from HCW: 72.0% from care-giving personnel, 12.2% from medical personnel and 15.4% from other personnel without contact with patients. The mean age of the responders was 37.8 years. The overall vaccine coverage against influenza was 26.9%, with significant differences between the three HCW categories: 21.0% for care-giving personnel, 57.7% for medical personnel and 29.1% for other personnel (p < 0.001). The main reason for HCWs to get vaccinated was their own protection (24.5%) whereas the protection of patients was mentioned by only 17.5% of them. The fact that the vaccination was not mandatory was the first reason to refuse it (33.2%) whereas the fear of vaccine adverse effects was mentioned by only 17.0% of the non vaccinated HCWs. Except for the medical personnel, the knowledge regarding influenza, its consequences in hospitals and its prevention was weak. A total of 41% of the responders mentioned that influenza is not a nosocomial infection suggesting that they ignore that non-vaccinated persons are at risk to transmit the virus within the hospital. This study highlights that important efforts are required to provide information on the nosocomial transmission of influenza and to promote vaccination among HCWs, especially nurses, in order to reduce the risk of influenza outbreak in health care facilities.

Olivier C c , Chevallier B b , Gaudelus J a , Reinert P d . a Pédiatrie, Hôpital Jean Verdier, Bondy, France, b Pédiatrie, Hôpital Ambroise Paré, Boulogne-Billancourt, France, c Pédiatrie, Hôpital Louis Mourier, Colombes, France, d Pédiatrie, Hôpital Intercommunal, Créteil, France Purpose: To assess influenza impact for hospitalized pediatric patients during viral seasonal (winter) epidemics.

Methods: During the week 50 of year 2003, four general pediatric wards belonging to Parisian region included all the hospitalized children aged at least 1 month and less than 5 years. The Surveillance Nets gave the epidemic pike's signal of Influenza. It occurred that an RSV epidemic was on an optimal plateau during the same week. All children had naso-pharyngeal sampling within the first 24 h of hospitalization allowing the virus identification: influenza (I+) and RSV by the Reference Center of Influenza; France Nord.

Results: One hundred and seventy children were included; 106 (62%) were positive either for I + 23/106 (22%) or RSV 78 /106(73%); five children were co-infected. The sex-ratio M/F was 1.11. The mean ages were 18.8 m (I+) and 7.4 m (RSV) [p = 0.002]. Among I + children, 40% were less than 6 m of age and 42% more than 1 year of age. Among RSV children, 70% were less than 6 m of age and 16% more than 1 year of age. The mean duration of hospitalization was no significantly different between I + (6.4 D) and RSV (4.3 J). The comparison between the two respective groups I + and RSV showed significant differences for fever occurrence (70% versus 31%, p = 0.001), respiratory diseases-bronchiolitis, coughing and/or respiratory distress-(26% versus 73%, p < 0.001) and non-significant for digestive symptoms (22% versus 17%). Considering the occurrence of complications between I + and RSV groups, the difference was significant for convulsions (22% versus 1%, p = 0.002), and non-significant for acute otitis media (30% versus 22%), pulmonary condensations (17% versus 15%). Among the daily care criteria taken in account, in the two respective groups, antibiotics prescription was more frequent among I + (60% versus 32%, p = 0.022); the rates of oxygeno-dependant children (29% versus 47%) and of children needing continuous gastric feeding and/or infusion (43% versus 61%) were non-significantly different.

Conclusion: This pilot study confirms the influenza impact in hospitalized young children, especially its prevalence before 1 year of age. Some clinical differences as well as their consequences are emphasized between influenza and RSV Objective: Respiratory viruses, and particularly influenza virus and respiratory syncytial virus (RSV), are often described as potential triggers of acute respiratory or cardiac failure in frail individuals. However, there is little virologic evidence to support this view.

Design, Setting, Patients: We undertook a virologic survey in a critical care unit during two consecutive winters. All patients admitted to the unit for acute respiratory or cardiac failure were enrolled. A nasal swab was taken for PCR detection of influenza virus, RSV, metapneumovirus, rhinovirus and coronavirus.

Results: One hundred and twenty-two patients were enrolled. Mean age was 69 years, 42% of patients were female, the SAPS II score on admission was 35.6, 94% of patients had acute respiratory failure, 14% reported 'flulike illness' before admission, and 11% of patients died in the unit. Nine patients (12%) tested positive for a respiratory virus during the first winter and 12 (25%) during the second winter. No link was found between virologic results and clinical outcome. A strong link was found between the rate of influenza virus positivity and the incidence of 'flu-like illness' in the community (p = 0.017).

Conclusion: These results support the view that respiratory viruses-and particularly influenza virus during epidemic periods-can trigger acute respiratory or cardiac failure. Methods: Retrospective study conducted from January 2000 to December 2003. CMIT and SPILF members received questionnaires by electronic and postal mail (also available at www.infectiologie.com).

Results obtained: Cases were defined by clinical, radiological and positive Legionella antigen detection in urine samples. Thirty departments (of which five intensive care units) provided 417 cases; mean age: 57,9 ± 17 y; men: 74%. Risk factors were cigarette smoking (56%), alcoholism (23%), recent travel or exposure to air conditioning (20%), immunosuppression (18%), cancer (15%), diabetes mellitus (10%) steroids (7%). Seventeen percent had no identified risk factors, 34% had two risk factors, 33% had three risk factors and less than 15% had more than two risk factors. Mean body temperature was 39.5 • C (53.5% had more than 40 • C). Neurological, digestive and myalgia occurred in 36%, 25 and 12% of patients, respectively. Creatinine kinase, hepatic transaminases were increased in 35% and 49% of patients, respectively, and PaO 2 and Na were decreased in 85% and 55%, respectively. X-ray showed alveolar infiltrates, interstitial infiltrates and alveolar + interstitial infiltrates in 59%, 12% and 30% of patients, respectively.

Mean hospital stay was 16 days (medical ward: 12 d, ICU: 12 d). Nasal oxygen and mechanical ventilation was required for 62% and 30% of patients, respectively.

Macrolides, quinolones and rifampicin were used in 71%, 70% and 18%, of patients, respectively. A macrolide + quinolone combination was used for 46% patients. Mean treatment duration was 14 d for both macrolides and quinolones. Death occurred in 48 patients (12%), 40 patients were in ICU.

Conclusion: This study confirms non-specificity of clinical, radiological and biological signs of Legionnaire's disease in most of cases, the favorable outcome for medical ward patients, the wide use of quinolones as monotherapy or combined with macrolides. In 2001 and 2003, 3231 and 3351 strains of Sp were isolated from blood cultures, cerebrospinal fluids and ears in adults, respectively. MICs of penicillin (P), amoxicillin (AMX) and cefotaxime (CTX) were determined by agar dilution and interpreted according to CA-SFM breakpoints. Erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TET), chloramphenicol (C), pristinamycin (PRI), fosfomycin (FOS) and rifampicin (RA) were tested by agar diffusion, ATB Pneumo or Vitek gallery (bioMérieux ® ). We observed a significant decrease of PDSP and conversely a significant increase of resistance (I + R) to amoxicillin. There were no differences between strains highly resistant to P (MIC > 1mg/l) (11.5% versus 10.6%) during the two periods, respectively. Strains highly resistant (MIC > 2 mg/L) to AMX (1.3% versus 1.2%) and to CTX (0.1% versus 0.2%) remained rare and stable but there was an increase of strains with a diminished susceptibility to AMX (0.5 mg/L < MIC ≤ 2 mg/L). The rates of Sp resistant (I + R) to P, AMX and CTX and to other antibiotics are shown in the following tables: Methods: A data-processing screening was used to identify all new HIVinfected patients (either first diagnosis or initial management of previously known seropositivity) seen in our setting during this period. Descriptive analysis of sociodemographic, clinical and virological characteristics was performed. Comparisons of two sub-groups, i.e. French and Sub-Saharan Africa native patients were done.

Results: During the study period, 300 new HIV-infected patients were identified. Their characteristics were: median age 34.5 years; sex ratio M/W 65/35; single 60%; HIV known sexual partner 24%; ethnic origin: Caucasian 43%, African 44%, Maghrebian 8%, Asian 3%; nationality: French 45%, Sub-Saharan African 44%; irregular situation in France for foreigners 65%; employed 51%; HIV transmission group: heterosexual 54%, homo/bisexual 39%, IV-drug user 1.3%, unknown 5%; circumstances for HIV diagnosis: history of HIV exposure: 34%, primary infection 9%, symptoms/AIDS 23%, pregnancy 6%, other 28%. Initially, CDC stage was: A 77%, B 9%, C 14% with median CD4 + 322/mm 3 and median plasma HIV-RNA 30780 cp/mL. Coinfection with HBV was 6.3% and HCV 4%. Outcome was: 88% still followed up in St. Antoine Hospital, 2% transferred in other hospital, 9% lost to follow up and 1% dead at the date point. In univariate analysis, comparison between French (n = 123) and African (n = 46) men showed a significant difference for heterosexual transmission (10% versus 91%; p < 0.001), being married (16% versus 59%; p < 0.001), working status (85% versus 28%; p < 0.001), CD4 + (383/mm 3 versus 251/mm 3 ; p = 0.002), outcome (lost to follow up 5% versus 24%; p = 0.002). Comparison between French (n = 13) and African (n = 85) women showed a significant difference for age (41 years versus 32 years; p = 0.04), working status (38% versus 10%; p = 0.02), and CDC stage A (54% versus 81%; p = 0.03). Comparison between African patients according to sex (46 men/85 women) showed a significant difference for age (39 years versus 32 years; p = 0.006), marital status (58% versus 37%; p = 0.02), working status (28% versus 10%; p = 0.01), outcome (lost to follow up 24% versus 6%; p = 0.004).

Conclusions: This study conducted in a large hospital in Paris highlights: (1) the continuous HIV epidemics in homosexual French native men; (2) the growing contribution of African migrants: they are diagnosed later in the course of HIV infection, their social status is precarious, women are over represented and drop from follow up is high.

Determinants of adherence in 138 patients taking antiretroviral chemoprophylaxis after sexual exposure to HIV Lacombe K b , Lebeau V b , Daguenel-nguyen A a , Girard PM b , Meyohas MC b . a Pharmacie centrale, Paris, France, b Service de maladies infectieuses, Hôpital Saint-Antoine, Paris, France Context: Since 1998, highly active antiretroviral therapy (HAART) is delivered in France for 28 days to HIV negative patients facing a sexual exposure to HIV. Despite the risk of becoming HIV-infected and the free access to treatment, adherence is usually suboptimal.

Objectives: To analyse the socio-cultural determinants of adherence to HAART in HIV-negative patients exposed to sexual contamination by HIV.

Methods: Data concerning patients seen for a sexual exposure to HIV between October 2001 and September 2002 at the Saint-Antoine hospital outpatient clinic have been retrospectively collected. Non-adherence has been defined as the non-completion of the 28 day-course of HAART and its determinants have been analysed by logistic regression (with p < 0.05 considered significant).

Results: One hundred and forty-one patients have been included in the study and 138 were analysed because three patients were tested HIV-positive at initial testing. Males are predominant (78.3%) and median age is 31. Patients are 94.9% Europeans and 5.1% come from Africa. HAART has been initiated in 92.8% of patients and 7.2% received a bitherapy because of early side effects with HAART. Estimation of adherence at the end of treatment is 80.3%. In univariate analysis, the following factors are associated to a good rate of adherence: European origin, former HIV-negative test, sexual exposure after anal intercourse and in men having sex with men. A trend for poor adherence is noted for sex with a sex worker. In multivariate analysis, European origin and sexual exposure after anal intercourse remained associated with optimal adherence.

Conclusion: Albeit HAART after sexual exposure may prevent the transmission of HIV, the 28-day adherence to treatment is not optimal and may be explained by socio-economical factors and the perception of the risk of transmission associated with the type of sexual intercourse. Prevention campaigns should thus target the African community and persons having vaginal intercourse or sex with sex workers. 1108 (94.1%), 110 (93.2%), 164 (87.2%), respectively, were validated. SAE included more than 20 different categories of symptoms and complications. Severity of events and relation to ART was assessed using the same procedure by a small group of experienced physicians, guarantying strong homogeneity of the validation process. This process was very productive, had a good acceptability, improved monitoring of specific events and was appropriate for detection of unexpected events. In the setting of large and multicenter cohort studies of long duration, an ECV with strict rules to assess events is needed to provide data of the best quality possible.

HCV-related factors but not HIV-related factors at baseline predict the response to treatment with peginterferon alfa-2a (40 kd) (pegasys) plus ribavirin (copegus) in patients with HIV-HCV co-infection: predictor analysis from the APRICOT study Background: In the APRICOT study, the combination Pegasys/Copegus produced significantly higher sustained virological response (SVR) rates in patients with HIV-HCV co-infection (40%) than either Pegasys monotherapy (20%) or the combination of interferon alfa-2a plus ribavirin (12%). The objective of the study was to identify baseline characteristics predictive of an SVR in patients treated with Pegasys + Copegus.

Methods: 289 HIV-HCV coinfected patients received Pegasys 180 g/week plus Copegus 800 mg/day for 48 weeks in this randomized, multinational study. All patients were followed for 24 weeks after the end of the treatment. The SVR was defined as a single undetectable (<50 IU/mL) HCV RNA at the end of follow-up (week 72) by qualitative PCR (COBAS AMPLICOR HCV Test v.2.0). The factors considered in a stepwise multiple logistic regression analysis of prognostic factors for SVR included: age, gender, race, body surface area, HCV RNA titer, HCV genotype, histological diagnosis, ALT quotient, CD4 cell count and use of active antiretroviral therapy (HAART).

Results: The only significant independent factors associated with SVR in patients treated with Pegasys/Copegus were: HCV RNA ≤800,000 versus >800,000 IU/mL (p < 0.0001) and the HCV genotype non-1 versus 1 (p < 0.0001). The absence of cirrhosis, the age, the ALT quotient, the CD4 cell count, the use of HAART were not significant predictors of an SVR. At week 12, 204 of 289 patients (71%) had an early virological response (defined as undetectable HCV RNA (<50 IU/mL) or a ≥ 2 log 10 decline in HCV RNA), of whom 114 (56%) achieved an SVR. Conversely, only two of 85 patients (2%) without an early virological response at week 12 achieved SVR.

Conclusions: In patients with HIV-HCV co-infection treated with the combination of Pegasys/Copegus, infection with HCV non-1 genotypes and an HCV RNA titer ≤ 800,000 IU/mL had the greatest impact of achieving an SVR. In the absence of an early virological response at week 12, it is highly unlikely that a patient will achieve an SVR (negative predictive value = 98%).

Syphilis revealed by uveitis, in relationship with HIV Results: All patients were men. Eleven eyes of the 10 patients exhibited active anterior non-granulomatous uveitis and vitritis. Three of the eleven eyes included a retinitis, one a neuroretinitis, and seven a papillitis. Laboratory testing (fluorescent treponemal antibody absorption) revealed positive serology for active syphilis in all ten patients. Human immunodeficiency virus antibody testing proved positive in eight of the ten. These eight patients had evidence of concomitant central nervous syndrome involvement. Dramatic responses were noted with high-dose beta lactamine treatment in all cases.

Conclusions: There is a need to be aware of the resurgence of ocular syphilis accompanying the increase in sexually transmitted disease on an international scale. Since syphilitic uveitis is a treatable infection, ophthalmologists shouldn't overlook it.

Phospholipases and cationic peptides neutralize Cryptosporidium parvum sporozoite infectivity by either parasiticidal or nonparasiticidal mechanisms Carryn S b , Schaefer DA b , Imboden M a , Homan EJ a , Bremel RD a , Riggs MW b . a IoGenetics LLC, Madison, WI, USA, b Department of Veterinary Science and Microbiology, University of Arizona, Tucson, AZ, USA Purpose: C. parvum is a common cause of gastrointestinal infection for which there is presently no parasite-specific curative therapy. Innate immunity is the first line of host defense against many infections, and previous studies have shown that some components of the response exert in vitro activity against bacteria and protozoa. We therefore tested cathelicidin (CAT), indolicidin (IND), ␤-defensin 1 (␤D1), lysozyme (LYZ), phospholipase A2 (PLA2), and phosphoinositol specific phospholipase C (PIPLC) for direct in vitro killing and ability to reduce infectivity of C. parvum sporozoites.

Methods: Sporozoites (8 × 10 6 /ml) were incubated (15 min) with 10 (g/ml of each compound, C. parvum neutralizing MAb 3E2, or medium. Parasiticidal activity was then assessed by addition of fluorescein diacetate and propidium iodide and quantitation of sporozoite viability by fluorescence microscopy. To assess infectivity, intracellular stages were quantified 24 h after inoculation of treated-sporozoites onto Caco-2 cells using a C. parvum-specific MAb and an automated immunofluorescence microscope. Non-specific toxicity of each compound for Caco-2 cells was assessed by LDH release.

Results: None of the compounds or MAb 3E2 was toxic for Caco-2 cells. CAT, IND and ␤D1 were highly parasiticidal (30.9 ± 4.5, 54.1 ± 4.7, 55.2 ± 5.4% sporozoite viability compared to control, respectively, P < 10 −4 ). In contrast, PLA2 and PIPLC showed significantly less activity (74.8 ± 2.2, and 76.6 ± 2.4% viability, respectively, P < 0.001). LYZ and MAb 3E2 had no significant parasiticidal activity (87.2 ± 3.2, and 91.9 ± 5.5% viability, P > 0.05). CAT, IND, ßD1, and MAb 3E2 also significantly decreased infection in Caco-2 cells (75.2 ± 7.0, 61.1 ± 15, 73.0 ± 9.5, 59.4 ± 4.0% decrease, respectively, P < 0.001). Interestingly, PLA2 and PI-PLC had similar activity as the cationic peptides in reducing sporozoite infectivity (65.5 ± 5.1, and 63.7 ± 3.2% decrease, respectively, P < 0.001). LYZ did not modify the infection.

Conclusion: Cationic peptides and phospholipases warrant further investigation as potential anticryptosporidial agents. However, the reduction of sporozoite infectivity exerted by both phospholipases shows that viability assessment alone is not sufficient to identify potentially active compounds against C. parvum. Methods: Setting: Abdominal surgery center including 15-bed intensive care unit (ICU) in a teaching Hospital. Systematic rectal swabs are performed in this unit to detect extended-spectrum beta-lactamase producing enterobacteriaceae. The index case was a patient transferred from Greece for a liver transplant. The day of his admission, this patient was carrying in his fecal flora an imipenem-resistant (VIM-1) K. pneumoniae. After detection of this case (a) all ICU patients were screened for IR-Kp by rectal swab upon admission and then once a week and (b) control measures were taken including barrier safety measures.

Results: Starting in December 2003, the outbreak involved eight patients over a 6 month-period where eight acquired IR-Kp, four in ICU and three in the acute surgical facility. Genotypic analysis including pulsed-field gel electrophoresis and resistance genes identification showed that all strains were closely related. The measures to control the multi-resistant strain dissemination included (a) IR-Kp carriers isolation in private rooms, (b) disinfection with alcohol-based-hand antiseptics, (c) wearing disposable gowns and gloves before entering the room of carriers, (d) daily staff training, (e) environmental cleaning. These measures have been reinforced at the end of may by (a) cohorting IR-Kp carriers in one separate section of ICU, (b) nurse staff exclusively dedicated to IR-Kp carriers, (c) decreasing admission in the surgical care center, (d) strict control of patient transfer to other care centers, (e) antibiotic prescription control. Screening of all patients was performed twice a week using imipenem containing plates (4 mg/l). IR-Kp carriers were informed by the medical staff of their status and given specific instructions that should be followed after their discharge from the hospital.

Conclusions: No new case of cross contamination has been detected between June 2 and August 31. Identification of the risk factors for acquisition of IR-Kp is currently being processed. Resistance to carbapenem is an emerging problem among Gram-negative hospital pathogens. We studied seven strains of Klebsiella pneumoniae resistant to imipenem that were involved in an outbreak in a French teaching hospital.

Methods: MICs were determined by the standard agar dilution. A synergy test using imipenem and EDTA was used to detect metallo-beta-lactamases. Class A extended-spectrum b-lactamases were detected by the synergy test between third generation cephalosporins and clavulanic acid. The clonal relation of the isolates was studied using 3 genotyping methods (ERIC-PCR, rep-PCR, PFGE). Transfer of resistance was assessed by conjugation with E. coli K12 J53-2 or by electroporation in E. coli DH10B. Plasmid contents were analyzed by alkaline lysis method. Fingerprinting analysis was performed with plasmid DNA digested with EcoRI. The genes encoding for TEM-, SHV-CTX-M-, CMY-, IMP-, VIM-, SPM-, ACC-, FOX-type blactamases were screened by PCR. Cloning experiments were performed with genomic DNA partially digested by Sau3A and the vector pACYC 184. The inserted DNA fragments coding for imipenem resistance were sequenced on both strands.

Results: All isolates were highly resistant to beta-lactams, including aztreonam and imipenem (MIC 16-32 mg/l) and were positive by the imipenem-EDTA disk synergy test. Strains were also resistant to almost aminoglycosides (MICs for gentamicin of 8 mg/l), newer quinolones, sulfamethoxazole and showed an intermediate level resistance to tetracycline (MIC 16 mg/l). A unique profile was observed with both rep-PCR and ERIC-PCR and PFGE identified one major profile and three subtypes. The PCRbased screening for various b-lactamases revealed the presence of the VIM-1 and the SHV-5 b-lactamases in all strains. Transfer of b-lactam resistance was achieved by electroporation. The analysis of plasmid contents of E. coli DH10B transformants expressing the VIM-1 beta-lactamase or the SHV-5 beta-lactamase confirmed that the two enzymes were coded by two different plasmids. EcoR1 fingerprinting of the plasmids carrying VIM-1 enzyme generated identical restriction patterns. The bla VIM-1 gene was part of a class 1 integron that also included aac6, dhfrI and aadA and was similar to those reported from strains isolated in Greece.

Conclusion: We report the characterization of the first strains of K. pneumoniae producing the VIM-1 beta-lactamase in France.

Adjidé CC c , Biendo M a , Locher G c , Lescure X b , Laurans G a , Schmit JL b , Eb F a . a Unité de bactériologie clinique, Laboratoire de bactériologiehygiène, CHU Hôpital Nord, France, b Pathologie infectieuse, France, c Unité d'hygiène hospitalière et de prévention des infections nosocomiales, Laboratoire de bactériologie-hygiène, CHU, Hôpital Nord, Amiens, France Objectives: This study aimed to understand the main patient-related risk factors of acquisition of extended-spectrum beta-lactamase (ESBL) producing Enterobacter aerogenes (EA) resistant to imipenem in Amiens' University Hospital (France) wards between December 2003 and July 2004.

Methods: This study incorporated 13 cases and 13 controls matched on age. Controls have imipenem sensitive strains of ESBL EA survey continuously. EA strains are isolated from 23 diagnostic and three screening rectal samples. Patients' data-age, sex, medical and nursing acts, medical antecedents, past history of hospitalization and antibiotic treatments are recorded from patient files. Univariate analysis-non-parametric Wilcoxontest, t-test-are performed with SPSS 11.0.1 for Windows. Statistical test significance is assessed by p-value ≤0.05. Results: During the outbreak, ESBL EA resistant to imipenem incidence raised to 0.04 [0.03-0.05] per 1000 hospital-stay days. In comparison, after 5 years uninterrupted surveillance, ESBL EA imipenem sensitive strains' incidence was 0.16 [0.10-0.30] per 1000 hospital-stay days and none imipenem resistant strain. Among cases seven were previously colonized by imipenem sensitive ESBL EA strains. Genotypic studies identified two different clones implicated in the epidemic. Controls and cases don't statistically differ with respect to sex, samples' nature, medical antecedents, past history of hospitalisation. Controls don't have more often (p = 0.059) or for longer time invasive acts or anti-microbial treatment. However, cases are more often catheterise (p = 0.02) and mostly have central catheters (p = 0.034), intubated (p = 0.034) and above all treated with imipenem (p = 0.014). In addition, imipenem consumption has increased in the health-care wards concerned by this outbreak.

Conclusion: ESBL EA strains resistant to imipenem are probably selected by anti-microbial treatment practice. Therefore, a reasonable, restrictive and controlled anti-microbial treatment policy is needed in our hospital. The treatment of patients positive for ESBL producing enterobacteria should, in consequence, avoid imipenem use. Moreover, a thorough grasp of the outbreak need in prior to adjust and adapt multi-drug resistant bacteria cross transmission guiding principles in our hospital wards.

Oxa-60, a chromosomal, inducible and imipenem-hydrolyzing class D ␤-lactamase from Ralstonia pickettii Girlich D, Naas T, Nordmann P. Bactériologie, Université Paris-Sud, Hopital de Bicêtre, Le Kremlin-Bicêtre, France A chromosomally-encoded oxacillinase, OXA-22 had been characterized from Ralstonia pickettii that did not explain by itself the resistance profile of this species to ␤-lactams.

Further analysis of the genetic background of this species led to identify another oxacillinase, OXA-60. Gene inactivation and induction studies of the bla OXA-60 and bla OXA−22 genes in R. pickettii were performed to identify the relative contribution of each oxacillinase to the resistance profile to ␤-lactams of R. pickettii. OXA-60 was expressed only after ␤-lactam induction and shared 19% amino acid identity with OXA-22. OXA-60 has a narrow-spectrum hydrolysis profile but including imipenem. OXA-60-like enzymes were identified in all R. pickettii isolates tested. This study identifies that (i) two unrelated oxacillinases may be found naturally in a single bacterial species, further underlining diversity of oxacillinases, (ii) two oxacillinase genes may be regulated, and (iii) a novel naturally-occurring oxacillinase with carbapenem-hydrolyzing property has been characterized.

Lartigue MF, Poirel L, Nordmann P. Bactériologie-Virologie, Hôpital de Bicêtre, AP/HP, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France Bordetella bronchiseptica and Bordetella parapertussis are closely related Gram-negative rods that may colonize the respiratory tract of mammals. B. bronchiseptica causes chronic respiratory infections in a wide range of animals but is rarely implicated as a human pathogen. B. parapertussis may cause a milder form of whooping cough. The complete genome sequences of B. bronchiseptica RB50 (5.3 Mb), and B. parapertussis 12,822 (4.7 Mb) have been published recently. In-silico analysis of these sequences identified the same open reading frame (orf) that shared 57% nucleotide identity with that of an Ambler class A ␤-lactamase gene of Stenotrophomonas maltophilia. Cloning experiments of the corresponding gene, bla BBR−1 , of B. bronchiseptica CIP102314 (reference strain) gave recombinant clones expressing a clavulanic-acid inhibited class A ␤-lactamase, BBR-1, with a pI value of 5.6 and a relative molecular mass of ca. 32 kDa. We sequenced also the gene bla BBR−1 of two clinical strains of B. bronchiseptica and of a reference strain of B. parapertussis CIP 63.33. In all cases, a same bla BBR−1 gene was found. BBR-1 shared 42 to 52% amino acid identity with the most closely related enzymes, the chromosomally encoded enzymes from Rhodopseudomonas palustris and Stenotrophomonas maltophilia. B. parapertussis was susceptible to all ␤-lactams except to cefoxitin whereas B. bronchiseptica was susceptible to amino-, carboxy-, ureidopenicillins, cephalothin and carbapenems but resistant to broad-spectrum cephalosporins, whereas reference strains of both species hydrolyze nitrocefin. Once cloned, the substrate profile of the non-inducible BBR-1 was that of a clavulanic-acid inhibited narrow-spectrum penicillinase. The ␤-lactamase BBR-1 hydrolyzed significantly benzylpenicillin, ampicillin, ticarcillin, piperacillin, at a lower level cephalothin whereas no activity was detectable against broad-spectrum cephalosporins and carbapenems. The study indicated that B. bronchiseptica and B. parapertussis harbor an identical and naturally-occurring Ambler class A penicillinase that may not contribute significantly to naturally-occurring resistance phenotype, at least in the case of B. parapertussis.

Emergence of DHA-1 producing Klebsiella spp. in the Paris area: genetic organization of acquired ampC and ampR genes from Morganella morganii Verdet C a,b , Benzerara Y b , Gautier V a , Arlet G a,b . a Bactériologie UPRES EA 2392, Faculté de médecine Saint-Antoine, Université Paris VI, France, b Bactériologie-Hygiène, Hôpital Tenon, Paris, France

Since 1999, 10 Klebsiella pneumoniae and one Klebsiella oxytoca clinical strains producing inducible DHA-1 class C beta-lactamase have been isolated in the Paris area. The horizontal transfer of one plasmid carrying bla DHA-1 could be shown for seven of these strains. The aim of this study was to compare the genetic organization of bla DHA-1 in these eleven strains. By analogy with previous results obtained for K. pneumoniae Kp760 and Salmonella enteritidis KF92, both producing plasmid-mediated DHA-1 enzyme, primers were designed for genome walking by PCR mapping. When this methodology failed, either resistance to cefoxitin was cloned in pBKCMV, or GenomeWalker TM DNA walking was used for finding unknown DNA sequences adjacent to bla DHA−1 . For all strains of Klebsiella spp., the region mobilized from Morganella morganii including ampC and ampR genes was inserted upstream to second copy of 3 -Conserved Segment (3 -CS) of a complex sulI-type integron, like In6/In7. For three strains, the M. morganii region of variable length was inserted in a complex sulI-type integron; each of them had a different cassette genes profile. For one strain, the M. morganii region lay straight downstream to the common region (CR), like it was previously described for Kp760 or KF92. The CR includes an orf513 presumably coding for a recombinase involved in the mobilization of resistance genes. For two strains, between the CR and the M. morganii region, was inserted an additional 10 kb fragment, partially identical to sap (ABC transporter) and psp (phage shock protein) operon from Salmonella typhimurium LT2. The genetic organization of bla DHA was identical for the other eight strains, seven of them harboring the same plasmid. Surprisingly, despite the presence of a truncated 3 -CS adjacent to ampR, no integron element was found, neither int gene, nor orf513. Nevertheless, upstream to the M. morganii region lay a part of the fragment identical to S. typhimurium LT2 including the psp operon. The emergence of acquired DHA-1 Klebsiella spp. in the Paris area was partially due to horizontal spread of one plasmid. bla DHA seems to have been mobilized from M. morganii by several independent recombination events, most often in complex sulI-type integrons including a putative recombinase.

Polymorphism and drug-selected mutations in the HIV-1 Reverse Transcriptase gene in naive and treated patient isolates from the Seine-Saint-Denis district in France: differences between B and non-B subtypes The comparison of phenotyping and genotyping results obtained from HIV-1 isolates has allowed to define anti-Reverse Transcriptase (RT) treatment algorithms which can be deduced from the amino-acid sequence of the RT. However, most of the collected data were obtained from B subtype isolates, and only few publications are available concerning RT gene mutations in non-B subtypes. We have collected and analyzed the HIV-1 RT sequences of 49 naive patients (22 B and 27 non-B subtypes), and 638 treated patients (457 [71.6%] B and 181 [28.4%] non-B subtypes). On one hand, the sequences were interpreted according to Stanford "virtual phenotype algorithm". On the other hand, they were aligned and statistically analyzed in order to detect eventual subtype-related differences between RT sequence profiles. In the naive group of patients, 8/22 B subtype isolates displayed anti-RT resistance mutations. Two of these isolates presented mutations associated with resistance to AZT, 3TC, d4T, EFV and NVP, three to AZT, 3TC, and d4T, and one to 3TC. One isolate displayed the mutation M41L and another Y115F. Only 1/27 non-B subtype isolate displayed anti-RT resistance mutations (K70R, and Y115F). Moreover, a significant difference in the amino-acid substitutions was found between B and non-B subtype isolates at 4 positions including 184, 210, and 215 which are associated to drug-resistance. In the treated group, the Stanford virtual phenotype algorithm indicated a higher prevalence of anti-RT resistance in B as compared to non-B subtype isolates (59.6% versus 50.4%). Amino acid substitution analysis in the RT sequence evidenced a significant difference between B and non-B subtype isolates in 30 positions including six drug-resistance associated sites (41, 44, 67, 74, 115, and 210 ) even though the treatment regimen was similar in both B and non-B infected patients. Our results indicate that the amino-acid profile of B and non-B subtype isolates is different, either because of their natural polymorphism or as a result of treatment history. The high prevalence of resistance mutations in naïve B subtype isolates should encourage the systematic RT gene sequencing, in order to adapt treatment strategy to the virus. Our results suggest that treatment algorithms based on B subtype cohort studies may need modifications to be applied to non-B subtype isolates. Efforts should be considered to study each subtype independently.

Chêne G a , Leport C e , Spire B b , Lewden C a , Pierret J h , Peytavin G g , Brun-Vezinet F f , Le Moing V c , Salamon R a , Raffi F d , and the Aproco-Copilote Study Group a,e . a Unité 593, Bordeaux, France, b Background: The vast majority of treated HIV-infected patients from western countries initiated highly active antiretroviral (HAART) regimens between 1996 and 1999. The long-term evolution of these patients and benefit of these regimens are best described in large prospective cohorts.

Methods: All consecutive PI-naive patients presenting at 47 French HIV clinical centers in 1997-1999 for whom a PI-containing regimen was initiated (except for primary infection) were prospectively included in the APROCO-ANRS EP11 study. Data were recorded at the initiation of PI therapy (baseline), at months 1, 4, and every 4 months thereafter: sociodemographic and clinical data, CD4+ and CD8+ cells counts, and plasma HIV-1 RNA level. All clinical and laboratory adverse events were prospectively recorded.

Results: 1281 patients were included, 45% antiretroviral-naïve, 77% males, mean age 38 years, 39% homosexuals, 16% injecting drug users, 33% heterosexuals. At baseline, mean HIV-1 RNA was 4.4 log 10 copies/ml, mean CD4+ cell count 294/mm 3 , 21% had AIDS. At 5 years, 648 patients were still followed-up and 84% still on HAART (40% without a PI), 4% on a dual antiretroviral combination and 7% had stopped antiretrovirals. Estimated survival was 90% (92% in patients without prior AIDS, 84% in those with prior AIDS), progression to a new AIDS-defining event 16% (6% in patients without prior AIDS, 28% in those with prior AIDS), the cumulative probability of any serious adverse effect (SAE) was 30%. At 5 years, 76% had HIV-1 RNA < 2.7 log 10 copies/ml. Mean CD4 + cell count was 573/mm 3 , 74% had gained more than 100 cells/mm 3 since baseline and 93% had CD4 + above 200/mm 3 .

At 5 years, the majority of patients still remain on a HAART regimen, although the proportion without a PI is high. Clinical progression and death is still seen on HAART, especially in patients with advanced disease at initiation. The occurrence of SAE is high, in the context of recent use of new drugs by clinicians. Strategies for optimal use of current antiretrovirals still need to be improved, to achieve sustained efficacy as well as better tolerance and improved quality of life in the setting of a lifelong chronic disease. Background: High rates of early virologic failure have been reported in naive patients receiving tenofovir (TDF), with either lamivudine (LAM) and didanosine, or LAM and abacavir (ABC). However, a once-daily zidovudine (ZDV), LAM, ABC and TDF regimen showed a high rate of virologic success, and the resistance pattern (less K65R or M184 V) suggested a role of ZDV in resistance modulation.

Methods: This is a pilot, open study, conducted in the HIV outpatient clinic of Strasbourg University Hospital. Treatment naïve subjects received a fixed dose combination of ZDV/LAM (300 mg/150 mg) twice a day, and TDF 300 mg once a day. CD4 cells count (flow cytometry) and HIV-1 viral load (Cobas Amplicor HIV Monitor V 1.5, Roche Diagnostic Systems) were assessed at baseline, 1 and 2 months of treatment, and then every 2 months. Early virologic response (1-2 weeks) was also evaluated.

Results: Thirty patients were included between April 2002 and June 2004 (26 males; six females; median age [range] of 40 [22-73] years). Most of them were asymptomatic: 24 in group A of 1993 CDC classification, 6 in group B and 2 in group C. At baseline, median (range) CD4 count was 230/mm 3 (69-425/mm 3 ), and median HIV-1 viral load was 4.9 log (3.14-> 5.89 log). Twelve subjects had CD4 < 200/mm 3 , and 15 had HIV RNA > 5 log. At 6 and 12 months (on treatment analysis), median viral load decrease was −3.24 log and −3.2 log, and 15/18 (83%) and 8/12 (67%) had viral load <50 copies/ml. Early virologic response was −1.66 log (median HIV RNA decrease after 1-2 weeks of treatment, 28 evaluable subjects). Median CD4 count increase was +85/mm 3 at 6 months, and +53/mm 3 at 12 months. Treatment interruptions (5/32 (16%)) for clinical side effects were seen (abdominal pain and nausea: 3; anemia: 2, probably due to ZDV). Only 1 renal deficit was observed, pre-existing to TDF therapy. During the first 12 months of treatment, 4 viral failures occurred, 1 with K65R mutation, 2 with M184V + 2 or 3 TAMS, and 1 with 2 TAMS. Two of them successfully changed the ARV treatment; the others remained on ZDV + LAM + TDF, with low viral loads.

Conclusion: Combination of ZDV + LAM + TDF in ARV naïve HIV-infected subjects induces a rapid and sustained HIV RNA decrease, associated with a good immunologic response, and is safe.

Raffi FR c , Antoun Z b , Le Camus C a . a Vertex Pharmaceuticals (Europe), Courbevoie, France, b GlaxoSmithKline, Marly Le Roy France, c Service des Maladies Infectieuses, CHU Hotel Dieu, Nantes, France Goal: Parallel assessment of the efficacy & adherence data collected in a subgroup of pts of a study comparing a treatment (tx) with FPV 1400 mg + ritonavir (r) 200 mg QD versus nelfinavir (NFV) 1250 mg BID (associated to abacavir + lamivudine BID) at the week 48 time point (W48).

Phase III multicentre open study, randomized in 2 arms, in tx naive HIV infected pts. A self-report Patient Medication Adherence Questionnaire (PMAQ) was administered in the five English-speaking countries every 12 weeks or upon early withdrawal. Pill counts for either FPV or NFV were collected at each visit, except weeks 1 and 2. A sub-analysis of pts who failed virologically & had completed the PMAQ assessed the incidence of virological failure according to the level of adherence.

Results: Six hundred and sixty pts included, 322 receiving FPV/r and 327 NFV BID. At baseline: median plasma HIV RNA level = 4.78 log 10 cp/mL [2.65-7.29] & 4.83 log 10 cp/mL [3.11-6.74], median CD4 count = 166 c/mm 3 [1-813] and 177 c/mm 3 [1-1055]. At W48: VL < 400 cp/mL in 68% and 65% pts in intention to treat analysis (ITT M = F) respectively, median CD4 count rise = +203 c/mm 3 [−36, +672] and +207 c/mm 3 [−67, +1005]. Rate of success was comparable between the two arms; however, the rate of virological failure is 4% with FPV/r QD versus 15% with NFV BID. The incidence of mutations in pts experiencing tx failure was statistically different between FPV/r & NFV: zero versus 50% 1 ary or 2 ary protease mutations, 13% versus 56% reverse transcriptase mutations (p < 0.001). The PMAQ, completed by 268 pts, indicated few barriers to adherence. While no significance testing was completed, more pts reported perfect adherence scores with FPV/r versus NFV, both at week 24 (90% versus 83%) & W48 (89% versus 85%). Among the virological failure population, 18% reported perfect adherence in the FPV/r arm (majority of failures occurred <90% adherence) versus 57% with NFV (& mutations occurred at all levels of adherence).

Discussion and conclusion: dosing convenience, low pill count and absence of food restriction can be related to better adherence with FPV/r. The fewer virological failures with FPV/r versus NFV and the apparent absence of correlation between these failures and the level of adherence suggest greater potency and a higher resistance barrier of this boosted regimen.

Clinical and virological follow-up of a cohort of HIV-1 infected patients receiving enfuvirtide Bienvenu B b , Krivine A a , Spiridon G b , Pietri MP b , Lebaut V b , Sicard D b , Lebon P a , Salmon D b , Launay O b . a Laboratoire de Virologie, Paris, France, b Service de Médecine Interne, Groupe Hospitalier Cochin-Saint Vincent de Paul, Paris, France Background: Enfuvirtide (ENF), an antiretroviral agent acting by inhibiting the virus-cell membrane fusion process, is now available in France; only few data regarding its clinical and virological efficiency have been shown.

Methods: Retrospective study of a cohort of HIV-1 infected pts who began ENF therapy between 11/2002 and 01/2004 at Cochin Hospital, Paris.

Results: The 16 patients (pts) included in the study (13 men and 3 women) had an advanced HIV-disease: 11 stage C, 1 B, and 4 A, and a median CD4 nadir at 45/mm 3 . They had previous exposure to a median of 12 antiretroviral drugs for a median duration of 9 years and their median genotypic sensitivity score was 2. At baseline, the median CD4 cell count was 121/mm 3 [5-320] and the median plasma HIV-1 RNA 52,700 copies/ml. ENF was given with an optimised regimen including a mean of 2.7 (S.D. ± 1.5) drugs, according to the results of the genotypic resistance test. Pts were individually educated for self-injections. Tolerance of treatment was good in 75% of the pts. Minor adverse events occurred in 25% of them (mostly injection-site reactions) that did not lead to discontinuation of therapy. Median duration of follow-up was 6 months. In 13 pts (81%), a response to therapy was observed since plasma HIV-1 RNA decreased by more than 1 log from baseline. Three pts experienced a viral rebound within 3 months, but in the other 10, the virologic response was sustained. Plasma HIV-1 RNA undetectability (<50 copies/ml) was reached by seven pts, and was sustained (>3 months) in five. In this group, the median CD4 cell count increase at M6 was 126/mm 3 . In only three pts, no virological response was observed. Analysis of resistance mutations in the HR1 region of gp41 in three of the six pts in virologic failure showed wild-type virus before treatment, and presence of described ENF-resistance mutations between M4 and M7: G36V + N42D in a non responder and V38A, G36V+V38A in two patients experiencing viral rebound.

Conclusion: ENF associated with optimised antiretroviral therapy showed sustained immuno-virologic efficiency and a good tolerance. In the event of virological failure, genotypic changes have been observed in the HR1 region of gp41. Their reversion after the ENF withdrawal, and their influence on the viral replication remain to be studied.

Incidence of and risk factors for hepatotoxicity associated with nevirapine in HIV-1 infected patients Background: Rash and hepatotoxicity are the most common and limiting toxicities of nevirapine (NVP). The objective of this study was to assess the incidence of and risk factors for developing hepatotoxicity within 12 weeks (w) after NVP initiation.

Methods: Two hundred pts enrolled in the VIZYR trial, a randomized, double blind, placebo-controlled trial showing no preventive effect of cetirizine on NVP-associated rash, had physical examination at study entry, and at weeks 2, 4, 8 and 12. Liver tests were performed at screening, and at weeks 2, 4 and 8. Trough NVP plasma concentrations were determined after 2, 4 and 8 w of treatment. Hepatotoxicity was defined as an increase of at least two-fold in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels compared with baseline values and ALT and/or AST levels > 2.5 times the upper limit of normal (ULN), severe hepatotoxicity as an increase in ALT and/or AST levels > 5 times the ULN. Statistical analysis was performed using a logistic regression test to assess risk factors of hepatotoxicity.

Results: Twenty-six pts (13%) developed hepatotoxicity in a median of 21 days [8-55 days], including 17 pts with severe hepatotoxicity. Findings included fever (n = 7), cutaneous reaction (n = 6) including two pts with hypersensitivity syndrome, eosinophilia (n = 10); five pts had no clinical symptom. All pts experienced restoration of transaminases levels and resolution of clinical symptoms. Mean NVP plasma concentrations at 2 w did not differ between pts developing hepatotoxicity and others: 3.7 ± 1.6 versus 3.4 ± 1.7 g/mL, respectively. Multivariate analysis does not identify any predictive risk factor for hepatotoxicity.

Conclusion: Close monitoring of liver enzyme levels is recommended in all pts starting a NVP containing regimen. Eosinophilia appears to be associated with hepatotoxicity.

Extended-spectrum ␤-lactamase-producing enterobacteria in the community setting: clinical and molecular analysis During an extra-hospital survey conducted from January to May 1999 by the Aquitaine Network of private laboratories, 39 enterobacteria (1.5% of the strains) produced an extended-spectrum ␤-lactamase (ESBLE). Among them, five were responsible for urinary tract infections (UTIs) in patients living at home (C1-C5): 1 E. coli producing the TEM-24b enzyme (patient C1), 1 E. coli expressing TEM-21 (patient C2), 1 K. neumoniae elaborating SHV-4 and TEM-15 (patient C3), and finally 2 E. aerogenes with TEM-24b (patients C4 and C5), including one imipenem resistant strain. The TEM-24b E. aerogenes belonged to the prevalent

Four patients (C1-C4) had recurrent UTIs, and in three (C2, C3, C5), former episodes were caused by an ESBLE (last record 2.5-11.5 months). The same ESBLE and/or the same ESBL-encoding plasmid were identified in the hospital ward (C2, C3) or in a clinic (C5) where they resided; patients C1 and C4, infected with different ESBLEs carrying the same plasmid, were hospitalized in the same unit. Persistence of the ESBLE over an at least 5-year period was demonstrated for patient C3. Thus, community-acquired UTIs in these at-risk patients likely resulted from nosocomially-acquired ESBLE or ESBL-encoding plasmid

Spread of novel expanded-spectrum beta-lactamases in enterobacteriaceae in an university hospital in the Paris area

France The emergence of novel inhibited clavulanic-acid extended-spectrum ␤-lactamases (ESBLs) that are non-TEM and non-SHV related have been reported recently in Enterobacteriaceae. To evaluate the prevalence of these ESBLs in Enterobacteriaceae in hospitalized patients at Bicêtre hospital in Paris area (France), a one-year retrospective study was carried out from January to December of 2002. During this period, twenty-eight nonduplicate clinical enterobacterial isolates were selected for ESBL phenotype according to the results of the double-disk synergy test. The ␤-lactamases genes were detected by PCR using specific primers for detection of the bla TEM

Enterobacter aerogenes (7%)

All CTX-M genes were associated with the insertion sequence ISEcp1.Two VEB-like and one PER-1 like ␤-lactamases were found. No GES-1/-2-type enzymes were detected. The TEM derivatives were TEM-24 like (6) and TEM-3 like (4)

This is the first description of bla VEB and bla CTX−M genes association in a single isolate. Ten out of the 28 strains were also producers of ␤-lactamase TEM-1, eight of them being associated with CTX-Ms. Thus, the CTX-M ␤-lactamases are the most prevalent ESBLs and mostly in E. coli. Other rare ESBLs such as VEB and PER enzymes were identified also indicating that ESBLs other than CTX-Ms may emerge

Countrywide spread of extended-spectrum ␤-lactamase (ctx-m-15)-producing Enterobacteriaceae in Lebanon

and screened for potential ESBL producing enterobacteriacae by culture on trypticase soy-5% sheep blood agar containing vancomycin (6 g/ml), amphotericin (2 g/ml), ceftazidime (2 g/ml) and clindamycin (1 g/ml). Patients were checked for ESBL producing strains upon admission, 72 h later and at weekly intervals over a 3 months period. Other participants were checked once. ESBL producing strains were detected by antimicrobial susceptibility testings and were then identified by the API 20E system. The type of ESBLs produced was detected by PCR analysis of bla genes, DNA sequencing and isoelectric focusing experiments. The genome of ESBL producing strains was analysed using pulsed-field gel electrophoresis. A total of 123 strains collected from 65 patients, two health workers and 10 healthy subjects were ESBL producing strains. The characterization of one representative strain by subject (n = 77) revealed that 79.2% of ESBL producing strains were Escherichia coli, 10.4% were Klebsiella pneumoniae, 9

In this study we identified the ␤-lactamases produced by two clinical isolates of Escherichia coli which harboured an unusual ␤-lactam resistance phenotype with resistance to amoxicillin and ticarcillin alone and in combination with clavulanate associated with resistance to extended-spectrum cephalosporins. ␤-lactamases genes were amplified using primers of known ␤-lactamases and sequenced. ␤-Lactams MICs determination and enzymatic parameters study of the purified enzymes were performed after cloning in E. coli BL21. Sequence analysis revealed two new Complex Mutants of TEM-1 ␤-lactamase (CMT) which contain ESBL and IRT specific substitutions

Analysis of the MICs and kinetic parameters showed that: (1) CMT-4 which contains two ESBL-specific substitutions and one IRT-specific substitution harboured an ESBL hydrolytic activity associated with a low level of resistance to inhibitors. (2) CMT-5 which contains three IRT-specific substitutions and one ESBL-specific substitution harboured an IRT enzymatic activity with a low level of catalytic efficiency against ceftazidime

eight Salmonella enterica serotype Virchow isolated from poultry and poultry product sources in different locations in the South West of France and one S. enterica rough strain isolated from human faeces, were found to produce extended-spectrum ␤-lactamase CTX-M-9. The human rough isolate had sequences of flagellin genes (fliC and fliB) typical of serotype Virchow and close similar ribotyping and pulsed-field-gel electrophoresis (PFGE) patterns as those of serotype Virchow strains. PFGE confirmed the clonal relationship between the poultry isolates, while the human isolate displayed a pattern with 94% homology. The bla CTX-M-9 gene was located on a conjugative plasmid

Outbreak of Aeromonas caviae producing the extended-spectrum beta-lactamase

In the era of active antiretroviral treatment (ART), apart from events related to disease progression, occurrence of toxicity-related events are also important to describe and analyse. Documentation and validation of events before analysis is less standardized in the context of observational epidemiological studies than of clinical trials. We describe the experience of events validation in the APROCO cohort which enrolled 1281 consecutive HIV infected patients in 1997-1999. All clinical and laboratory serious and severe adverse events (SAE) or AIDS-related events (ARE) were prospectively recorded with all available documentation at each clinical center. The following characteristics of each event were described in a standardized questionnaire: diagnosis, evolution and outcome, onset and ending dates, as well as any treatment modification. Exhaustiveness and quality of the records was expected because of monitoring visits in the clinical centers. SAE were defined as death, event threatening vital prognosis, requiring hospitalization or an extension of hospitalization, laboratory or clinical grade 3 or grade 4 events. SAE and ARE with completed information were validated by an Events Validation Committee (EVC) composed of eight clinical experts on HIV infection. All SAE and ARE were independently scored by two experts of the EVC to assess the severity of event using the standardized definition of ANRS and the relation to ART using EMEA recommendations. The ARE were validated using WHO definitions. From May 1997 to June 2004, 1178 SAE (incidence density: 19.2% person-year), 118 deaths and 188 ARE were reported and

Background: The aim of this study was to characterize the extendedspectrum beta-lactamase (ESBL) produced by eight clinical isolates of Aeromonas caviae during an outbreak in an Intensive Care Unit.Methods: Eight isolates of A. caviae with a positive double-disk synergy test were collected from patients in the Intensive Care Unit in Colmar's hospital, France. A genotypic comparison of the strains was achieved by pulsed-field gel electrophoresis. Isoelectric focusing was performed with a detection of the beta-lactamase activity by an iodine starch procedure. For cloning experiments total DNA was extracted, partially digested by Sau3AI and ligated into pK18-BamHI digested. The ligation product was introduced in E. coli DH5à and the transformants were selected on kanamycin (20 mg/l) and ticarcillin (30 mg/l).Results: The six strains were clonally related. The bla PER-3 (pI about 5.4) was cloned on a 2.7 kb fragment. PER-3 differed from PER-1 by the following amino acid substitution: H129 to L129. bla PER-3 was located on a complex orf513-bearing integron as already described for some betalactamases.Conclusion: This report is the first description of an ESBL belonging to the PER family in A. caviae and confirm the spread of members of this family among different species.